"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"AOU_MODENA",2000,18,9.11111111111111,4.22222222222222,0.666666666666667,0.333333333333333,0.666666666666667,1.01351351351351,0.923076923076923,0.857142857142857,0.923076923076923,0.388888888888889,2,10,3,0,5,0.56,0.17,0,0.28,48.33,1.06623187652653,NA,0.277777777777778,0.5,0.426,0,0,0,"STEFANO CASCINU;V. SILINGARDI;UMBERTO VITOLO;CHIARA CASARINI;GILLIAN FRANK;GERARDO GUARINO;GIOVANNI GUARALDI;V. CATALANO;MICHELE MORETTI;MARIO LUPPI;ELISABETTA SANSONI;PAOLO LAURIOLA;MARCO ZOLI;L ORTONA;PAOLO VERDERIO;ALESSANDRO SCHIAVI;F LEYNADIER;DANIELA TURCHETTI;GIANLUCA AGUIARI;ROBERTA PIVA","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MICHELE MORETTI;FABIO MANENTI;GUIDO GUASTI;BENIAMINO PALMIERI;G GOZZI;P BOSIO;ANDRÉA BARBIERI;V LEONELLI;F LEYNADIER;ALBERTO GIANNETTI;MARGARITA MURRIETA‐AGUTTES;G LORETTE;RS PEREIRA;ALBERTO BARBIERI;A. MERIGHI;ROBERTO VIVOLI;SERGIO ROVESTI;A. SCARCELLI;ROBERTO RONCAGLIA;RENATA MENOZZI","1;1;0.33;0.33;0.33;0.33;0.33;0.33;0.2;0.2;0.2;0.2;0.2;0.17;0.17;0.17;0.17;0.17;0.17;0.17","STEFANO CASCINU;V. SILINGARDI;CHIARA CASARINI;GERARDO GUARINO;GIOVANNI GUARALDI;DANIELA TURCHETTI;ALBERTO BARBIERI;A. MERIGHI;ROBERTO VIVOLI;SERGIO ROVESTI;A. SCARCELLI;ROBERTO RONCAGLIA;M CHERUBINI;GIULIANO FRANCO;MAUNZIO CANTORE;D. ZAMAGNI;ALBERTO GIANNETTI;RENATA MENOZZI;MASSIMO AMICOSANTE;FRANCESCO AZZOLINI","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FABIO MANENTI;BENIAMINO PALMIERI;V LEONELLI;ALBERTO GIANNETTI;ALBERTO BARBIERI;A. MERIGHI;ROBERTO VIVOLI;SERGIO ROVESTI;A. SCARCELLI;ROBERTO RONCAGLIA;RENATA MENOZZI;FRANCESCO AZZOLINI;MARIA VENNERI;CLAUDIA CREMONINI;PAOLA BORELLA;MORENO BONDI;A VELARDO;LORENZO CAMELLINI;ANNALISA BARGELLINI;A. BALDINI","1;0.33;0.33;0.2;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17","MICHELE MORETTI;ANTONIO CUNEO;CAROLA BOCCOMINI;GIAMPIERO BELLESI;GINO SANTINI;L RESEGOTTI;LUCA BALDINI;LUIGI RIGACCI;MARINA LIBERATI;MASSIMO FEDERICO;MASSIMO MAGAGNOLI;MAURA BRUGIATELLI;PASQUALE NISCOLA;PIER LUIGI ZINZANI;TEODORO CHISESI;UMBERTO VITOLO;VERA CLÒ;VINCENZO PAVONE;ALESSANDRA GOVONI;ANDREA ANTINORI","319;186;186;186;186;186;186;186;186;186;186;186;186;186;186;186;186;186;106;106","MASSIMO FEDERICO;BRUNO DE RIENZO;CRISTINA MUSSINI;MARIA CHIARA CERRI;NICOLA MONGIARDO;ROBERTO ESPOSITO;VANNI BORGHI;A R DI BIASE;F. BALLI;ALBERTO BARBIERI;ANNALISA BARGELLINI;PAOLA BORELLA;ROBERTO RONCAGLIA;ROBERTO VIVOLI;SERGIO ROVESTI;A VELARDO;A. BALDINI;G. DEL RIÓ;MARIA VENNERI;MORENO BONDI","186;106;106;106;106;106;106;77;77;63;63;63;63;63;63;37;37;37;37;37","V. SILINGARDI;A R DI BIASE;A VELARDO;A. BALDINI;A. MERIGHI;A. SCARCELLI;ALBERTO BARBIERI;ALBERTO FRANCHI;ALBERTO GIANNETTI;ANNALISA BARGELLINI;BRUNO DE RIENZO;CESARE SALTINI;CLAUDIA CREMONINI;CRISTINA MUSSINI;E. ROVATTI;ENRICO GIRARDI;F. BALLI;FRANCESCO AZZOLINI;G CIONI;G. DEL RIÓ","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;COMPUTER SCIENCE;PHYSICS;BIOLOGY;CHEMISTRY;ECONOMICS;ART;ENGINEERING;HISTORY;MATHEMATICS;PSYCHOLOGY","17;4;3;2;2;2;1;1;1;1;1","INTERNAL MEDICINE;PATHOLOGY;GASTROENTEROLOGY;SURGERY;ANESTHESIA;IMMUNOLOGY;ECONOMIC GROWTH;NURSING;OPTICS;ANIMAL SCIENCE;ARCHAEOLOGY;BIOCHEMISTRY;CLINICAL PSYCHOLOGY;COMPUTER SECURITY;DATA MINING;DERMATOLOGY;ELECTRICAL ENGINEERING;EMERGENCY MEDICINE;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GENETICS;INTENSIVE CARE MEDICINE;MEDICAL EDUCATION;MEDICAL EMERGENCY;MOLECULAR BIOLOGY;ONCOLOGY;OPERATING SYSTEM;PEDIATRICS;PROGRAMMING LANGUAGE;RADIOLOGY;STATISTICS;THERMODYNAMICS;VIROLOGY;VISUAL ARTS;WORLD WIDE WEB","11;6;4;4;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALTERNATIVE MEDICINE;CANCER;DIARRHEA;HEALTH CARE;INCIDENCE (GEOMETRY);MECHANICAL VENTILATION;PERCUTANEOUS;VIRUS;ABLATION;ACCIDENT AND EMERGENCY;ADVERSE EFFECT;ANGIOEDEMA;ANTIBODY;ANTIHISTAMINE;ARTERIAL BLOOD;BASAL METABOLIC RATE;BONE MARROW;BURNOUT;CANNULA;CATECHOLAMINE;CHEMOPROPHYLAXIS;CHEMOTHERAPY;CIRRHOSIS;CLINICAL TRIAL;CONFIDENCE INTERVAL;CONFIDENTIALITY;COPD;DISCONTINUATION;DOCUMENTATION;ENZYME;ERYTHROCYTE SEDIMENTATION RATE;EXCRETION;FOLLICULAR PHASE;GENE;HEPATOCELLULAR CARCINOMA;INTENSIVE CARE;INTERVENTION (COUNSELING);INTUBATION;ITCHING;KIDNEY;LYMPHOMA;MULTIVARIATE ANALYSIS;OBESITY;OCCUPATIONAL EXPOSURE;OCCUPATIONAL SAFETY AND HEALTH;PEPTIC ULCER;PHOTOGRAPHY;PLAN (ARCHAEOLOGY);PNEUMONIA;PUBLIC HEALTH;PULSE OXIMETRY;RADIATION THERAPY;RELATION (DATABASE);RESPIRATORY FAILURE;RETROSPECTIVE COHORT STUDY;SAMPLE (MATERIAL);SARCOMA;SESSION (WEB ANALYTICS);SOFTWARE DEPLOYMENT;SOMATOSTATIN;STOMA (MEDICINE);THERAPEUTIC EFFECT;TRACHEOTOMY;TRANSMISSION (TELECOMMUNICATIONS);TUBERCULOSIS","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","VIRAL DISEASE;AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE;B SYMPTOMS;BREAST CANCER;COLORECTAL CANCER;DIFFUSE LARGE B-CELL LYMPHOMA;ENCEPHALITIS;EXON;FLUOROURACIL;FOLLICULAR LYMPHOMA;GASTRODUODENAL ULCER;HORIZONTAL TRANSMISSION;HUMAN HERPESVIRUS;INFORMED CONSENT;INTRON;LACTATE DEHYDROGENASE;LOPERAMIDE;MUTATION;MYCOBACTERIUM TUBERCULOSIS;OCTREOTIDE;PLACEBO;PNEUMOCYSTIS JIROVECII;POLYCYSTIC KIDNEY DISEASE;RADIOFREQUENCY ABLATION;RNA;SYMPATHOADRENAL SYSTEM;TUBERCULIN;WEIGHT LOSS","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HERPESVIRIDAE;INTERNATIONAL PROGNOSTIC INDEX;KAPOSI'S SARCOMA;MISSENSE MUTATION;OPPORTUNISTIC INFECTION;PERCUTANEOUS ETHANOL INJECTION;PKD1;PNEUMOCYSTIS CARINII;RNA SPLICING;SIDA","1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;ITALY;;AGED;BURNOUT, PROFESSIONAL;CARCINOMA, HEPATOCELLULAR;LIVER NEOPLASMS;ACCIDENTS, TRAFFIC;ACQUIRED IMMUNODEFICIENCY SYNDROME;ANXIETY;BENZIMIDAZOLES;DIARRHEA;HERPESVIRIDAE INFECTIONS;HISTAMINE H1 ANTAGONISTS;HIV INFECTIONS;OBESITY","13;10;9;8;7;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;BIOLOGICAL AND CLINICAL EFFECTS OF IONIZING RADIATION;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL BLEEDING;DIAGNOSIS AND MANAGEMENT OF URTICARIA;EPIDEMIOLOGY AND PATHOGENESIS OF PNEUMOCYSTIS PNEUMONIA;ETHICAL CONSIDERATIONS IN CLINICAL PHOTOGRAPHY AND DOCUMENTATION;HEPATOCELLULAR CARCINOMA;IMPACT OF BURNOUT ON HEALTHCARE PROFESSIONALS AND STUDENTS;IMPACT OF TRAUMA CARE SYSTEMS ON MORTALITY;INTERMITTENT FASTING AND HEALTH EFFECTS;LYMPHOID NEOPLASMS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;TRANSFORMATION OF MEDICAL EDUCATION AND PROFESSIONALISM;TUBERCULOSIS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","KAPOSI'S SARCOMA;ACCIDENT AND EMERGENCY;AMBULANCE DIVERSION;ARTERIAL BLOOD;AUTOPSY VALIDATION;AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE;B SYMPTOMS;BREAST CANCER;BURNOUT;CHEMOPROPHYLAXIS;CLINICAL PHOTOGRAPHY;DISCONTINUATION;ERYTHROCYTE SEDIMENTATION RATE;FACULTY DEVELOPMENT;FOLLICULAR LYMPHOMA;GASTRODUODENAL ULCER;HEPATOCELLULAR CARCINOMA;HERPESVIRIDAE INFECTIONS;HORIZONTAL TRANSMISSION;HUMAN HERPESVIRUS 8","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACCIDENT DEATHS;ALCOHOL INJECTION;ANTI-DIARRHEIC THERAPY;AUTOSOMAL DOMINANT;AVOIDABLE VEHICLE;BLOT TEST;BREAST CANCER;CANCER PATIENTS;CARE WORKERS;CATECHOLAMINE EXCRETION;CHILDREN EVIDENCE;CHRONIC URTICARIA;CIRRHOTIC PATIENT;CLINICAL SIGNIFICANCE;COLORECTAL CANCER;CONFIDENTIAL ENQUIRY;DIOSMECTITE DIOSMECTAL;DISEASE PKD;DOMINANT POLYCYSTIC;ESTHETIC SURGERY;FAT-FREE MASS;FEMALE OBESE;FLUOROURACIL-INDUCED DIARRHEA;FOLLICULAR LYMPHOMA;FORIPNEUMOCYSTIS CARINIIIPNEUMONIA;GASTRODUODENAL ULCER;GENE EXPRESSION;HEALTH CARE;HEPATOCELLULAR CARCINOMA;HIGH-DOSE LOPERAMIDE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE RESPIRATORY;RESPIRATORY FAILURE;CARINII PNEUMONIA;CELLS CD;INVASIVE VENTILATION;LATE NIMV;NIMV FAILURE;PERSONAL ACCOMPLISHMENT;SEM KG;SEM NA;TOXOPLASMIC ENCEPHALITIS;BURNOUT INVENTORY;CELL COUNTS;CONTINUATION ARM;DISCONTINUATION ARM;DISEASE-ASSOCIATED MUTATIONS;EMOTIONAL EXHAUSTION;HHV- INFECTION;IMMUNE VARIABLES;JOB CHARACTERISTICS;KAPOSIS SARCOMA;LED INDUCED;MASLACH BURNOUT;NORADRENALIN EXCRETION;OBESE PATIENTS;PRIMARY PROPHYLAXIS;RESPIRATORY ICU;SEM NMOL;SYMPATHOADRENAL SYSTEM;URINARY EXCRETION","5;5;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",5,0.28,6,2,0,0,0,1,2,0,1.5,2,0,0,0,0,0,0,0,0,0,0,0,87,87,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0,300,1.37,0,0,37,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;LUNG CANCER;ORPHAN DRUG;PATIENT SAFETY;RARE DISEASES","1;1;1;1;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","1;1","LUNG CANCER","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1;1",1,1176528,15899.03,6,74,14,1,10,2649.83783783784,6.79286850801681,"ANDALUSIAN HEALTH SERVICE;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;AZIENDA OSPEDALIERA DI PADOVA;BAMBINO GESÙ CHILDREN'S HOSPITAL;CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY;CATHOLIC UNIVERSITY OF THE SACRED HEART;CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT-PIERRE;CHILDREN'S HEALTH IRELAND AT CRUMLIN;DÉLÉGATION PARIS 11;EALING HOSPITAL NHS TRUST;ERASMUS MC;GUY'S AND ST THOMAS' NHS FOUNDATION TRUST;HEINRICH HEINE UNIVERSITY DÜSSELDORF;HOSPICES CIVILS DE LYON;HOSPITAL DE BASURTO;HOSPITAL DE DONA ESTEFÂNIA;HOSPITAL DEL MAR;HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN;HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE;HOSPITAL UNIVERSITARIO 12 DE OCTUBRE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CON - COORDINATION OF RESEARCH ACTIONS (FUNDING SCHEME);FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME)","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY","1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HIV/AIDS;INFECTIOUS DISEASES;PEDIATRIC","1;1;1;1;1","INFECTION","1","5.1 PHARMACEUTICALS;5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT);6.1 PHARMACEUTICALS;6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION)","1;1;1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_MODENA",2001,15,5.8,1.73333333333333,0.466666666666667,0.266666666666667,0.466666666666667,1.1304347826087,1,1,1,0.0666666666666667,1,6,1,4,4,0.4,0.07,0.27,0.27,27.27,0.596743645506116,NA,0.133333333333333,0.533333333333333,0.366,0.119,0.167,0.119,"I PICCAGLI;GIANNI NATALINI;GIOVANNI SANTACROCE;ALBERTO BAGNI;MARGHERITA GAVIOLI;LUCIA LONGO;OANA CALUSERIU;DANIELE CAMPIOLI;CLAUDIO RUGGIERO;ELISABETTA BERTELLINI;F LEYNADIER;MARA FORASARIG;ELENA RIGHI;EMILIO IANNITTO;T ARTUSI;STEFANIA CARRARA;ALBERTO BARBIERI;GORETTA BONACORSI;DESIDERIO PASSÀLI;MAURIZIO GENUARDI","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GIULIANO FRANCO;GIOVANNI FRANCO;BICCHI CARLO;I PICCAGLI;GIANNI NATALINI;GIOVANNI SANTACROCE;ALBERTO BAGNI;MARGHERITA GAVIOLI;ELISABETTA BERTELLINI;FABIO GAZZOTTI;AHMAD EL TASSI;DESIDERIO PASSÀLI;V. OLDANI;AURELIO SCOTTI;PIETRO AVETA;ROSARIO ROSSI;MARIA GRAZIA MODENA;ALBERTO MENOZZI;RUGGERO BALLI;LUCIA LONGO","1;0.5;0.5;0.4;0.4;0.4;0.4;0.4;0.33;0.33;0.33;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.2","GIANNI NATALINI;ALBERTO BAGNI;MARGHERITA GAVIOLI;DANIELE CAMPIOLI;ROBERTO RONCAGLIA;E BALDINI;GIULIANO FRANCO;ALBERTO GIANNETTI;F. BOSELLI;LAURE FIORENTINO;FABIO GAZZOTTI;MARIA MARIANO;ANTONIO PERCESEPE;PIETRO AVETA;BICCHI CARLO;ANNA CARBONIERI;ROSARIO ROSSI;MONICA PEDRONI;MARIA GRAZIA MODENA;ALBERTO MENOZZI","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GIULIANO FRANCO;BICCHI CARLO;GIANNI NATALINI;ALBERTO BAGNI;MARGHERITA GAVIOLI;FABIO GAZZOTTI;PIETRO AVETA;ROSARIO ROSSI;MARIA GRAZIA MODENA;ALBERTO MENOZZI;RUGGERO BALLI;ALBERTO GIANNETTI;FRANCESCO RIVASI;F. BOSELLI;ROBERTO RONCAGLIA;LAURE FIORENTINO;DANIELE CAMPIOLI;E BALDINI;MARIA MARIANO;ANNA CARBONIERI","1;0.5;0.4;0.4;0.4;0.33;0.25;0.25;0.25;0.25;0.25;0.2;0.2;0.17;0.14;0.12;0.11;0.11;0.11;0.11","ALBERTO MENOZZI;MARIA GRAZIA MODENA;PIETRO AVETA;ROSARIO ROSSI;ANNA CARBONIERI;ANTONELLO PIETRANGELO;CINZIA GARUTI;DANIELE CAMPIOLI;E BALDINI;ELISA PIGNATTI;GIULIANA MONTOSI;MARIA MARIANO;STEFANO CASSANELLI;F. BOSELLI;G. OCTO BARNETT;HANS CHRISTIAN WULF;IRINA CAIRO;MALCOLM J PRICE;R PATEL;CHIARA BROGLIA","97;97;97;97;68;68;68;68;68;68;68;68;68;60;60;60;60;60;60;52","ALBERTO MENOZZI;MARIA GRAZIA MODENA;PIETRO AVETA;ROSARIO ROSSI;ANNA CARBONIERI;DANIELE CAMPIOLI;E BALDINI;MARIA MARIANO;F. BOSELLI;MASSIMO FEDERICO;ROBERTO RONCAGLIA;ANTONIO PERCESEPE;MONICA PEDRONI;FRANCESCO RIVASI;LAURE FIORENTINO;ALBERTO BAGNI;GIANNI NATALINI;MARGHERITA GAVIOLI;RUGGERO BALLI;FABIO GAZZOTTI","97;97;97;97;68;68;68;68;60;52;42;27;27;25;11;10;10;10;8;6","ALBERTO BAGNI;GIANNI NATALINI;MARGHERITA GAVIOLI;ALBERTO GIANNETTI;ALBERTO MENOZZI;ANNA CARBONIERI;ANTONIO PERCESEPE;DANIELE CAMPIOLI;E BALDINI;F. BOSELLI;FABIO GAZZOTTI;FRANCESCO RIVASI;GIULIANO FRANCO;LAURE FIORENTINO;MARIA GRAZIA MODENA;MARIA MARIANO;MASSIMO FEDERICO;MONICA PEDRONI;PIETRO AVETA;ROBERTO RONCAGLIA","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;ECONOMICS;CHEMISTRY;COMPUTER SCIENCE;PHILOSOPHY;PSYCHOLOGY;ART;BUSINESS;GEOGRAPHY;HISTORY;MATHEMATICS;POLITICAL SCIENCE","15;5;3;2;2;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;PATHOLOGY;ANESTHESIA;ENVIRONMENTAL HEALTH;GENETICS;IMMUNOLOGY;NURSING;BIOCHEMISTRY;ECONOMIC GROWTH;EPISTEMOLOGY;GASTROENTEROLOGY;PHARMACOLOGY;RADIOLOGY;ANATOMY;ARCHAEOLOGY;CANCER RESEARCH;CARDIOLOGY;CARTOGRAPHY;ENDOCRINOLOGY;FAMILY MEDICINE;HUMANITIES;INTENSIVE CARE MEDICINE;KNOWLEDGE MANAGEMENT;MACROECONOMICS;MANAGEMENT;MARKETING;MEDICAL EDUCATION;ONCOLOGY;OPERATING SYSTEM;PALEONTOLOGY;PEDAGOGY;PEDIATRICS;PROGRAMMING LANGUAGE;PUBLIC RELATIONS;STATISTICS;SURGERY;TOXICOLOGY","8;7;3;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;LYMPHATIC SYSTEM;LYMPHOMA;POPULATION;ALTERNATIVE MEDICINE;CHEMOTHERAPY;GENE;HEALTH CARE;LYMPH;LYMPH NODE;QUALITY (PHILOSOPHY);RECTAL ADMINISTRATION;RECTUM;SUBMUCOSA;ADVERSE EFFECT;ALDOSTERONE;ANALGESIC;ANTIBODY;BIOPSY;BLOOD PRESSURE;BUPIVACAINE;CONFOUNDING;CONNECTIVE TISSUE;CROSS-SECTIONAL STUDY;CURRICULUM;DISEASE;DOCUMENTATION;DRUG;ENZYME;FERRITIN;FORMATIVE ASSESSMENT;HARROW;HEMOCHROMATOSIS;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;IN VITRO;ISOFLURANE;LIPOMA;LOCAL ANAESTHETIC;LYMPHOCYTE;MYOCARDIAL INFARCTION;NIMESULIDE;OCCUPATIONAL SAFETY AND HEALTH;ORTHOPEDIC SURGERY;PROCESS (COMPUTING);PRODUCTIVITY;PROPORTIONAL HAZARDS MODEL;PSYCHOLOGICAL INTERVENTION;QUALITY OF LIFE (HEALTHCARE);RANDOMIZED CONTROLLED TRIAL;RATIONALIZATION (ECONOMICS);REFERRAL;REGIONAL ANAESTHESIA;ROPIVACAINE;SAMPLE SIZE DETERMINATION;SCIENTIFIC EVIDENCE;SERVICE (BUSINESS);SEX ORGAN;STAGE (STRATIGRAPHY);ULTRASOUND;VIRUS;VISUAL ANALOGUE SCALE","3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MALT LYMPHOMA;ALLELE;MUTATION;ANGIOTENSIN-CONVERTING ENZYME;B CELL;CD5;CD8;CERVIX;COLORECTAL CANCER;CYCLOOXYGENASE;CYTOTOXIC T CELL;DIAPHYSIS;EVIDENCE-BASED MEDICINE;EVIDENCE-BASED PRACTICE;GENOTYPE;HEREDITARY HEMOCHROMATOSIS;HERPES SIMPLEX VIRUS;IMMUNE STATUS;INFARCTION;LEVOBUPIVACAINE;OCCUPATIONAL MEDICINE;PLACEBO;RENIN–ANGIOTENSIN SYSTEM;SERUM FERRITIN;SYPHILIS;T CELL;TOLERABILITY;WORK PRODUCTIVITY","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CD3;COMPOUND HETEROZYGOSITY;DNA MISMATCH REPAIR;FRAMESHIFT MUTATION;GENITAL HERPES;GENOTYPING;GERMINAL CENTER;GERMLINE MUTATION;LOSS OF HETEROZYGOSITY;LYMPHOCYTE SUBSETS;MICROSATELLITE;MUCOSA-ASSOCIATED LYMPHOID TISSUE;NATURAL KILLER CELL;PROBAND;SEXUALLY TRANSMITTED DISEASE;TRANSFERRIN SATURATION","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;LYMPHOMA, B-CELL, MARGINAL ZONE;MALE;MIDDLE AGED;FEMALE;RECTAL NEOPLASMS;ADULT;OCCUPATIONAL MEDICINE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;RIBS;UTERINE CERVICAL NEOPLASMS;;BONE NEOPLASMS;COLLAGEN;COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS;HERPES GENITALIS;HYPERTROPHY, LEFT VENTRICULAR;IMMUNE SYSTEM;LIPOMA;PERIOSTEUM","11;8;8;8;7;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3","LYMPHOID NEOPLASMS;MEDICAL EQUIPMENT MAINTENANCE AND MANAGEMENT;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER;GRANULAR CELL TUMOR: CLINICAL AND PATHOLOGICAL CHARACTERISTICS;HERPESVIRUSES: EPIDEMIOLOGY, PATHOGENESIS, AND MANAGEMENT;IMPACT OF PHARMACEUTICAL INDUSTRY SPONSORSHIP ON RESEARCH;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;MOLECULAR MECHANISMS OF CARDIAC REMODELING AND REPAIR;NEUROTOXIC EFFECTS OF ANESTHETIC AGENTS ON BRAIN DEVELOPMENT;REGULATION OF IRON METABOLISM AND ANEMIA","4;2;1;1;1;1;1;1;1;1;1","CLINICAL ENGINEERING;RECTAL ADMINISTRATION;SUBMUCOSA;BARRETT'S ESOPHAGUS;CARDIAC REMODELING;CD16;CD5;COMPOUND HETEROZYGOSITY;CROSS-SECTIONAL STUDY;DIAPHYSIS;DNA MISMATCH REPAIR;EVIDENCE-BASED MEDICINE;EVIDENCE-BASED PRACTICE;FDG-PET/CT IMAGING;GENERAL ANESTHETICS;HARROW;HEMOCHROMATOSIS;HEREDITARY HEMOCHROMATOSIS;HIV INTERACTION;IMMUNE STATUS","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ENDORECTAL SONOGRAPHIC;LOCAL RECURRENCE;MALT LYMPHOMA;RECTAL MALT;SONOGRAPHIC APPEARANCES;ACUTE OTITIS;ADULT POPULATION;ADVANCED HODGKIN;ALDOSTERONE INHIBITION;ANAESTHETIC GASES;ANAESTHETICS BUPIVACAINE;ANTERIOR MYOCARDIAL;ATYPICAL HEREDITARY;AUTHORS REPLY;BIOCHEMICAL EXPRESSION;CHRONIC EXPOSURE;COLLAGEN SYNTHESIS;COLORECTAL CANCER;COMMON ENDOCERVICAL;CONTROLLED DOUBLE-BLIND;CYHD HEMOCHROMATOSIS;DOUBLE-BLIND RANDOMIZED;EFFICACY EVIDENCE;ENDOCERVICAL POLYP;GENE MSH;GENE MUTATIONS;GENITAL HERPES;HEALTHY ADULT;HEMOCHROMATOSIS HFE;HEREDITARY NONPOLYPOSIS","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HODGKIN DISEASE;ADVANCED HD;ADVANCED STAGE;AMERICAN CANCER;ANALYZED UNIVARIATELY;CANCER AMERICAN;CANCER CENTER;CANCER SOCIETY;CLINICAL DATA;CLINICAL OUTCOME;DATA INTEGRATION;DISCRIMINATORY CAPACITY;DISEASE HD;DRAMATICALLY IMPROVED;FACTOR PROJECT;FAILURE RISK;FAILURE RISKS;FREE SURVIVAL;HAZARDS MODEL;HTTPWWWUNIMOITGISLDEFAULTHTM CANCER;IDENTIFYING PATIENTS;INDIVIDUAL DISCRIMINATORY;INDIVIDUAL PERFORMANCES;INTEGRATED INDEX;INTERNATIONAL DATABASE;INTERNATIONAL PROGNOSTIC;JOINT PERFORMANCES;LINEAR MODEL;MEMORIAL SLOAN-KETTERING;MODEL DRAMATICALLY","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",1,0.07,6,3,0,0,0,0,0,0,1,3,0,0,0,0,2,0,0,0,0,0,0,19,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,14,2899.5,8.7,1,0.5,175,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,1,1,0,2,0,0,0,0,0,0,0,0,0,"Belgium;Canada;Italy","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","2;2;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;BREAST CANCER;ORPHAN DRUG;RARE DISEASES;UROLOGIC DISEASES","2;2;2;2;1;1;1;1","CANCER","2","6.1 PHARMACEUTICALS","2","BLADDER CANCER;BREAST CANCER","1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_MODENA",2002,27,6.59259259259259,2.55555555555556,0.666666666666667,0.444444444444444,0.703703703703704,1.078125,0.947368421052632,0.923076923076923,0.95,0.185185185185185,0,12,5,5,3,0.44,0.19,0.19,0.11,42.07,0.762643782682984,NA,0.222222222222222,0.555555555555556,0.303,0.157,0.198,0.154,"GIULIO ROSSI;ANTONINO MAIORANA;DANIELA TURCHETTI;FABRIZIO FERRARI;ANDREA LETI ACCIARO;MASSIMO FEDERICO;ANGELO CAGNACCI;LAURA CORTESI;GABRIELE LUPPI;ANTONIO LANDI;ALBERTO FRANCHI;FRANCESCO BARCA;GIAN LUCA GRAZI;DORELLA BRICALLI;G NATALINI;LUCIA STIPO;M AMADORI;F MASCIA;SARA COLZANI;MARIO LUPPI","3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","ANDREA LETI ACCIARO;ANTONINO MAIORANA;GIULIO ROSSI;ANTONIO LANDI;ANNA MARIA CESINARO;SUSANNA GENEDANI;ROSARIA DI LORENZO;FRANCESCO BARCA;VINCENZO ARIGLIANO;T ARTUSI;A. MARCUZZI;G. PALMIERI;GIAN MARIA GALEAZZI;MARCO RIGATELLI;VINCENZO SPINA;L PICCININI;FABRIZIO FERRARI;DANIELA TURCHETTI;MASSIMO FEDERICO;LAURA CORTESI","0.67;0.61;0.61;0.58;0.5;0.5;0.5;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.32;0.31;0.31;0.31","GIULIO ROSSI;DANIELA TURCHETTI;FABRIZIO FERRARI;ANDREA LETI ACCIARO;MASSIMO FEDERICO;ANGELO CAGNACCI;GABRIELE LUPPI;ANTONIO LANDI;ALBERTO FRANCHI;LUCIA STIPO;M AMADORI;F MASCIA;SARA COLZANI;ANNA MARIA CESINARO;FRANCESCA ZANELLI;STEFANIA CORRADO;CESARE CARANI;GIAN MARIA CAVALLINI;PAOLO MOLINARI;MICOL PIFFERI","3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","ANDREA LETI ACCIARO;GIULIO ROSSI;ANTONIO LANDI;ANNA MARIA CESINARO;ROSARIA DI LORENZO;A. MARCUZZI;G. PALMIERI;GIAN MARIA GALEAZZI;MARCO RIGATELLI;L PICCININI;FABRIZIO FERRARI;DANIELA TURCHETTI;MASSIMO FEDERICO;ANGELO CAGNACCI;GABRIELE LUPPI;NORMAN DELLA ROSA;F. BOSELLI;G. CASERTA;RICCARDO VALLI;PIETRO TORRICELLI","0.67;0.61;0.58;0.5;0.5;0.33;0.33;0.33;0.33;0.33;0.32;0.31;0.31;0.29;0.27;0.25;0.25;0.25;0.25;0.25","FABRIZIO FERRARI;ANDREA RANZI;AREND F. BOS;CHRISTA EINSPIELER;GIOVANNI CIONI;H.F.R. PRECHTL;MARIA FEDERICA ROVERSI;PAOLA B. PAOLICELLI;A ALBERTAZZI;ANNAMARIA MANICONE;B REDAELLI;CARLO DELLA ROCCA;CESARE CARANI;EMMANUELE A. JANNINI;F MASCIA;FRANCESCO LOCATELLI;GIOVANNI SPERA;LEONARDO LUCCHI;LUCIA STIPO;LUCIO GNESSI","304;237;237;237;237;237;237;237;103;103;103;103;103;103;103;103;103;103;103;103","FABRIZIO FERRARI;A ALBERTAZZI;B REDAELLI;CESARE CARANI;F MASCIA;FRANCESCO LOCATELLI;LEONARDO LUCCHI;LUCIA STIPO;MARIA CARLA BIGI;MONICA CREPALDI;SARA COLZANI;SIMEONE ANDRULLI;ANDREA LETI ACCIARO;GIUSEPPE TORELLI;ROSA MARIA IEMMOLO;ANTONIO LANDI;CRISTINA MUSSINI;A. MARCUZZI;ALBERTO BERARDI;FRANCESCA CAVALLERI","304;103;103;103;103;103;103;103;103;103;103;103;100;97;95;91;80;73;67;67","ANDREA LETI ACCIARO;ANGELO CAGNACCI;ANTONIO LANDI;FABRIZIO FERRARI;GABRIELE LUPPI;A ALBERTAZZI;A FALCHI;A. MARCUZZI;A. VENTURI;ADRIANA LOMBARDI;ALBERTO BERARDI;ALBERTO FRANCHI;ALESSANDRA FORTUNA;ANNA CARBONIERI;ANNA MARIA CESINARO;ANTONIO DI STASI;B REDAELLI;CESARE CARANI;CRISTINA MUSSINI;DANIELA TURCHETTI","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY","25;8;2;2;2;1;1;1;1","INTERNAL MEDICINE;PATHOLOGY;IMMUNOLOGY;SURGERY;RADIOLOGY;BIOCHEMISTRY;GENETICS;ONCOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;PSYCHIATRY;ANESTHESIA;CANCER RESEARCH;ENVIRONMENTAL HEALTH;GYNECOLOGY;MOLECULAR BIOLOGY;OPTICS;PALEONTOLOGY;PHYSICAL MEDICINE AND REHABILITATION;VIROLOGY","17;10;7;6;5;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2","CANCER;VIRUS;DISEASE;GENE;IMMUNOHISTOCHEMISTRY;ANXIETY;CARCINOMA;CLINICAL HISTORY;INCIDENCE (GEOMETRY);MAGNETIC RESONANCE IMAGING;MOOD;OSTEOID OSTEOMA;OSTEOMA;POPULATION;RANDOMIZED CONTROLLED TRIAL;REGIMEN;TOXICITY;TRANSPLANTATION;ABLATION;ALTERNATIVE MEDICINE;AMINO ACID;ANKLE;APOPTOSIS;BIOPSY;BLOOD PRESSURE;BLOOD VOLUME;BODY MASS INDEX;BODY WEIGHT;BONE MARROW;BONE SCINTIGRAPHY;BRAINSTEM;CATARACT SURGERY;CEREBRAL PALSY;CHEMOTHERAPY;CLINICAL DIAGNOSIS;CONFIDENCE INTERVAL;CORONARY ARTERY DISEASE;CYTOKINE;DERMATOFIBROSARCOMA PROTUBERANS;DIALYSIS;EMBOLIZATION;EPIDEMIOLOGY;FLOW CYTOMETRY;GALLBLADDER;GALLSTONES;GENETIC COUNSELING;GENETIC TESTING;GUIDELINE;HEMODIALYSIS;HEPATITIS;HEPATITIS C;HEPATOCELLULAR CARCINOMA;HEPATOLOGY;IMMUNE SYSTEM;IN VITRO;INFLAMMATION;INSULIN;LESION;LIAISON PSYCHIATRY;LIDOCAINE;LOCAL ANESTHETIC;LYMPHOMA;MEDLINE;MEMBRANE;META-ANALYSIS;MITOCHONDRION;MYELOID LEUKEMIA;MYOCARDIAL INFARCTION;NAUSEA;NEOPLASM;NEUROLOGICAL EXAMINATION;NODAL;NODULE (GEOLOGY);OBESITY;ODDS RATIO;OSTEOID;OUTCOME (GAME THEORY);OVARY;PERCUTANEOUS;PHYSICAL EXAMINATION;PREGNANCY;PROSPECTIVE COHORT STUDY;PSYCHOLOGICAL INTERVENTION;PSYCHOSOMATIC MEDICINE;RADIATION THERAPY;RECEPTOR;REFERRAL;REHABILITATION;RETROSPECTIVE COHORT STUDY;ROPIVACAINE;SARCOMA;SCHIZOPHRENIA (OBJECT-ORIENTED PROGRAMMING);SPINAL CORD;STAGE (STRATIGRAPHY);STEM CELL;STROMAL CELL;TABLE (DATABASE);TESTOSTERONE (PATCH);TOPICAL ANESTHESIA;TRANSDERMAL;TUMOR NECROSIS FACTOR ALPHA;VERRUCA VULGARIS;VISUAL ANALOGUE SCALE;VOMITING;WRIST","7;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;COLORECTAL CANCER;ADENOCARCINOMA;ANTIPSYCHOTIC;BIOELECTRICAL IMPEDANCE ANALYSIS;BIPOLAR DISORDER;BLAST CRISIS;C-REACTIVE PROTEIN;CANCER REGISTRY;CD30;CD34;CHEMORADIOTHERAPY;CHROMOGRANIN A;CLOZAPINE;CYTOPENIA;DIASTOLE;DIFFUSION MRI;EFFECTIVE DIFFUSION COEFFICIENT;ESOPHAGEAL CANCER;FLUOROURACIL;GROWTH FACTOR;HEART RATE;HEPATITIS C VIRUS;HORMONE REPLACEMENT THERAPY (FEMALE-TO-MALE);HUMAN CYTOMEGALOVIRUS;HYPERINTENSITY;INNER MITOCHONDRIAL MEMBRANE;INTRAVASCULAR VOLUME STATUS;LEAN BODY MASS;LEPTIN;LEUCINE;LIVER BIOPSY;LIVER TRANSPLANTATION;MITOCHONDRIAL DNA;MOOD DISORDERS;MUTATION;OBSTETRICS AND GYNAECOLOGY;OLANZAPINE;PANCYTOPENIA;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PHOSPHOLIPID;PLACEBO;POLYMERASE CHAIN REACTION;QUETIAPINE;RADIOFREQUENCY ABLATION;RISPERIDONE;S100 PROTEIN;SCOPUS;SMALL-CELL CARCINOMA;SPINAL CORD INJURY;T CELL;TOPICAL ANESTHETIC;TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION;VIMENTIN;VIRAL DISEASE;VIRAL LOAD;VIREMIA;WHITE MATTER;WRIST PAIN","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FOLINIC ACID;ANTIRETROVIRAL THERAPY;ATYPICAL ANTIPSYCHOTIC;CARDIOLIPIN;DESMIN;FIBROADENOMA;GANCICLOVIR;HEMOPHAGOCYTOSIS;HERPESVIRIDAE;INTERNAL CAPSULE;MAMMOGRAPHY;MANIA;MAPLE SYRUP URINE DISEASE;MASTECTOMY;OXALIPLATIN;PERCUTANEOUS ETHANOL INJECTION;PLATELET-DERIVED GROWTH FACTOR RECEPTOR;TETRAPLEGIA;ZIPRASIDONE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;BREAST NEOPLASMS;ADULT;AGED;BONE NEOPLASMS;OSTEOMA, OSTEOID;COLORECTAL NEOPLASMS;DERMATOFIBROSARCOMA;FLUOROURACIL;GALLBLADDER NEOPLASMS;LEUCOVORIN;ACQUIRED IMMUNODEFICIENCY SYNDROME;ADOLESCENT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BERYLLIOSIS;CEREBRAL PALSY;ESTRADIOL","25;19;14;14;12;10;7;7;7;5;5;5;5;5;4;4;4;4;4;4","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;CHOLANGIOCARCINOMA;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;CLINICAL CHARACTERISTICS AND MANAGEMENT OF SARCOIDOSIS;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF BIPOLAR DISORDER;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;HEPATITIS C INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;IMPACT OF MATERNAL MENTAL HEALTH ON OFFSPRING;INFLAMMATION AND OBESITY-RELATED METABOLIC DISORDERS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;METABOLIC DISORDERS AND BIOCHEMICAL GENETICS;MOLECULAR MECHANISMS OF KIDNEY DEVELOPMENT AND DISEASE;NEONATAL BRAIN INJURY AND DEVELOPMENTAL CONSEQUENCES;NEUROENDOCRINE REGULATION OF APPETITE AND BODY WEIGHT","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CANCER RISK;CANCER SUSCEPTIBILITY;CLINICAL HISTORY;FOLINIC ACID;METASTATIC COLORECTAL CANCER;OSTEOID OSTEOMA;OSTEOMA;REGIMEN;TREATMENT;BIOELECTRICAL IMPEDANCE ANALYSIS;BIOMECHANICAL EVALUATION;BIPOLAR DISORDER;BLAST CRISIS;BONE SCINTIGRAPHY;BRCA1;BREAST CANCER SCREENING;C-REACTIVE PROTEIN;CANCER INCIDENCE;CD30+ LYMPHOPROLIFERATIVE DISORDERS","2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CELL CARCINOMA;COLORECTAL CANCER;OSTEOID OSTEOMA;POSTMENOPAUSAL WOMEN;ACTIVE ANTIRETROVIRAL;ADVANCED COLORECTAL;ALCOHOL ADMINISTRATION;ANTIRETROVIRAL THERAPYRELATED;ATYPICAL ANTIPSYCHOTICS;BERYLLIUM-STIMULATED PERIPHERAL;BIPOLAR DISORDERS;BLAST CRISIS;BLOOD MONONUCLEAR;BLOOD VOLUME;C-REACTIVE PROTEIN;CANCER INCIDENCE;CARCINOMA COMPARISON;CATARACT SURGERY;CD-POSITIVE LYMPHOID;CEREBRAL PALSY;CHRONIC MYELOID;CLINICAL CENTERS;CONSULTATION-LIAISON PSYCHIATRY;CRAMPED SYNCHRONIZED;DERMATOFIBROSARCOMA PROTUBERANS;DIFFUSION-WEIGHTED MRI;DISEASE ENCEPHALOPATHY;DISORDERS EFFICACY;DNA CONTENT","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BIOPSY SPECIMENS;ACUTE HEPATITIS;CHRONIC HEPATITIS;HEPATOCELLULAR APOPTOSIS;HUMAN LEUCOCYTE;IL- IL-;MONONUCLEAR CELLS;PDGF SYSTEM;TUMOUR NECROSIS;BERYLLIOSIS RISK;BESOSUBSUB-STIMULATED BLOOD;BLOOD MONONUCLEAR;CHAIN REACTION;CONTROL SUBJECTS;FRESH PBL;GERM CELLS;HCV ANTIGENS;HCV-INFECTED HEPATOCYTES;HEALTHY CONTROL;IMMUNOHISTOCHEMICAL LOCALIZATION;KAPOSI SARCOMA;LYMPHOCYTES PBL;MT FUNCTIONALITY;MTDNA CONTENT;PERIPHERAL CYTOPENIA;POLYMERASE CHAIN;SEVERE PERIPHERAL;SPECIMENS OBTAINED;T-CELL ACTIVATION;TRANSPLANT RECIPIENTS","4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",2,0.07,0.81,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,10.5,10.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,10,472,1.59,0,0,57,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"Belgium","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;ORPHAN DRUG;RARE DISEASES","1;1;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS","1","LEUKEMIA / LEUKAEMIA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_MODENA",2003,37,6.62162162162162,2.32432432432432,0.702702702702703,0.378378378378378,0.702702702702703,1.38709677419355,1.44444444444444,1.27272727272727,1.44444444444444,0.405405405405405,4,21,3,6,4,0.57,0.08,0.16,0.11,30.59,0.578042839487137,NA,0.0810810810810811,0.486486486486487,0.538,0.339,0.363,0.339,"ANGELO CAGNACCI;ANNIBALE VOLPE;SERENELLA ARANGINO;GIULIANA GALASSI;FRANCESCO VINCENZO M. BALDASSARI;ANNARITA PECCHI;MARCELLO BERTESI;CARMELINA RODINÒ;RENATO ROMAGNOLI;ALBERTO BARBIERI;CHIARA ALESSANDRINI;FABIO FACCHINETTI;ANDREA SCHIAVONE;ANTONELLO PIETRANGELO;GIANCARLO BISAGNI;SCARONE PC;R SUOZZI;GABRIELE LUPPI;FRANCESCO FIORICA;PIETRO TORRICELLI","8;7;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANGELO CAGNACCI;ANTONELLO PIETRANGELO;ANNIBALE VOLPE;GIULIANA GALASSI;SERENELLA ARANGINO;R SUOZZI;ALBERTO BARBIERI;ALESSANDRA ARIATTI;FRANCESCO VINCENZO M. BALDASSARI;ANNA LISA ZANNI;PIETRO TORRICELLI;ANNARITA PECCHI;RENATO ROMAGNOLI;FABIO FACCHINETTI;GABRIELE LUPPI;CHIARA ALESSANDRINI;ANDREA SCHIAVONE;SCARONE PC;GIUSEPPE TASSONE;ROBERTO FERRONE","3.24;2;1.44;1.25;0.77;0.67;0.58;0.58;0.57;0.53;0.5;0.42;0.42;0.39;0.38;0.37;0.37;0.37;0.33;0.33","ANGELO CAGNACCI;ANNIBALE VOLPE;SERENELLA ARANGINO;GIULIANA GALASSI;FRANCESCO VINCENZO M. BALDASSARI;ANNARITA PECCHI;ALBERTO BARBIERI;CHIARA ALESSANDRINI;FABIO FACCHINETTI;ANDREA SCHIAVONE;ANTONELLO PIETRANGELO;R SUOZZI;GABRIELE LUPPI;FRANCESCO FIORICA;ANNA LISA ZANNI;L SIMONI;ALESSANDRA ARIATTI;ROBERTO SABBATINI;ANTONINO MAIORANA;FRANCESCA ZANELLI","8;7;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","ANGELO CAGNACCI;ANTONELLO PIETRANGELO;ANNIBALE VOLPE;GIULIANA GALASSI;SERENELLA ARANGINO;R SUOZZI;ALBERTO BARBIERI;ALESSANDRA ARIATTI;FRANCESCO VINCENZO M. BALDASSARI;ANNA LISA ZANNI;ANNARITA PECCHI;FABIO FACCHINETTI;GABRIELE LUPPI;CHIARA ALESSANDRINI;ANDREA SCHIAVONE;GIUSEPPE TASSONE;ROBERTO FERRONE;GIANNI NATALINI;MARÍA EUGENIA LEONE;PIER CARLO SCARONE","3.24;2;1.44;1.25;0.77;0.67;0.58;0.58;0.57;0.53;0.42;0.39;0.38;0.37;0.37;0.33;0.33;0.33;0.33;0.33","ANGELO CAGNACCI;ANNIBALE VOLPE;SERENELLA ARANGINO;FRANCESCO VINCENZO M. BALDASSARI;CARMELINA RODINÒ;GIANCARLO BISAGNI;GIOVANNI RIVOLTA;ANNARITA PECCHI;RENATO ROMAGNOLI;PIETRO TORRICELLI;ALBERTO ROSA BIAN;ANGELO SIDONI;ANNA MARIA MOSCONI;BRUNO MAZZOCCHI;E BUCCIARELLI;GUIDO BELLEZZA;LORENZA PISTOLA;MARIANTONIETTA COLOZZA;MAURIZIO TONATO;ROBERTA CHERUBINI","393;303;194;182;159;159;131;128;128;95;93;93;93;93;93;93;93;93;93;93","ANGELO CAGNACCI;ANNIBALE VOLPE;SERENELLA ARANGINO;ROBERTO SABBATINI;GABRIELE LUPPI;A RENZI;MASSIMO FEDERICO;S. ZIRONI;MASSIMO GIRARDIS;L SIMONI;ANNARITA PECCHI;GIANNI NATALINI;PIER CARLO SCARONE;ROBERTO FERRONE;CLODOVEO FERRI;ANDREA BEDINI;CRISTINA MUSSINI;MARIA CHIARA CERRI;NICOLA MONGIARDO;ROBERTO ESPOSITO","393;236;154;93;92;71;71;66;59;51;49;44;44;44;39;35;35;35;35;35","ANGELO CAGNACCI;ANNIBALE VOLPE;SERENELLA ARANGINO;ANDREA SCHIAVONE;ANNA LISA ZANNI;ANTONELLO PIETRANGELO;FRANCESCO FIORICA;GABRIELE LUPPI;L SIMONI;A FALCHI;A RENZI;ALBERTO FARINETTI;ALESSANDRO MARTELLA;ANDREA BEDINI;ANDREA LANDI;ANDREA LETI ACCIARO;ANNARITA PECCHI;ANTONELLA RENZI;ANTONINO MAIORANA;ANTONIO FRASSOLDATI","8;5;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;MATERIALS SCIENCE;PHYSICS;PSYCHOLOGY;SOCIOLOGY","35;7;3;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;ANESTHESIA;GASTROENTEROLOGY;GENETICS;ENDOCRINOLOGY;GYNECOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;ONCOLOGY;PSYCHIATRY;RADIOLOGY;BIOCHEMISTRY;PEDIATRICS;COMPUTATIONAL BIOLOGY;GENERAL SURGERY;OBSTETRICS;ORGANIC CHEMISTRY;PALEONTOLOGY","30;15;8;6;6;6;5;5;4;4;4;4;4;4;3;3;2;2;2;2;2","CANCER;POPULATION;CHEMOTHERAPY;WEAKNESS;ALTERNATIVE MEDICINE;BIOPSY;CONFIDENCE INTERVAL;DISEASE;LAPAROTOMY;RANDOMIZED CONTROLLED TRIAL;ABDOMEN;ABDOMINAL PAIN;ABDOMINAL SURGERY;ANTIBODY;ATROPHY;BLOOD PRESSURE;CONTEXT (ARCHAEOLOGY);CRANIAL NERVES;FERRITIN;FUNCTION (BIOLOGY);GUILLAIN-BARRE SYNDROME;HORMONE;IMMUNOHISTOCHEMISTRY;IN VITRO;LESION;ODDS RATIO;OSTEOPOROSIS;PARESIS;PREGNANCY;RADIATION THERAPY;REGIMEN;THROMBOSIS;TRANSFERRIN;UPPER LIMB","10;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;COLORECTAL CANCER;PLACEBO;BONE MINERAL;CYCLOPHOSPHAMIDE;POLYRADICULONEUROPATHY;RESEARCH METHODOLOGY;TRANSFERRIN RECEPTOR;ABDOMINAL TRAUMA;ABORTION;ADJUVANT THERAPY;AMBULATORY BLOOD PRESSURE;AMYOTROPHIC LATERAL SCLEROSIS;ANDROGEN;AUTOANTIBODY;AUTOIMMUNE DISEASE;AUTOIMMUNITY;BLOT;C-PEPTIDE;CALCINOSIS;CD34;CERVIX;CHOLECYSTITIS;CISPLATIN;CLINICAL ENDPOINT;CORONARY ARTERY CALCIUM;CORONARY ATHEROSCLEROSIS;CYANOCOBALAMIN;DOXORUBICIN;DYDROGESTERONE;DYNAMIC CONTRAST-ENHANCED MRI;ENDOTHELIAL STEM CELL;ETOPOSIDE;F WAVE;FLUOROURACIL;FOLLICULAR CYST;GALLBLADDER STONE;GESTATION;GRANULATION TISSUE;GRAVES' DISEASE;HEART RATE;HORMONE REPLACEMENT THERAPY (FEMALE-TO-MALE);HUMAN CYTOMEGALOVIRUS;HYPERHOMOCYSTEINEMIA;INGUINAL HERNIA;INSULIN RESISTANCE;INTERSTITIAL LUNG DISEASE;IRON-BINDING PROTEINS;LOG-RANK TEST;LUTEAL PHASE;MEDROXYPROGESTERONE ACETATE;MISCARRIAGE;MISMATCH NEGATIVITY;MITOXANTRONE;MOTOR NEURON;MUSCLE ATROPHY;MYOMA;NERVE CONDUCTION STUDY;NEURORADIOLOGY;NORETHISTERONE ACETATE;OVARIAN CYST;OXYGEN METABOLISM;PAIN MEDICINE;PERIPHERAL BLOOD MONONUCLEAR CELL;PERIPHERAL NEUROPATHY;PNEUMOCYSTIS JIROVECII;PROGESTIN;PROGRAMMED CELL DEATH;PROINFLAMMATORY CYTOKINE;PROLACTIN;PROTEIN S;PULMONARY FIBROSIS;RANDOMIZATION;SCLERODERMA (FUNGUS);SEPTIC SHOCK;SEX RATIO;SKIN BIOPSY;SODIUM NITROPRUSSIDE;SURGICAL MESH;T CELL;THROMBOPHILIA;THYROIDITIS;TIBOLONE;ULCERATIVE COLITIS;UNIVARIATE ANALYSIS;VASCULAR ENDOTHELIAL GROWTH FACTOR;VENOUS THROMBOSIS;VIRAL DISEASE;WARFARIN;WESTERN BLOT","5;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EPIRUBICIN;ESTROGEN RECEPTOR;FAMILY PLANNING;AUTOIMMUNE THYROIDITIS;CASPASE;CERVICAL CANAL;COLECTOMY;COLONOSCOPY;CYPROTERONE ACETATE;ETHINYLESTRADIOL;FACTOR V LEIDEN;FAS LIGAND;FAS RECEPTOR;GLUCOSE TOLERANCE TEST;HERPESVIRIDAE;IMPAIRED GLUCOSE TOLERANCE;LOWER MOTOR NEURON;LYMPHOPROLIFERATIVE RESPONSE;MAMMOGRAPHY;MULTIFOCAL MOTOR NEUROPATHY;NORETHISTERONE;OSTEOPENIA;PNEUMOCYSTIS CARINII;POLYCYSTIC OVARY;RECURRENT MISCARRIAGE;UPPER MOTOR NEURON","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;MIDDLE AGED;MALE;AGED;;OSTEOPOROSIS, POSTMENOPAUSAL;POSTMENOPAUSE;BREAST NEOPLASMS;POSTOPERATIVE COMPLICATIONS;RECTAL NEOPLASMS;TREATMENT OUTCOME;ENDOTHELIUM, VASCULAR;NORETHINDRONE;ADOLESCENT;AIDS-RELATED OPPORTUNISTIC INFECTIONS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BLOOD GLUCOSE;BLOOD PRESSURE","28;27;18;18;14;12;9;8;8;6;6;6;6;5;5;4;4;4;4;4","EFFECTS OF HORMONES ON MENOPAUSAL WOMEN'S HEALTH;GUILLAIN-BARRÉ SYNDROME AND RELATED NEUROPATHIES;REGULATION OF IRON METABOLISM AND ANEMIA;BIOMEDICAL OPTICAL IMAGING AND SPECTROSCOPY;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND PATHOGENESIS OF PNEUMOCYSTIS PNEUMONIA;GASTRIC CANCER RESEARCH AND TREATMENT;GENDER IMBALANCE IN EAST AND SOUTH ASIA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HERNIA REPAIR TECHNIQUES AND MATERIALS;LYMPHOID NEOPLASMS;MANAGEMENT OF SPINAL METASTATIC TUMORS;MANAGEMENT OF SPLEEN TRAUMA IN POLYTRAUMA PATIENTS;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION","3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ESTROGEN;PERIPHERAL NERVE IMAGING;CRANIAL NERVES;DESOGESTREL;EPIRUBICIN;NEOADJUVANT THERAPY;PARESIS;POLYRADICULONEUROPATHY;RALOXIFENE;REGIMEN;TRANSFERRIN RECEPTOR;TREATMENT;ADJUVANT THERAPY;ALIMENTARY TRACT;ANTICOAGULANT THERAPY;APOPTOTIC CELLS;ARRHYTHMIA DETECTION;AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME;AUTOIMMUNE THYROIDITIS;BLUNT TRAUMA","3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","ITALIAN PERIPHERAL;NERVE STUDY;PERIPHERAL NERVE;POSTMENOPAUSAL WOMEN;BLOOD PRESSURE;FRACTIONATED RADIOTHERAPY;POST-MENOPAUSAL WOMEN;RECTAL CANCER;ACTIVITY CHARACTERIZATION;ADJUVANT SYSTEMIC;ADVANCED GASTRIC;AMBULATORY BLOOD;ANDOR RECURRENT;ANTI-ENDOTHELIAL CELL;ANTICOAGULATION PRIOR;ARTERIAL CALCIFICATIONS;ARTERY CALCIFICATIONS;ASSISTED MINILAPAROTOMY;ATLANTA GEORGIA;AUTOIMMUNE THYROID;BILE DUCT;BLOOD PROGENITOR;BLOT ANALYSIS;BONE METASTASES;BONE MINERAL;BOWEL OBSTRUCTION;BREAST ARTERIAL;BREAST CANCER;BREAST CANCERAN;BS DEVELOPMENT","4;4;4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","IRON METABOLISM;IRON PROTEINS;TRANSFERRIN RECEPTOR;CONFIDENCE INTERVAL;IRON HOMEOSTASIS;IU DL;SEX RATIO;FAS FUNCTION;CELL BIOLOGY;CONTROL SUBJECTS;DL COMPARED;FVIIIC LEVELS;FVIIIC PLASMA;GENETICS BIOCHEMISTRY;INDIRECT IMMUNOFLUORESCENT;IRON PROTEIN;IRON TRAFFICKING;IRON-REGULATORY PROTEINS;ODDS RATIO;PHYSIOLOGICAL ASPECTS;PLASMA LEVELS;RISK FACTOR;VENOUS THROMBOEMBOLISM;BACTERIAL VAGINOSIS;BREAST CANCER;CANCER PATIENTS;EFS PROJECTIONS;GLUCOSE TOLERANCE;HDS CHEMOTHERAPY;INSULIN SENSITIVITY","18;8;8;7;6;6;6;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3",7,0.19,3,1,0,0,0,0,2.5,0,1,2,0,0,1,0,0,0,0,1,0,0,0,38,38,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,9.5,510,5.17,0,0,63.67,0,0,0,0,3,0,0,0,0,3,0,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"Japan","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES","3;2;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;HEMATOLOGY;LYMPHOMA;ORGAN TRANSPLANTATION;ORPHAN DRUG;TRANSPLANTATION","2;2;2;1;1;1;1;1;1",NA,NA,"6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","2;1","NON-HODGKIN'S LYMPHOMA","2",NA,NA,2,1632178,185307.53,4,8,5.5,1,4,95303.6045045045,0.388232955011174,"POLICLINICO DI MODENA;AIX-MARSEILLE UNIVERSITY;CENTRE ÎLE-DE-FRANCE - JOUY-EN-JOSAS - ANTONY;CONMED (FINLAND);DÜSSELDORF UNIVERSITY HOSPITAL;HERO ESPAÑA (SPAIN);HUMBOLDT-UNIVERSITÄT ZU BERLIN;KAROLINSKA INSTITUTET;MIDDLE EAST TECHNICAL UNIVERSITY;SKÅNE UNIVERSITY HOSPITAL;TAMPERE UNIVERSITY;TAMPERE UNIVERSITY HOSPITAL;UNIVERSITY COLLEGE CORK;UNIVERSITY OF GLASGOW;UNIVERSITY OF GRANADA","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME);CSC - COST-SHARING CONTRACTS (FUNDING SCHEME);DEM - DEMONSTRATION CONTRACTS (FUNDING SCHEME)","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3210 NUTRITION AND DIETETICS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","1;1;1;1","AGING;ARTHRITIS;AUTOIMMUNE DISEASE;BIOENGINEERING;CLINICAL RESEARCH;DIGESTIVE DISEASES;NUTRITION;OBESITY;PEDIATRIC;PREVENTION","1;1;1;1;1;1;1;1;1;1","INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;MUSCULOSKELETAL;ORAL AND GASTROINTESTINAL","1;1;1;1","3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;3.3 NUTRITION AND CHEMOPREVENTION;5.3 MEDICAL DEVICES","1;1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;B12 ENGINEERING","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_MODENA",2004,48,8.45833333333333,2.58333333333333,0.645833333333333,0.291666666666667,0.666666666666667,1.26530612244898,1.24,1.16666666666667,1.18518518518519,0.354166666666667,5,26,4,6,6,0.54,0.08,0.12,0.12,70.54,1.49917640939265,NA,0.25,0.708333333333333,0.469,0.285,0.25,0.277,"ANGELO CAGNACCI;ROSARIO ROSSI;MASSIMO FEDERICO;ANNIBALE VOLPE;MARIA GRAZIA MODENA;MICHELE MASETTI;PIETRO ROVERSI;ANDREA COSSARIZZA;ROBERTO ESPOSITO;GUY HÉDELIN;ANTONIO LA MARCA;LEONARDO M. FABBRI;MONICA PECORARI;PHILLIP RUIZ;LEONARDA TROIANO;LUCA RICHELDI;JOSETTE MACÉ-LESEC’H;NICOLA DE RUVO;FRANCESCA CAVALLERI;SIMONE GIULINI","5;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","ANGELO CAGNACCI;GUIDO LIGABUE;LANDI ANTONIO;R ROSSI;ROSARIO ROSSI;MARIA GRAZIA MODENA;ANDREA CELLI;ANNIBALE VOLPE;E NICOLI;ANDREA LETI ACCIARO;FRANCESCO BARCA;GIORGIA ORIGLIANI;ALBERTO PASETTO;LUIGI TARALLO;ROBERTO ADANI;PIETRO ROVERSI;GIOVANNI FRANCO;GEORGINA CORONA;ELVIRA TUCCILLO;ANTONIO LA MARCA","2.49;1.17;1;1;0.9;0.87;0.64;0.6;0.5;0.5;0.5;0.5;0.42;0.39;0.39;0.36;0.33;0.33;0.33;0.31","ANGELO CAGNACCI;ROSARIO ROSSI;MASSIMO FEDERICO;ANNIBALE VOLPE;MICHELE MASETTI;PIETRO ROVERSI;ROBERTO ESPOSITO;ANTONIO LA MARCA;LEONARDO M. FABBRI;MONICA PECORARI;LUCA RICHELDI;NICOLA DE RUVO;FRANCESCA CAVALLERI;SIMONE GIULINI;KATIE EWER;ALBERTO PASETTO;STEFANIA MALMUSI;AJIT LALVANI;LUIGI TARALLO;MONICA LOSI","5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","ANGELO CAGNACCI;GUIDO LIGABUE;LANDI ANTONIO;R ROSSI;ROSARIO ROSSI;ANDREA CELLI;ANNIBALE VOLPE;ANDREA LETI ACCIARO;GIORGIA ORIGLIANI;ALBERTO PASETTO;LUIGI TARALLO;ROBERTO ADANI;PIETRO ROVERSI;ELVIRA TUCCILLO;ANTONIO LA MARCA;MICHELE MASETTI;FRANCESCA CAVALLERI;SIMONE GIULINI;STEFANIA MALMUSI;RAOUL ORVIETO","2.49;1.17;1;1;0.9;0.64;0.6;0.5;0.5;0.42;0.39;0.39;0.36;0.33;0.31;0.31;0.31;0.31;0.31;0.31","ALESSANDRO LIBERATI;ANDREW D OXMAN;BOB PHILLIPS;DAVID C. ATKINS;DAVID HENRY;DIANNE L. O’CONNELL;GORDON GUYATT;GUNN ELISABETH VIST;HOLGER J. SCHÜNEMANN;JOHN W WILLIAMS;MARTIN ECCLES;SIGNE FLOTTORP;SUZANNE HILL;TESSA TAN-TORRES EDEJER;MASSIMO FEDERICO;ROSARIO ROSSI;PIETRO ROVERSI;ANTONELLA GROTTOLA;CALOGERO CAMMÀ;CHIARA VECCHI","1079;1079;1079;1079;1079;1079;1079;1079;1079;1079;1079;1079;1079;1079;430;362;302;252;252;252","ALESSANDRO LIBERATI;MASSIMO FEDERICO;CHIARA VECCHI;M. DE PALMA;ANNIBALE VOLPE;ANTONIO LA MARCA;RAOUL ORVIETO;SIMONE GIULINI;AJIT LALVANI;KATIE EWER;LEONARDO M. FABBRI;LUCA RICHELDI;MONICA LOSI;PIETRO ROVERSI;GIORGIA ORIGLIANI;ALBERTO BAGNI;STEFANIA MALMUSI;LEO FISCHER TAMARO;PAOLA LEVRATTI;CRISTINA MUSSINI","1079;430;252;252;236;215;215;215;212;212;212;212;212;212;200;198;196;187;187;158","ANGELO CAGNACCI;ANNIBALE VOLPE;MASSIMO FEDERICO;CRISTINA MUSSINI;A.D. PINNA;AJIT LALVANI;ANDREA CELLI;ANTONIO LA MARCA;GIORGIA ORIGLIANI;GUIDO LIGABUE;KATIE EWER;LEONARDO M. FABBRI;LUCA RICHELDI;LUIGI TARALLO;MICHELE MASETTI;MONICA LOSI;PIETRO ROVERSI;RAOUL ORVIETO;ROBERTO ADANI;ROBERTO ESPOSITO","4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;ECONOMICS;GEOGRAPHY;PHILOSOPHY","46;13;3;3;3;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;ENVIRONMENTAL HEALTH;PATHOLOGY;GENETICS;IMMUNOLOGY;ENDOCRINOLOGY;RADIOLOGY;ONCOLOGY;VIROLOGY;BIOCHEMISTRY;CARDIOLOGY;ECOLOGY;NURSING;PHARMACOLOGY;DEMOGRAPHY;GYNECOLOGY;INTENSIVE CARE MEDICINE;OBSTETRICS;OPTICS;PEDIATRICS","32;14;10;10;7;7;6;6;5;5;4;4;4;4;4;3;3;3;3;3;3","POPULATION;TRANSPLANTATION;CANCER;CONFIDENCE INTERVAL;HORMONE;MENOPAUSE;ALTERNATIVE MEDICINE;PREGNANCY;BLOOD PRESSURE;ESTROGEN;GRADING (ENGINEERING);HUMAN IMMUNODEFICIENCY VIRUS (HIV);INCIDENCE (GEOMETRY);VIRUS;CARCINOMA;CELL CULTURE;CHEMOTHERAPY;INFLAMMATION;INSULIN;LUNG;OBSERVATIONAL STUDY;PROSPECTIVE COHORT STUDY;QUALITY OF LIFE (HEALTHCARE);RADIOGRAPHY;RANDOMIZED CONTROLLED TRIAL;REPRODUCTION;TESTOSTERONE (PATCH);TRANSDERMAL;TUBERCULOSIS","8;6;5;5;5;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","VIRAL DISEASE;BREAST CANCER;CANCER REGISTRY;VIRAL LOAD;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BASAL (MEDICINE);C-REACTIVE PROTEIN;CHEMOTHERAPY REGIMEN;CYCLOPHOSPHAMIDE;EVIDENCE-BASED MEDICINE;HORMONE REPLACEMENT THERAPY (FEMALE-TO-MALE);MYCOBACTERIUM TUBERCULOSIS;OFFSPRING;PROGESTIN;QUARTILE;SEX RATIO;TUBERCULIN;ANAPHYLAXIS;ANATOMICAL PATHOLOGY;ANTI-MÜLLERIAN HORMONE;ARSENIC TRIOXIDE;BRACHIAL ARTERY;BRONCHOALVEOLAR LAVAGE;CD8;CELL CYCLE;CHOP;CIRCUMFLEX;COLORECTAL CANCER;CONTRAINDICATION;CORONARY ANGIOGRAPHY;CORONARY ARTERIES;CRITICAL APPRAISAL;DIASTOLE;DIFFUSION MRI;EFFECTIVE DIFFUSION COEFFICIENT;EPSTEIN–BARR VIRUS;FETUS;FIBULA;FIXATION (POPULATION GENETICS);FLEXIBLE BRONCHOSCOPY;GESTATION;HEALTH INFORMATICS;HEART RATE;INDUCTION CHEMOTHERAPY;INFERTILITY;INFLUENZA VACCINE;INFLUENZA-LIKE ILLNESS;INNER MITOCHONDRIAL MEMBRANE;INTESTINAL FAILURE;K562 CELLS;KIDNEY TRANSPLANTATION;LAMINA PROPRIA;LEFT VENTRICULAR HYPERTROPHY;LUTEINIZING HORMONE;LYMPHADENECTOMY;MANTLE CELL LYMPHOMA;MENSTRUAL CYCLE;METASTASIS;METHIONINE;MITOCHONDRIAL TOXICITY;MULTISLICE COMPUTED TOMOGRAPHY;MYELITIS;NEURORADIOLOGY;NOREPINEPHRINE;NORETHISTERONE ACETATE;OCCUPATIONAL MEDICINE;OVULATION;PENICILLIN;PLACEBO;POSITIVE END-EXPIRATORY PRESSURE;PROGRESSION-FREE SURVIVAL;PROTEASE;RADIAL HEAD;RADIATION ENTERITIS;RECORD LINKAGE;RELATIVE RISK;RENIN–ANGIOTENSIN SYSTEM;RESEARCH METHODOLOGY;RESPIRATORY DISEASE;RESPIRATORY TRACT;RESTENOSIS;RETINOIC ACID;RNA;SHORT BOWEL SYNDROME;SYRINGOMYELIA;T CELL;TELMISARTAN;THYROID CARCINOMA;TYPE 2 DIABETES;VARICELLA ZOSTER VIRUS;VENOUS THROMBOSIS;WEB SITE;WEIGHT GAIN","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIRETROVIRAL THERAPY;ELISPOT;RELATIVE SURVIVAL;SIDA;ACUTE PROMYELOCYTIC LEUKEMIA;ANTHRACYCLINE;BREAST CARCINOMA;BRONCHUS;CELL CYCLE CHECKPOINT;CORONARY STENT;CRYPTOCOCCAL MENINGITIS;DIASTOLIC FUNCTION;DNA MISMATCH REPAIR;DUCTAL CARCINOMA;FOLLICLE-STIMULATING HORMONE;HERPESVIRIDAE;HORMONE RECEPTOR;INTERNATIONAL PROGNOSTIC INDEX;LYMPHOVASCULAR INVASION;MEAN ARTERIAL PRESSURE;MEDULLARY CARCINOMA;NORETHISTERONE;OPPORTUNISTIC INFECTION;OVARIAN RESERVE;OVULATION INDUCTION;PANCREAS TRANSPLANTATION;PLASMA RENIN ACTIVITY;RADIAL HEAD FRACTURE;REVERSE TRANSCRIPTASE;RIGHT CORONARY ARTERY;TRETINOIN;TUBERCULOSIS DIAGNOSIS;VINCRISTINE;ZIDOVUDINE","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;MIDDLE AGED;MALE;AGED;TRANSPLANTATION, HOMOLOGOUS;TUBERCULOSIS, MULTIDRUG-RESISTANT;;ESTRADIOL;INTESTINE, SMALL;ITALY;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ADOLESCENT;BREAST NEOPLASMS;CROSS INFECTION;GRAFT REJECTION;PROSPECTIVE STUDIES;BRAIN DAMAGE, CHRONIC","40;24;22;19;18;10;10;9;8;7;7;7;7;7;6;6;6;6;6;5","ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;EFFECTS OF HORMONES ON MENOPAUSAL WOMEN'S HEALTH;EPIDEMIOLOGY AND MANAGEMENT OF FUNGAL INFECTIONS;GENDER IMBALANCE IN EAST AND SOUTH ASIA;KIDNEY TRANSPLANTATION;MICROSURGICAL RECONSTRUCTION TECHNIQUES;PROVISION AND ASSESSMENT OF NUTRITION SUPPORT THERAPY;TUBERCULOSIS;;ADVANCEMENTS IN MEDICAL SCIENCE AND PRACTICE;ANKLE INJURIES AND DISORDERS IN SPORTS MEDICINE;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;CLINICAL AND MOLECULAR CHARACTERISTICS OF GLOMUS TUMORS;COMPREHENSIVE APPROACH TO SCHOOL HEALTH PROMOTION;DEVELOPMENT AND EVALUATION OF CLINICAL GUIDELINES;DIAGNOSIS AND MANAGEMENT OF CEREBRAL VEIN THROMBOSIS;DIAGNOSIS AND MANAGEMENT OF CHRONIC COUGH;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME;DIAGNOSIS AND TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA;DIFFUSION MAGNETIC RESONANCE IMAGING","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","ESTROGEN;GRADING (ENGINEERING);HORMONE THERAPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BASAL (MEDICINE);BREAST CANCER;CHEMOTHERAPY REGIMEN;ELISPOT;EVIDENCE-BASED MEDICINE;GENDER BIAS;HYPERTENSION;MICROSURGICAL RECONSTRUCTION;MYCOBACTERIUM TUBERCULOSIS;PROGESTIN;QUARTILE;RELATIVE SURVIVAL;TRANSPLANTATION;ADRENAL VEIN SAMPLING;ANAPHYLAXIS;ANATOMICAL PATHOLOGY","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","POSTMENOPAUSAL WOMEN;ACUTE CELLULAR;C-REACTIVE PROTEIN;CELLULAR REJECTION;ESTROGEN-INDUCED INCREASE;HUMAN OFFSPRING;MATERNAL WEIGHT;SECONDARY SEX;SEX RATIO;ACTIVE ANTIRETROVIRAL;ACUTE NEUROLOGICAL;ADULT PATIENTS;AIDS TREATED;ALLOGRAFTS RESULTS;ANTHRACYCLINE-BASED CHEMOTHERAPY;ANTI-MÜLLERIAN HORMONE;ANTIRETROVIRAL THERAPY;ARSENIC TRIOXIDE;ARTERY STENTS;AUTOLOGOUS STEM;BASED MEDICINE;BETA-AND GAMMA-HERPESVIRUSES;BIOLOGICAL EFFECTS;BLOOD SUPPLY;BOWEL ALLOGRAFTS;BOWEL TRANSPLANT;BOWELMULTIVISCERAL TRANSPLANTATION;BRAIN DAMAGE;BREAST CANCER;BREAST CARCINOMA","4;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PUBMED SCOPUS;CROSSREF PUBMED;LIVER DISEASE;UTERINE LEIOMYOMATA;UTERINE ARTERY;BLOOD DONORS;GGT LEVELS;HBSAG CARRIERS;UTERINE VOLUME;ALCOHOL INTAKE;HBV DNA;ALT LEVELS;CHRONIC HEPATITIS;CLEARED HBSAG;FOLLOW-UP PERIOD;MEDICAL COMORBIDITIES;NORMAL IUL;POSTMENOPAUSAL WOMEN;STATISTICALLY SIGNIFICANT;AST LEVELS;SURFACE ANTIGEN;ULTRASOUND EXAMINATION;UPPER LIMIT;UTERINE ARTERIES;ACUTE HEPATITIS;ARTERY BLOOD;BODY MASS;CHRONIC HBV;CHRONIC SYMPTOMLESS;CONFIDENCE INTERVAL","35;19;17;13;12;11;9;9;9;8;8;7;7;7;7;7;7;7;7;6;6;6;6;6;5;5;5;5;5;5",12,0.25,6,2,1,1,0,1,3,0,2,4.25,0,0,3.25,0,2.75,0,0,3.25,0,0,0,58,58,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,6,424.25,7.45,1,0.14,53.14,0,0,2,1,2,0,1,1,0,4,0,0,1,0,0,0,0,5,2,0,5,2,0,0,0,0,0,0,0,0,"Belgium;Germany","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;43 HISTORY, HERITAGE AND ARCHAEOLOGY;4303 HISTORICAL STUDIES","6;4;3;2;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CHILDHOOD LEUKEMIA;HEMATOLOGY;PEDIATRIC;PEDIATRIC CANCER;RARE DISEASES;ATHEROSCLEROSIS;BIOMEDICAL IMAGING;CARDIOVASCULAR;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HIV/AIDS;INFECTIOUS DISEASES;LUNG;LUNG CANCER;ORPHAN DRUG;PATIENT SAFETY;REGENERATIVE MEDICINE","4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFECTION","4;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","4;1","LEUKEMIA / LEUKAEMIA;BREAST CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA","2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_MODENA",2005,66,10.1666666666667,3.43939393939394,0.560606060606061,0.378787878787879,0.575757575757576,1.42405063291139,1.19354838709677,1.31578947368421,1.1875,0.318181818181818,0,27,12,15,10,0.41,0.18,0.23,0.15,52.3,0.987898503774237,NA,0.212121212121212,0.757575757575758,0.395,0.391,0.419,0.387,"MICHELE MASETTI;NICOLA CAUTERO;FABRIZIO DI BENEDETTO;ANTONIO DANIELE PINNA;AUGUSTO LAURO;ANNIBALE VOLPE;A. DAZZI;CRISTIANO QUINTINI;NICOLA DE RUVO;ANDREA COSSARIZZA;MILENA NASI;LEONARDA TROIANO;GIOVANNI RAMACCIATO;MARCELLO PINTI;CRISTINA MUSSINI;ANTONIO LA MARCA;RENATO ROMAGNOLI;B. BEGLIOMINI;ANGELO CAGNACCI;GABRIELE LUPPI","8;8;8;8;8;7;7;6;6;6;5;5;5;5;5;4;4;4;4;4","ANNIBALE VOLPE;GIULIANO FRANCO;RENATO ROMAGNOLI;ANTONIO LA MARCA;GUIDO LIGABUE;ANGELO CAGNACCI;MICHELE MASETTI;NICOLA CAUTERO;FABRIZIO DI BENEDETTO;AUGUSTO LAURO;ANTONIO DANIELE PINNA;SERENELLA ARANGINO;MARIA GRAZIA MODENA;A. DAZZI;ANDREA COSSARIZZA;G MONDUZZI;P. DE GRANDI;CRISTIANO QUINTINI;MILENA NASI;LEONARDA TROIANO","1.23;1;0.95;0.88;0.75;0.69;0.62;0.62;0.62;0.62;0.59;0.57;0.57;0.55;0.53;0.5;0.5;0.49;0.47;0.47","MICHELE MASETTI;NICOLA CAUTERO;FABRIZIO DI BENEDETTO;ANTONIO DANIELE PINNA;AUGUSTO LAURO;ANNIBALE VOLPE;A. DAZZI;CRISTIANO QUINTINI;NICOLA DE RUVO;ANDREA COSSARIZZA;GIOVANNI RAMACCIATO;CRISTINA MUSSINI;ANTONIO LA MARCA;RENATO ROMAGNOLI;B. BEGLIOMINI;ANGELO CAGNACCI;GABRIELE LUPPI;ROBERTO ESPOSITO;GIOVANNI GUARALDI;ROBERTO D’AMICO","8;8;8;8;8;7;7;6;6;6;5;5;4;4;4;4;4;4;3;3","ANNIBALE VOLPE;GIULIANO FRANCO;RENATO ROMAGNOLI;ANTONIO LA MARCA;GUIDO LIGABUE;ANGELO CAGNACCI;MICHELE MASETTI;NICOLA CAUTERO;FABRIZIO DI BENEDETTO;AUGUSTO LAURO;ANTONIO DANIELE PINNA;A. DAZZI;ANDREA COSSARIZZA;G MONDUZZI;P. DE GRANDI;CRISTIANO QUINTINI;PAOLO NICHELLI;NICOLA DE RUVO;CRISTINA MUSSINI;GABRIELE LUPPI","1.23;1;0.95;0.88;0.75;0.69;0.62;0.62;0.62;0.62;0.59;0.55;0.53;0.5;0.5;0.49;0.44;0.42;0.42;0.37","PAOLO NICHELLI;ALESSANDRO RUSSO;E. FORAPANI;F. PIAMARTA;ILDEBRANDO APPOLLONIO;M. L. VILLA;MARÍA EUGENIA LEONE;T. CONSOLI;VALERIA ISELLA;ANNIBALE VOLPE;GABRIELE LUPPI;ROBERTO D’AMICO;ALESSANDRO LIBERATI;ANDREW D OXMAN;BOB PHILLIPS;DAVID C. ATKINS;DIANNE O’CONNELL;GORDON GUYATT;GUNN ELISABETH VIST;HOLGER J. SCHÜNEMANN","596;590;590;590;590;590;590;590;590;530;424;400;319;319;319;319;319;319;319;319","MARÍA EUGENIA LEONE;PAOLO NICHELLI;T. CONSOLI;ANNIBALE VOLPE;ALESSANDRO LIBERATI;FABIO RUMPIANESI;P. MARCHEGIANO;ANTONIO LA MARCA;GABRIELE LUPPI;BARBARA MARIA BERGAMINI;BARBARA MECCUGNI;GIOVANNI FERRARA;LEONARDO M. FABBRI;LUCA RICHELDI;MARISA MEACCI;MONICA LOSI;PIETRO ROVERSI;ROBERTO D’AMICO;ROBERTO PIRO;CRISTINA MUSSINI","590;590;590;339;319;318;318;302;275;251;251;251;251;251;251;251;251;251;251;233","FABRIZIO DI BENEDETTO;MICHELE MASETTI;NICOLA CAUTERO;CRISTINA MUSSINI;ANNIBALE VOLPE;ANGELO CAGNACCI;ANTONIO LA MARCA;CRISTIANO QUINTINI;B. BEGLIOMINI;CHARLES M. MILLER;RENATO ROMAGNOLI;ROBERTO ESPOSITO;VANNI BORGHI;ANDREA COSSARIZZA;ANDREA RISALITI;ANTONIO DANIELE PINNA;CLODOVEO FERRI;DILIA GIUGGIOLI;FABIO RUMPIANESI;FABRIZIO DI FRANCESCO","8;7;7;5;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;ECONOMICS;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;POLITICAL SCIENCE;PSYCHOLOGY;BUSINESS;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY","60;23;6;6;6;4;3;3;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;ENDOCRINOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;PATHOLOGY;BIOCHEMISTRY;CARDIOLOGY;VIROLOGY;ENVIRONMENTAL HEALTH;PALEONTOLOGY;PSYCHIATRY;ANDROLOGY;ECONOMIC GROWTH;GYNECOLOGY;NURSING;ONCOLOGY;OPTICS;PHARMACOLOGY;PHYSICAL THERAPY","48;20;14;12;12;11;9;7;7;7;6;5;5;4;4;4;4;4;4;4;4","TRANSPLANTATION;CANCER;CHEMOTHERAPY;GENE;POPULATION;PREGNANCY;DISEASE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);STAGE (STRATIGRAPHY);INCIDENCE (GEOMETRY);RECEPTOR;REGIMEN;SEPSIS;TOXICITY;VIRUS;CLINICAL TRIAL;DIABETES MELLITUS;DRUG;HEALTH CARE;HORMONE;LYMPHOMA;OCCUPATIONAL SAFETY AND HEALTH;RADIATION THERAPY","11;10;7;7;7;7;6;6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3","TACROLIMUS;COLORECTAL CANCER;LIVER TRANSPLANTATION;VIRAL LOAD;BREAST CANCER;GEMCITABINE;LUTEINIZING HORMONE;MITOCHONDRIAL TOXICITY;POLYMERASE CHAIN REACTION;VIRAL DISEASE;ALEMTUZUMAB;CD8;COCHRANE LIBRARY;FLUOROURACIL;GESTATION;MITOCHONDRIAL DNA;NEUTROPENIA;OCCUPATIONAL MEDICINE;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PROGRAMMED CELL DEATH;REAL-TIME POLYMERASE CHAIN REACTION;RITUXIMAB;RNA","6;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;THYMOGLOBULIN;DACLIZUMAB;FAS LIGAND;FOLLICLE-STIMULATING HORMONE;REVERSE TRANSCRIPTASE;AMNIOTIC FLUID;CEREBRAL AMYLOID ANGIOPATHY;COLONOSCOPY;CONNECTIVE TISSUE DISEASE;DELTA-9-TETRAHYDROCANNABINOL;DESMOPLASIA;DISTANT METASTASIS;DMT1;DRIVING UNDER THE INFLUENCE;EPIRUBICIN;FAS RECEPTOR;FERROPORTIN;FOLINIC ACID;GERMLINE MUTATION;GONADOTROPIN-RELEASING HORMONE;HAPLOINSUFFICIENCY;HERPESVIRIDAE;HORMONE ANTAGONIST;HORMONE RECEPTOR;INTERGENIC REGION;INTRACYTOPLASMIC SPERM INJECTION;KLEBSIELLA PNEUMONIAE;LATENT TUBERCULOSIS;LENTIVIRUS;LYMPHOCYTIC CHORIOMENINGITIS;MAMMOGRAPHY;MEDULLARY CARCINOMA;MEDULLARY THYROID CANCER;MISSENSE MUTATION;OXALIPLATIN;PANCREAS TRANSPLANTATION;PENETRANCE;PERMISSIVENESS;PORTAL VENOUS PRESSURE;PRENATAL DIAGNOSIS;SERRATIA MARCESCENS;SHORT-TERM MEMORY;SIDA;SPITZ NEVUS;TAQMAN;TUBERCULOSIS DIAGNOSIS;VINCRISTINE;ZIDOVUDINE","4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;MIDDLE AGED;MALE;AGED;HIV INFECTIONS;RETROSPECTIVE STUDIES;;LIVER TRANSPLANTATION;IMMUNOSUPPRESSIVE AGENTS;RECTAL NEOPLASMS;ITALY;ADENOCARCINOMA;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CD4-POSITIVE T-LYMPHOCYTES;GRAFT REJECTION;TREATMENT OUTCOME;DEOXYCYTIDINE;KIDNEY FAILURE, CHRONIC","54;38;33;33;32;18;15;12;11;11;10;10;9;8;8;8;8;8;7;7","HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;PROVISION AND ASSESSMENT OF NUTRITION SUPPORT THERAPY;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DEVELOPMENTAL ORIGINS OF ADULT HEALTH AND DISEASE;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;LYMPHOID NEOPLASMS;MAGNETIC RESONANCE IMAGING APPLICATIONS IN MEDICINE;PANCREATIC CANCER RESEARCH AND TREATMENT;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;DEVELOPMENT AND EVALUATION OF CLINICAL GUIDELINES;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;ENHANCING WORKPLACE SAFETY CULTURE AND PRACTICES","4;4;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","LIVER TRANSPLANTATION;ANTIRETROVIRAL THERAPY;REGIMEN;MITOCHONDRIAL TOXICITY;THYMOGLOBULIN;ANTI-MULLERIAN HORMONE;CARDIAC IMAGING;CARDIOVASCULAR MRI;DACLIZUMAB;FAS LIGAND;IMMUNOSUPPRESSION;LIVING DONOR LIVER TRANSPLANTATION;LOW BIRTH WEIGHT;PATHOGENESIS;REVERSE-TRANSCRIPTASE INHIBITOR;RITUXIMAB;TRANSPLANTATION;ACANTHOSIS;ACUTE NECROTIZING ENCEPHALOPATHY;ADJUVANT CHEMOTHERAPY","6;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","LIVER TRANSPLANTATION;CELL COUNT;ADULT PATIENTS;ANTIRETROVIRAL THERAPY;BOWEL TRANSPLANTATION;CD CELL;CLINICAL PRACTICE;CORONARY ARTERY;EVIDENCE-BASED OCCUPATIONAL;MITOCHONDRIAL RNA;PANCREATIC CANCER;PHASE II;PRACTISING EVIDENCE-BASED;PREOPERATIVE RADIOCHEMOTHERAPY;RNA PRODUCTION;TREATMENT INTERRUPTION;ABSENCE CAUSED;ACTIVITY CHARACTERIZATION;ACUTE ISCHEMIC;ADJUVANT SYSTEMIC;ADMINISTRATION DECREASES;ADULT ISOLATED;ADULTS EXPERIENCE;ADVANCED NON-SMALL-CELL;ADVANCED PANCREATIC;AGONIST FLARE-UP;ALTERED MITOCHONDRIAL;AMNIOTIC FLUID;AMYLOID POLYNEUROPATHY;ANTEROLATERAL THIGH","4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","THYMUS ALTERATIONS;MITOCHONDRIAL DNA;AMH LEVELS;EBM PARADIGM;EVIDENCE PROFILES;HEALTH CARE;MONTHS RANGE;CEAC ANALYSIS;DNA CONTENT;FOLLICULAR PHASE;HCV PATIENTS;MATURE OOCYTES;MM HG;MM NA;MONTHS NA;MTDNA CONTENT;MULTIVISCERAL GRAFTS;OOCYTES RETRIEVED;PICO MODEL;POOR-RESPONDER PATIENTS;POSTMENOPAUSAL WOMEN;PROGRESSION-FREE SURVIVAL;PROGRESSIVE DISEASE;RADIOLOGICAL THYMUS;SIGNIFICANT INCREASE;SSC PATIENTS;WOMEN BORN;ABNORMALLY ENLARGED;ADVANCED PANCREATIC;APPARENTLY HEALTHY","6;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2",11,0.17,7,3,1,1,0,1,2.5,0,2,3.5,0,0,2.75,0,1,0,1,2,0,0,0,85.5,86,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,5.75,1374.5,7.8,0,0,31.36,0,0,5,1,2,0,2,1,0,3,1,0,0,0,0,0,0,10,1,0,4,7,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3103 ECOLOGY;3207 MEDICAL MICROBIOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;4203 HEALTH SERVICES AND SYSTEMS;43 HISTORY, HERITAGE AND ARCHAEOLOGY;4303 HISTORICAL STUDIES;50 PHILOSOPHY AND RELIGIOUS STUDIES","9;5;2;2;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;RARE DISEASES;CANCER;LYMPHOMA;PATIENT SAFETY;TRANSPLANTATION","3;2;2;2;1;1;1;1","CANCER;BLOOD;INFECTION","5;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","3;1;1","COLON AND RECTAL CANCER;KIDNEY CANCER;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;ANAL CANCER;BREAST CANCER;CERVICAL CANCER;GASTROINTESTINAL TRACT;HODGKIN'S DISEASE;KAPOSI'S SARCOMA;LEUKEMIA / LEUKAEMIA;STOMACH CANCER","2;2;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","4;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_MODENA",2006,73,8.49315068493151,2.58904109589041,0.465753424657534,0.287671232876712,0.493150684931507,1.24161073825503,1.21428571428571,1.4,1.24137931034483,0.191780821917808,5,27,16,11,10,0.37,0.22,0.15,0.14,36.27,0.71016534457852,NA,0.191780821917808,0.643835616438356,0.471,0.305,0.254,0.305,"GIULIANO FRANCO;MICHELE MASETTI;ANGELO CAGNACCI;LIVIO PRESUTTI;GIOVANNI GUARALDI;MAURO CODELUPPI;KARL ANDREAS SCHLEGEL;FABRIZIO DI BENEDETTO;NICOLA DE RUVO;KLAUS GARDNER;HENDRIK TERHEYDEN;STEFANO BUSANI;MASSIMO GIRARDIS;ANNIBALE VOLPE;ANTONIO LANDI;ROBERTO ESPOSITO;R. ZIMMERMANN;MARIA GRAZIA MODENA;JUNG HO PARK;JÖRG WILTFANG","5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","GIULIANO FRANCO;ANGELO CAGNACCI;A CRISTANI;ELISA ROMAGNOLI;C. CASALI;LIVIO PRESUTTI;ANTONIO LANDI;DANIELE MARCHIONI;LUIGI TARALLO;ROBERTO ADANI;STEFANO BUSANI;MASSIMO GIRARDIS;ANDREA LETI ACCIARO;ANGELO GHIDINI;G. CASERTA;MARIANNA CANNOLETTA;ANNIBALE VOLPE;MARIA GRAZIA MODENA;MICHELE MASETTI;FABIO FACCHINETTI","3.5;1.82;1;1;1;0.96;0.75;0.58;0.58;0.58;0.56;0.56;0.5;0.5;0.5;0.5;0.47;0.44;0.43;0.39","GIULIANO FRANCO;MICHELE MASETTI;ANGELO CAGNACCI;LIVIO PRESUTTI;FABRIZIO DI BENEDETTO;NICOLA DE RUVO;STEFANO BUSANI;MASSIMO GIRARDIS;ANNIBALE VOLPE;ANTONIO LANDI;MARIA GRAZIA MODENA;LUIGI CHIARINI;A CAMPAGNA;GIORGIO ENRICO GERUNDA;FABRIZIO FERRARI;BARBARA MECCUGNI;FABIO RUMPIANESI;NICOLA CAUTERO;LUCA RICHELDI;FAUSTO BARBIERI","5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","GIULIANO FRANCO;ANGELO CAGNACCI;A CRISTANI;ELISA ROMAGNOLI;C. CASALI;LIVIO PRESUTTI;ANTONIO LANDI;DANIELE MARCHIONI;LUIGI TARALLO;ROBERTO ADANI;STEFANO BUSANI;MASSIMO GIRARDIS;ANDREA LETI ACCIARO;ANGELO GHIDINI;G. CASERTA;MARIANNA CANNOLETTA;ANNIBALE VOLPE;MARIA GRAZIA MODENA;MICHELE MASETTI;FABIO FACCHINETTI","3.5;1.82;1;1;1;0.96;0.75;0.58;0.58;0.58;0.56;0.56;0.5;0.5;0.5;0.5;0.47;0.44;0.43;0.39","CRISTINA MUSSINI;FABIO RUMPIANESI;BARBARA MECCUGNI;MARISA MEACCI;LUCA RICHELDI;ALESSANDRO ANDREANI;BARBARA MARIA BERGAMINI;GIOVANNI FERRARA;I. MARCHETTI DORI;LEONARDO M. FABBRI;MONICA LOSI;PIETRO ROVERSI;ROBERTO D’AMICO;ROBERTO PIRO;ANNIBALE VOLPE;ALESSANDRA TIRELLI;ANTONIO LA MARCA;EMMA BERTUCCI;SIMONE GIULINI;SUSANNA XELLA","596;596;516;516;508;491;491;491;491;491;491;491;491;491;351;318;318;318;318;318","FABIO RUMPIANESI;BARBARA MECCUGNI;MARISA MEACCI;I. MARCHETTI DORI;ALESSANDRA TIRELLI;EMMA BERTUCCI;SIMONE GIULINI;SUSANNA XELLA;TIZIANA MARSELLA;ALFIO BERTOLINI;ANNA FERRARI;SHEILA LEONE;E. MERELLI;LIVIO PRESUTTI;CLAUDIA VENTURELLI;LUIGI CHIARINI;C. DANIELLI;STEFANO RIVETTI;FAUSTO BARBIERI;ANGELO GHIDINI","596;516;516;491;318;318;318;318;318;269;269;269;219;162;115;76;75;75;73;71","ANGELO CAGNACCI;LIVIO PRESUTTI;MICHELE MASETTI;ANTONIO LANDI;LUIGI CHIARINI;MASSIMO GIRARDIS;A CAMPAGNA;ALBERTO GIANNETTI;ANDREA LETI ACCIARO;ANNIBALE VOLPE;BARBARA MECCUGNI;CLAUDIA VENTURELLI;FABIO FACCHINETTI;FABIO RUMPIANESI;FABRIZIO DI BENEDETTO;FAUSTO BARBIERI;G. CASERTA;GIULIANO FRANCO;GIUSEPPE GERACI;MARIA GRAZIA MODENA","4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;SOCIOLOGY;BUSINESS;CHEMISTRY;ECONOMICS;MATERIALS SCIENCE;POLITICAL SCIENCE;MATHEMATICS;PHILOSOPHY;ART","71;19;8;6;5;5;5;4;4;4;3;3;2;2;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;ENDOCRINOLOGY;CARDIOLOGY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;ONCOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;BIOCHEMISTRY;OPTICS;BOTANY;DEMOGRAPHY;PEDIATRICS;ANATOMY;AUDIOLOGY;ECONOMIC GROWTH;FAMILY MEDICINE;GYNECOLOGY;INTENSIVE CARE MEDICINE;LAW;MICROBIOLOGY;PSYCHIATRY","49;26;14;9;8;7;7;7;7;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3","CANCER;TRANSPLANTATION;CHEMOTHERAPY;CONFIDENCE INTERVAL;DISEASE;POPULATION;PREGNANCY;GENUS;HEALTH CARE;HORMONE;INCIDENCE (GEOMETRY);REGIMEN;COHORT;MYOCARDIAL INFARCTION;PROSPECTIVE COHORT STUDY;SPLEEN;STENT;TUBERCULOSIS;ABDOMINAL SURGERY;ALTERNATIVE MEDICINE;ANEMIA;BASAL CELL;BODY MASS INDEX;CARCINOMA;COHORT STUDY;CORONARY ARTERY DISEASE;GENE;GOLD STANDARD (TEST);IMMUNOSUPPRESSION;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;INCINERATION;INTRACARDIAC INJECTION;ISCHEMIA;LUNG CANCER;MENOPAUSE;OCCUPATIONAL SAFETY AND HEALTH;PHONATION;PUBLIC HEALTH;RADIATION THERAPY;RADIOGRAPHY;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;REFRACTORY (PLANETARY SCIENCE);SCAFFOLD;SIROLIMUS;SURVIVAL RATE","9;9;8;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LIVER TRANSPLANTATION;SINUS (BOTANY);BREAST CANCER;COLORECTAL CANCER;CUMULATIVE INCIDENCE;CYCLOPHOSPHAMIDE;GEMCITABINE;MYCOBACTERIUM TUBERCULOSIS;NEUTROPENIA;RELATIVE RISK;TUBERCULIN;CISPLATIN;MENSTRUAL CYCLE;OCCUPATIONAL MEDICINE;OFFSPRING;PERCUTANEOUS CORONARY INTERVENTION;SPLENECTOMY;ABDOMINAL COMPARTMENT SYNDROME;ABORTION;ACUTE CARE;AGONIST;ALEMTUZUMAB;AMPHOTERICIN B;AMYOTROPHIC LATERAL SCLEROSIS;ANTI-MÜLLERIAN HORMONE;ANTIMETABOLITE;ARTERIAL DISEASE;ASTROCYTOMA;BENEFICENCE;BENIGN PAROXYSMAL POSITIONAL VERTIGO;BIG FIVE PERSONALITY TRAITS;BLEOMYCIN;BLOCKADE;CANDIDA GLABRATA;CANDIDA PARAPSILOSIS;CANDIDA TROPICALIS;CANNABINOID;CARDIOGENIC SHOCK;CARDIOMYOPATHY;CERVIX;CHEMOTHERAPY REGIMEN;CLIVUS;COGNITIVE IMPAIRMENT;CONGENITAL MALFORMATIONS;CONVENTIONAL PCI;CORONARY ARTERY CALCIUM;CRITICAL APPRAISAL;DIGITAL RADIOGRAPHY;DILATED CARDIOMYOPATHY;DINOPROSTONE;EJECTION FRACTION;ELITE;ELITE ATHLETES;ENDOCANNABINOID SYSTEM;ENDOCRINE SYSTEM;ETOPOSIDE;EVIDENCE-BASED MEDICINE;EVIDENCE-BASED PRACTICE;FLAT PANEL DETECTOR;FLUCONAZOLE;FORSKOLIN;FUNGEMIA;GENE KNOCKDOWN;GESTATION;GESTATIONAL AGE;HAEMATOPOIESIS;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEPCIDIN;HEREDITARY HEMOCHROMATOSIS;HIPPO SIGNALING PATHWAY;HORMONE REPLACEMENT THERAPY (FEMALE-TO-MALE);HUMAN HERPESVIRUS;IMAGE QUALITY;IN VITRO FERTILISATION;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INFERTILITY;INFLUENZA VACCINE;INSULIN RESISTANCE;IRON DEFICIENCY;IRON-DEFICIENCY ANEMIA;ITRACONAZOLE;KERNICTERUS;KIDNEY TRANSPLANTATION;LABOR INDUCTION;LARYNGEAL NEOPLASM;LEVOFLOXACIN;LUNATE;LUTEAL PHASE;MACROPHAGE;MEDICAL COSTS;MELPHALAN;METASTASIS;METFORMIN;METHIONINE;MISCARRIAGE;MYOCARDIAL PERFUSION IMAGING;NEUROBLASTOMA;NEUROTICISM;OPEN LABEL;ORGAN PROCUREMENT;OVULATION;PANCREATIC CANCER;PEDIATRIC ONCOLOGY;PERIPHERAL ARTERIAL OCCLUSIVE DISEASE;PERITONEAL MESOTHELIOMA;PLACEBO;PLAQUE PSORIASIS;PNEUMONECTOMY;PORTAL HYPERTENSION;PORTAL VEIN THROMBOSIS;PREECLAMPSIA;PROGESTIN;PROSTATE;PSORIASIS AREA AND SEVERITY INDEX;QUARTILE;RECOMBINANT DNA;REPERFUSION INJURY;RESTENOSIS;REVASCULARIZATION;RHOA;SALVAGE THERAPY;SCAPHOLUNATE LIGAMENT;SEX RATIO;SINUS RHYTHM;SKIN TEST;SOCIOECONOMIC STATUS;SPHENOIDAL SINUS;SPUTUM;TACROLIMUS;TYPE 2 DIABETES;TYPE 2 DIABETES MELLITUS;UNIVARIATE ANALYSIS;VASCULAR SMOOTH MUSCLE;VINBLASTINE;VIRAL DISEASE;VIRAL LOAD","5;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LATENT TUBERCULOSIS;MACE;OXALIPLATIN;VINCRISTINE;ACTIVE TUBERCULOSIS;ANTIRETROVIRAL THERAPY;BASAL BODY TEMPERATURE;BISHOP SCORE;CANDIDA KRUSEI;CANNABINOID RECEPTOR;CAPECITABINE;CARBOPLATIN;CARDIAC RESYNCHRONIZATION THERAPY;CARMUSTINE;COLD ISCHEMIA;COMPUTED RADIOGRAPHY;CORONARY CALCIUM SCORE;CORONAVIRUS DISEASE 2019 (COVID-19);DACLIZUMAB;DETECTIVE QUANTUM EFFICIENCY;DNA MISMATCH REPAIR;DRUG-ELUTING STENT;EFALIZUMAB;ETHAMBUTOL;EXTRAVERSION AND INTROVERSION;FEBRILE NEUTROPENIA;FERROPORTIN;FLUDARABINE;HERPESVIRIDAE;HORMONE THERAPY;INFLUENZA SEASON;IRON STATUS;KAPOSI'S SARCOMA;LIVING DONOR LIVER TRANSPLANTATION;LUNATE BONE;MAMMOGRAPHY;METASTASECTOMY;METASTATIC BREAST CANCER;NEOINTIMA;OCCLUSIVE ARTERIAL DISEASE;OVARIAN HYPERSTIMULATION SYNDROME;OVARIAN RESERVE;POLYCYSTIC OVARY;PORTAL VENOUS PRESSURE;POSACONAZOLE;PROSTATE CARCINOMA;PYRAZINAMIDE;SPHEROCYTOSIS;SPLENIC DISEASE;THYMOGLOBULIN;TRASTUZUMAB;VINORELBINE","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CARCINOMA, SQUAMOUS CELL;DEOXYCYTIDINE;LUNG NEOPLASMS;AGED, 80 AND OVER;POSTOPERATIVE COMPLICATIONS;ITALY;TREATMENT OUTCOME;ADOLESCENT;CARCINOMA, NON-SMALL-CELL LUNG;RETROSPECTIVE STUDIES;SIROLIMUS;TUBERCULOSIS","55;38;34;31;28;20;15;12;10;10;10;9;9;8;8;7;7;7;7;7","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;ENVIRONMENTAL JUSTICE AND INEQUALITY IN URBAN DEVELOPMENT;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;LYMPHOID NEOPLASMS;REGULATION OF IRON METABOLISM AND ANEMIA;TREATMENT AND OUTCOMES OF HAND INJURIES;TUBERCULOSIS;ABDOMINAL COMPARTMENT SYNDROME AND INTRA-ABDOMINAL HYPERTENSION;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN LUNG CANCER RESEARCH;BREAST CANCER SCREENING TECHNOLOGY;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CRANIOFACIAL RECONSTRUCTION TECHNIQUES;DEVELOPMENTAL PHARMACOLOGY IN PEDIATRIC DRUG USE;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS","3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","REGIMEN;SINUS (BOTANY);CUMULATIVE INCIDENCE;LIVER TRANSPLANTATION;MYCOBACTERIUM TUBERCULOSIS;CHEMOTHERAPY;CORONARY STENTS;DRUG-ELUTING STENTS;GOLD STANDARD (TEST);HYPERTENSION;IMMUNOSUPPRESSION;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;KAPOSI'S SARCOMA;LIVING DONOR LIVER TRANSPLANTATION;MACE;QUANTIFERON;REFRACTORY (PLANETARY SCIENCE);SIROLIMUS;TRANSPLANTATION;TREATMENT","4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","AUGMENTATION STEPS;CELL-SCAFFOLD CONSTRUCTS;CLINICAL APPLICATION;CONSTRUCTS SUITABLE;LIVER TRANSPLANTATION;OCCUPATIONAL HEALTH;SINUS AUGMENTATION;CLINICAL EXPERIENCE;EXPERIENCE ACQUIRED;FIRST-LINE TREATMENT;HEALTH CARE;IMPLANTABLE CARDIOVERTER;LUNG CANCER;MODERN MUNICIPAL;MULTIPLE SCLEROSIS;MUNICIPAL SOLID;MYCOBACTERIUM TUBERCULOSIS;POSTMENOPAUSAL WOMEN;PROSPECTIVE STUDY;SOLID WASTE;ACTIVITY CHARACTERIZATION;ACUTE MYOCARDIAL;ADMINISTRATION INCREASES;ADMINISTRATION MODULATES;ADULT ASTROCYTOMA;ADULT PATIENTS;ADVANCED HODGKINS;ADVANCED NON-SMALL-CELL;ALL-ORAL COMBINATION;ALLOGENEIC HAEMATOPOIETIC","3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","SEX RATIO;SECONDARY SEX;MIC MGL;PATIENTS SINUSES;PUBMED SCOPUS;DR JONGBLOET;IMPLANT PLACEMENT;MATERNAL WEIGHT;AUTOLOGOUS SERUM;BIRTH DEFECTS;BODY WEIGHT;HUMAN OFFSPRINGFERTIL;INTERMEDIATE EXPOSURE;MATERNAL BODY;OFFSPRINGFERTIL STERIL;OVARIAN RESPONSE;REMAINING MUNICIPAL;SINUSES CELLS;STERIL -ABSTRACT;WASTE INCINERATOR;AMH QUARTILE;CANDIDA SPP;CONGENITAL ANOMALIES;CROSSREF PUBMED;DOSE INTENSITY;ENERGY STORE;MENSTRUAL CYCLE;MUNICIPAL POPULATION;MUNICIPAL WASTE;PERFORMANCE STATUS","20;8;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3",10,0.14,5.3,5.75,2,0,0,4,4.5,0,1,5.75,2,1,8,1,7.75,1,0,7.75,0,0,0,81.5,81.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,4.67,526.33,7.91,1,0.09,61.64,0,0,3,1,3,0,3,1,0,5,1,0,0,0,0,0,0,8,3,0,6,5,0,0,0,0,0,0,0,0,"Italy;United Kingdom;United States","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;43 HISTORY, HERITAGE AND ARCHAEOLOGY;4303 HISTORICAL STUDIES","9;4;3;3;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;LYMPHOMA;PATIENT SAFETY;AUTOIMMUNE DISEASE;CARDIOVASCULAR;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;HEART DISEASE;IMMUNIZATION;KIDNEY DISEASE;LUNG;LUPUS;MIND AND BODY;OVARIAN CANCER;PREVENTION;REGENERATIVE MEDICINE;STEM CELL RESEARCH","6;5;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;BLOOD;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;RENAL AND UROGENITAL;RESPIRATORY","4;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.3 MANAGEMENT AND DECISION MAKING","6;2;1;1","NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LUNG CANCER;OVARIAN CANCER","2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_MODENA",2007,64,8.84375,3.171875,0.46875,0.328125,0.5,1.28846153846154,1.11111111111111,1.10526315789474,1.10344827586207,0.3125,2,37,12,8,4,0.58,0.19,0.12,0.06,47.94,0.908320225659426,NA,0.234375,0.828125,0.353,0.223,0.309,0.23,"GIORGIO ENRICO GERUNDA;GIULIO ROSSI;MICHELE MASETTI;FABRIZIO DI BENEDETTO;A ALBERTAZZI;ROBERTO ESPOSITO;GIOVANNI GUARALDI;NICOLA DE RUVO;MASSIMO FEDERICO;ANTONIO DANIELE PINNA;FEDERICA FIOCCHI;VANNI BORGHI;FEDERICA BERTOLINI;FRANCO NARNI;CRISTINA MUSSINI;MARIA GRAZIA MODENA;GIANNI CAPPELLI;VALERIO M. JASONNI;STEFANO DI SANDRO;GIOVANNA TAGLIABUE","5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2","ANTONIO LANDI;MAURIZIO MORETTI;GIULIO ROSSI;A ALBERTAZZI;VALERIO M. JASONNI;GIULIA LIGABUE;GIULIANO FRANCO;PAMELA GRANDI;GIORGIO ENRICO GERUNDA;ULIANO MORANDI;A CRISTANI;ELISA ROMAGNOLI;FEDERICA FIOCCHI;GIANNI CAPPELLI;MARIA GRAZIA MODENA;MATTEO ALICANDRI‐CIUFELLI;DANIELE MARCHIONI;FRANCESCO MATTIOLI;LIVIO PRESUTTI;ALESSANDRO MARCHIONI","1;1;0.8;0.77;0.64;0.5;0.5;0.5;0.5;0.45;0.44;0.44;0.43;0.41;0.37;0.37;0.37;0.37;0.37;0.34","GIORGIO ENRICO GERUNDA;GIULIO ROSSI;MICHELE MASETTI;FABRIZIO DI BENEDETTO;A ALBERTAZZI;ROBERTO ESPOSITO;NICOLA DE RUVO;MASSIMO FEDERICO;ANTONIO DANIELE PINNA;FEDERICA FIOCCHI;VANNI BORGHI;FEDERICA BERTOLINI;FRANCO NARNI;CRISTINA MUSSINI;MARIA GRAZIA MODENA;GIANNI CAPPELLI;VALERIO M. JASONNI;STEFANO DI SANDRO;MATTEO ALICANDRI‐CIUFELLI;CRISTINA DEALIS","5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2","ANTONIO LANDI;MAURIZIO MORETTI;GIULIO ROSSI;A ALBERTAZZI;VALERIO M. JASONNI;GIULIA LIGABUE;GIULIANO FRANCO;PAMELA GRANDI;GIORGIO ENRICO GERUNDA;ULIANO MORANDI;A CRISTANI;ELISA ROMAGNOLI;FEDERICA FIOCCHI;GIANNI CAPPELLI;MARIA GRAZIA MODENA;MATTEO ALICANDRI‐CIUFELLI;DANIELE MARCHIONI;FRANCESCO MATTIOLI;LIVIO PRESUTTI;ALESSANDRO MARCHIONI","1;1;0.8;0.77;0.64;0.5;0.5;0.5;0.5;0.45;0.44;0.44;0.43;0.41;0.37;0.37;0.37;0.37;0.37;0.34","BARRY A. BORLAUG;CAROLYN S.P. LAM;DAVID A. KASS;FRANCESCA BURSI;MARGARET M. REDFIELD;RICHARD J. RODEHEFFER;STEVE R. OMMEN;VÉRONIQUE L. ROGER;GIULIO ROSSI;CESARE CARANI;ROBERTO ESPOSITO;CRISTINA MUSSINI;FRANCO NARNI;ANNA FABIO;CLAUDIO CERMELLI;GIULIANA FABIO;P QUAGLIO;ALFREDO PONTECORVI;ANTONELLA MIRAGLIA;ELENA RADIGHIERI","528;528;528;528;528;528;528;528;291;253;251;230;221;216;216;216;216;211;211;211","FRANCESCA BURSI;BARRY A. BORLAUG;CAROLYN S.P. LAM;DAVID A. KASS;MARGARET M. REDFIELD;RICHARD J. RODEHEFFER;STEVE R. OMMEN;VÉRONIQUE L. ROGER;FRANCO NARNI;ANNA FABIO;GIAMPAOLO PAPI;CRISTINA MUSSINI;ROBERTO ESPOSITO;ALDO TROTTA;CARLO SALVARANI;CARLO UMBERTO MANZINI;CATHERINE KLERSY;FABRIZIO CANTINI;GENE G. HUNDER;GIUSEPPE PAOLAZZI","528;524;524;524;524;524;524;524;221;216;211;199;197;181;181;181;181;181;181;181","GIORGIO ENRICO GERUNDA;CRISTINA MUSSINI;FABRIZIO DI BENEDETTO;FEDERICA BERTOLINI;FRANCO NARNI;MASSIMO FEDERICO;MICHELE MASETTI;NICOLA DE RUVO;A ALBERTAZZI;A CRISTANI;CHARLES M. MILLER;CRISTIANO QUINTINI;CRISTINA DEALIS;DECENZIO BONUCCHI;FEDERICA FIOCCHI;FRANCESCA BURSI;GABRIELE LUPPI;GIANNI CAPPELLI;GIULIA LIGABUE;GUIDO LIGABUE","4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;POLITICAL SCIENCE;MATHEMATICS;SOCIOLOGY;ECONOMICS;PHILOSOPHY;BUSINESS;COMPUTER SCIENCE;GEOGRAPHY;MATERIALS SCIENCE;PSYCHOLOGY","61;14;6;5;5;4;3;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;PATHOLOGY;IMMUNOLOGY;RADIOLOGY;BIOCHEMISTRY;CARDIOLOGY;ENDOCRINOLOGY;ONCOLOGY;ENVIRONMENTAL HEALTH;GENETICS;LAW;PSYCHIATRY;UROLOGY;VIROLOGY;OPTICS;DEMOGRAPHY;FAMILY MEDICINE;GYNECOLOGY;MICROBIOLOGY;NUCLEAR MEDICINE;PALEONTOLOGY","46;20;13;12;9;8;6;6;6;6;5;5;5;5;5;5;4;3;3;3;3;3;3","CANCER;TRANSPLANTATION;DISEASE;INCIDENCE (GEOMETRY);CHEMOTHERAPY;POPULATION;GENE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);LUNG;LUNG CANCER;ANTIBIOTICS;DIFFERENTIAL DIAGNOSIS;HEART FAILURE;IMMUNOHISTOCHEMISTRY;LYMPHOMA;MULTIVARIATE ANALYSIS;PLATELET;REGIMEN;RENAL FUNCTION;VIRUS","12;8;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;COLORECTAL CANCER;LIVER TRANSPLANTATION;ADENOCARCINOMA;ALLELE;CANCER INCIDENCE;CANCER REGISTRY;CUMULATIVE INCIDENCE;CYCLOPHOSPHAMIDE;EJECTION FRACTION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;INSULIN RESISTANCE;METASTASIS;PROSTATE CANCER;STOMACH CANCER;VIRAL DISEASE;VIRAL LOAD;VON WILLEBRAND FACTOR;APOLIPOPROTEIN E;ARTERIAL STIFFNESS;ARTERIOLOSCLEROSIS;ATELECTASIS;AUTOANTIBODY;AUTOIMMUNITY;B SYMPTOMS;BECK DEPRESSION INVENTORY;BEVACIZUMAB;BONE MINERAL;BRACHIAL ARTERY;BUCCAL FAT PAD;CARCINOGENESIS;CD20;CD30;CD68;CHROMOSOME;CISPLATIN;CORPUS ALBICANS;CYTARABINE;DEMENTIA;DIASTOLE;DILATED CARDIOMYOPATHY;DRUGS OF ABUSE;DYSLIPIDEMIA;ECONOMIC SHORTAGE;ENDOMETRIAL CANCER;ENDOTHELIN 1;ENDOTHELIN RECEPTOR;ENTEROCOCCUS FAECIUM;EPOETIN ALFA;ESTROGEN REPLACEMENT THERAPY;ETOPOSIDE;FETUS;FOLLICULAR LYMPHOMA;FRACTAL DIMENSION;GEMCITABINE;GENE EXPRESSION;GENERAL HEALTH QUESTIONNAIRE;GENOTYPE;GLIAL FIBRILLARY ACIDIC PROTEIN;GRAFT-VERSUS-HOST DISEASE;HAEMOPHILIA A;HAEMOPHILUS INFLUENZAE;HEPATITIS B VIRUS;HIGH-RESOLUTION COMPUTED TOMOGRAPHY;HORMONE REPLACEMENT THERAPY (FEMALE-TO-MALE);HUMAN CYTOMEGALOVIRUS;HYPERLIPIDEMIA;HYPERTENSIVE HEART DISEASE;HYPERVISCOSITY;HYPERVISCOSITY SYNDROME;IMMUNE THROMBOCYTOPENIA;IMMUNODEFICIENCY;IMMUNOSTAINING;INFLIXIMAB;KIDNEY TRANSPLANTATION;LACTATE DEHYDROGENASE;LUNG TRANSPLANTATION;LUTEINIZING HORMONE;MELPHALAN;METFORMIN;MULTIDETECTOR COMPUTED TOMOGRAPHY;NEPHROPATHY;NEUROFILAMENT;OCCUPATIONAL MEDICINE;PACLITAXEL;PHOSPHATASE;PLACEBO;PLASMA VISCOSITY;PNEUMONECTOMY;PORTAL HYPERTENSION;PROGRAMMED CELL DEATH;PROTEASE;PROTEASES;PROTEIN TYROSINE PHOSPHATASE;PSEUDOMONAS AERUGINOSA;PSYCHOLOGICAL DISTRESS;PULMONARY TOXICITY;REPERFUSION INJURY;RESTENOSIS;RITUXIMAB;SEROMA;SOLITARY PULMONARY NODULE;SPLENECTOMY;STAPHYLOCOCCUS AUREUS;STREPTOCOCCUS PNEUMONIAE;SYNAPTOPHYSIN;THROMBOCYTOPENIC PURPURA;THYROIDECTOMY;TYROSINE PHOSPHORYLATION;VAGINAL DISEASE;VASCULITIS;VERO CELL;WEDGE RESECTION","5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIRETROVIRAL THERAPY;FLUDARABINE;ANTHRACYCLINE;AROMATASE;BRONCHIOLITIS OBLITERANS;CARBOPLATIN;CETUXIMAB;DNA FRAGMENTATION;DOPPLER ECHOCARDIOGRAPHY;ESTROGEN RECEPTOR;FLUORESCENCE IN SITU HYBRIDIZATION;GANCICLOVIR;GIANT CELL ARTERITIS;HAEMOPHILIA B;HOMEOBOX;HORMONE THERAPY;HYPERINSULINEMIA;IMMUNODEFICIENCY SYNDROME;IN UTERO;LACUNARITY;LAMIVUDINE;LENTIVIRUS;LEYDIG CELL;LOSS OF HETEROZYGOSITY;MICROSATELLITE;MILAN CRITERIA;MUCINOUS CARCINOMA;PEPSTATIN;POLYCYSTIC OVARY;PORTAL VENOUS PRESSURE;SIDA;SPLENIC DISEASE;STENOTROPHOMONAS MALTOPHILIA;STROKE VOLUME;SYSTOLE;THIOTEPA;TOTAL BODY IRRADIATION;TUMOR SUPPRESSOR GENE;VON WILLEBRAND DISEASE;ZIDOVUDINE","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;HIV INFECTIONS;TREATMENT OUTCOME;;LUNG NEOPLASMS;ITALY;KIDNEY DISEASES;LIVER CIRRHOSIS;LIVER NEOPLASMS;ADOLESCENT;AGED, 80 AND OVER;BIOMARKERS, TUMOR;HEMATOLOGIC NEOPLASMS;POSTOPERATIVE COMPLICATIONS;VIDARABINE","50;40;35;32;28;21;13;13;12;10;9;8;8;8;7;7;7;7;7;7","LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;HEMATOPOIETIC STEM CELL BIOLOGY;LYMPHOID NEOPLASMS;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;ANTIMICROBIAL PROPERTIES OF ESSENTIAL OILS IN FOODS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHOLANGIOCARCINOMA;CHOLESTEROL-LOWERING TREATMENT;CLASSIFICATION AND INTERVENTIONS FOR CEREBRAL PALSY;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;CLINICAL IMPLICATIONS OF UTERINE ANOMALIES AND TREATMENT;CUTANEOUS ADNEXAL NEOPLASMS AND RELATED SYNDROMES;DIAGNOSIS AND MANAGEMENT OF CHRONIC COUGH;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA","3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","HIV;LIVER TRANSPLANTATION;REGIMEN;BREAST CANCER SCREENING;CANCER INCIDENCE;CUMULATIVE INCIDENCE;ECHOCARDIOGRAPHY;HEMATOPOIETIC CELL TRANSPLANTATION;LEFT VENTRICULAR FUNCTION;LIVER CIRRHOSIS;LIVING DONOR LIVER TRANSPLANTATION;STOMACH CANCER;TREATMENT OUTCOMES;;ABDOMINAL WALL DEFECTS;ADNEXAL NEOPLASMS;ANTIRETROVIRAL THERAPY;APOLIPOPROTEIN E;APPROPRIATE USE CRITERIA;ARRHYTHMIAS","3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","LIVER TRANSPLANTATION;PATIENTS TREATED;CANCER INCIDENCE;CARDIAC STRUCTURE;COUNTY MINNESOTA;EJECTION FRACTION;HEART FAILURE;HIV PATIENTS;HORMONE REPLACEMENT;LUNG CANCER;OBSERVED CANCER;OLMSTED COUNTY;PRESERVED EJECTION;REPLACEMENT THERAPY;VALIDATION STUDY;VENTRICULARVASCULAR FUNCTION;A- CORRELATION;ACTIVATOR CERA;ACTIVE ANTIRETROVIRAL;ADENOMATOID MALFORMATION;ADULT-TO-ADULT LIVING;ADVANCED MULTIPLE;ADVANCED NSCLC;ADVANCED RECTAL;ALLOGENEIC STEM;ANTHRACYCLINE-CONTAINING REGIMENS;ANTIRETROVIRAL THERAPY;ARTERY DISEASE;ARTICLE CARDIAC;ASPARTYL PROTEASE","4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HEART FAILURE;CROSSREF PUBMED;PUBMED SCOPUS;EJECTION FRACTION;CARDIOVASCULAR DISEASES;DIFFERENTIAL DIAGNOSIS;DISEASES MAYO;FOUNDATION ROCHESTER;GI-TRACT METASTASIS;INCIDENCE RATES;LUNG CANCER;MAYO CLINIC;ROCHESTER MINN;BETAM LEVELS;CANCER REGISTRIES;CD CELL;END-SYSTOLIC ELASTANCE;LEFT VENTRICULAR;LIPOID PNEUMONIA;ARTERIAL ELASTANCE;CD CD;CELL COUNT;DCM PATIENTS;HFNLEF PATIENTS;HR CI;LEYDIG CELL;LIPID PNEUMONIA;NEUROENDOCRINE CELL;NORMAL EJECTION;OLMSTED COUNTY","12;11;11;8;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4",10,0.16,7.88,2.75,6,1,0,1,2,1,1.25,3.75,0,1,6.25,0,3,0,0,8,1,0,0,71.75,71.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,3.78,818,12.5,3,0.18,19.76,0,0,7,0,5,0,5,0,0,8,0,0,0,0,0,0,0,14,3,0,8,9,0,0,0,0,0,0,0,0,"Italy;Japan","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;43 HISTORY, HERITAGE AND ARCHAEOLOGY;47 LANGUAGE, COMMUNICATION AND CULTURE;31 BIOLOGICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;37 EARTH SCIENCES;3705 GEOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4303 HISTORICAL STUDIES;4705 LITERARY STUDIES;50 PHILOSOPHY AND RELIGIOUS STUDIES;5002 HISTORY AND PHILOSOPHY OF SPECIFIC FIELDS","13;8;7;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;DIGESTIVE DISEASES;PATIENT SAFETY;RARE DISEASES;AGING;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;AUTOIMMUNE DISEASE;BIOENGINEERING;BIOTECHNOLOGY;BREAST CANCER;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;ESTROGEN;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HEMATOLOGY;KIDNEY DISEASE","8;7;5;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFECTION;RENAL AND UROGENITAL;SKIN","7;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","11;1","BREAST CANCER;PANCREATIC CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER","2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","7",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_MODENA",2008,66,9.53030303030303,3.45454545454545,0.575757575757576,0.454545454545455,0.666666666666667,1.52027027027027,1.2258064516129,1.42857142857143,1.22222222222222,0.212121212121212,0,34,9,9,7,0.52,0.14,0.14,0.11,31,0.564952490435217,NA,0.212121212121212,0.772727272727273,0.378,0.343,0.383,0.342,"GIULIO ROSSI;MARIA GRAZIA MODENA;MATTEO ALICANDRI‐CIUFELLI;MARIO LUPPI;MICHELE MASETTI;MONICA MORSELLI;MASSIMO FEDERICO;DECENZIO BONUCCHI;MARIA CHIARA SIGHINOLFI;ANNIBALE VOLPE;LIVIO PRESUTTI;PIETRO TORRICELLI;GIANNI CAPPELLI;LEONARDO POTENZA;GIUSEPPE TORELLI;GIOVANNI GUARALDI;ALBERTO CAVAZZA;SALVATORE MICALI;GIOVANNI RIVA;A ALBERTAZZI","9;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3","GIULIO ROSSI;ANNIBALE VOLPE;MARIA GRAZIA MODENA;MATTEO ALICANDRI‐CIUFELLI;LIVIO PRESUTTI;ANGELO CAGNACCI;MARIA CHIARA SIGHINOLFI;ROSARIO ROSSI;ALESSANDRA TIRELLI;MARCO MARIETTA;A ALBERTAZZI;GIORGIA ORIGLIANI;ANNACHIARA NUZZO;IMMACOLATA BLASI;FRANCESCO MATTIOLI;PIETRO TORRICELLI;MICHELE MASETTI;GIANNI CAPPELLI;SALVATORE MICALI;DECENZIO BONUCCHI","1.19;0.95;0.91;0.82;0.82;0.7;0.65;0.64;0.53;0.53;0.52;0.5;0.5;0.5;0.49;0.47;0.46;0.46;0.45;0.44","GIULIO ROSSI;MARIA GRAZIA MODENA;MATTEO ALICANDRI‐CIUFELLI;MARIO LUPPI;MICHELE MASETTI;MONICA MORSELLI;MASSIMO FEDERICO;DECENZIO BONUCCHI;MARIA CHIARA SIGHINOLFI;ANNIBALE VOLPE;LIVIO PRESUTTI;PIETRO TORRICELLI;GIANNI CAPPELLI;LEONARDO POTENZA;GIUSEPPE TORELLI;GIOVANNI GUARALDI;SALVATORE MICALI;GIOVANNI RIVA;A ALBERTAZZI;ANGELO CAGNACCI","9;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3","GIULIO ROSSI;ANNIBALE VOLPE;MARIA GRAZIA MODENA;MATTEO ALICANDRI‐CIUFELLI;LIVIO PRESUTTI;ANGELO CAGNACCI;MARIA CHIARA SIGHINOLFI;ROSARIO ROSSI;ALESSANDRA TIRELLI;MARCO MARIETTA;A ALBERTAZZI;GIORGIA ORIGLIANI;ANNACHIARA NUZZO;IMMACOLATA BLASI;FRANCESCO MATTIOLI;PIETRO TORRICELLI;MICHELE MASETTI;GIANNI CAPPELLI;SALVATORE MICALI;DECENZIO BONUCCHI","1.19;0.95;0.91;0.82;0.82;0.7;0.65;0.64;0.53;0.53;0.52;0.5;0.5;0.5;0.49;0.47;0.46;0.46;0.45;0.44","MARIA GRAZIA MODENA;ROSARIO ROSSI;ANNACHIARA NUZZO;GIORGIA ORIGLIANI;ALBERTO BERARDI;C. DANIELA RINAUDO;CAROL J. BAKER;CESIRA L. GALEOTTI;CLAUDIA GHEZZO;DOMENICO MAIONE;ELENA BUTTAZZONI;ELEONORA TRESOLDI;GUIDO GRANDI;IMMACULADA MARGARIT;JOHN L. TELFORD;MARIROSA MORA;MASSIMILIANO PAGANI;ROBERTA CRETI;ROBERTO ROSINI;SCILLA BUCCATO","336;334;320;320;223;223;223;223;223;223;223;223;223;223;223;223;223;223;223;223","MARIA GRAZIA MODENA;ANNACHIARA NUZZO;GIORGIA ORIGLIANI;ROSARIO ROSSI;ALBERTO BERARDI;GIULIO ROSSI;LIVIO PRESUTTI;GIULIANA SARTORI;MARIO MIGALDI;STEFANO SACCHI;RENZO LODI;LAURA SCHIROSI;MASSIMO FEDERICO;CHIARA QUADRELLI;DANIELA VALLERINI;GIOVANNI RIVA;GIUSEPPE TORELLI;LEONARDO POTENZA;MARIO LUPPI;PATRIZIA BAROZZI","322;320;320;320;223;217;204;163;163;137;132;119;102;91;91;91;91;91;91;91","GIULIO ROSSI;DECENZIO BONUCCHI;GIANNI CAPPELLI;MARIA GRAZIA MODENA;MICHELE MASETTI;ANNIBALE VOLPE;LIVIO PRESUTTI;ANGELO CAGNACCI;CHIARA QUADRELLI;DANIELA VALLERINI;GIAMPAOLO BIANCHI;GIOVANNI RIVA;GIUSEPPE TORELLI;LEONARDO POTENZA;MARIA CHIARA SIGHINOLFI;MARIO LUPPI;MATTEO ALICANDRI‐CIUFELLI;MONICA MORSELLI;PATRIZIA BAROZZI;SALVATORE MICALI","9;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;ENGINEERING;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;ART;CHEMISTRY;ENVIRONMENTAL SCIENCE;PHILOSOPHY;PSYCHOLOGY","64;16;5;5;3;3;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;ENVIRONMENTAL HEALTH;GENETICS;CARDIOLOGY;RADIOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;ONCOLOGY;OBSTETRICS;UROLOGY;VIROLOGY;ANESTHESIA;CANCER RESEARCH;FAMILY MEDICINE;GYNECOLOGY;INTENSIVE CARE MEDICINE;OPTICS;PEDIATRICS;PHYSICAL THERAPY","48;17;15;11;11;9;9;7;7;6;6;5;4;4;3;3;3;3;3;3;3;3","CANCER;POPULATION;BLOOD PRESSURE;COHORT;GENE;HEART FAILURE;PREGNANCY;TRANSPLANTATION;BIOPSY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);BODY MASS INDEX;COHORT STUDY;CONFIDENCE INTERVAL;IMMUNE SYSTEM;IMMUNOSUPPRESSION;INCIDENCE (GEOMETRY);KIDNEY;PLATELET;ASYMPTOMATIC;BASAL CELL;CARCINOMA;CHEMOTHERAPY;CHOLESTEROL;CONCOMITANT;DIABETES MELLITUS;DIALYSIS;DIFFERENTIAL DIAGNOSIS;EVEROLIMUS;HEART DISEASE;INSULIN;LAPAROSCOPY;LOGISTIC REGRESSION;LUNG;LUNG CANCER;LYMPHOMA;MAGNETIC RESONANCE IMAGING;MALIGNANCY;MYOCARDIAL INFARCTION;OBESITY;OPEN SURGERY;OUTPATIENT CLINIC;PERCUTANEOUS;PROSPECTIVE COHORT STUDY;RADIATION THERAPY;RECEPTOR;RECOMBINANT FACTOR VIIA;RENAL FUNCTION;SEEDING;VIRUS","16;11;5;5;5;5;5;5;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","VIRAL LOAD;METASTASIS;BREAST CANCER;T CELL;ADENOCARCINOMA;BLADDER CANCER;BRACHIAL ARTERY;COLORECTAL CANCER;EJECTION FRACTION;FETUS;GENOTYPE;HUMAN HERPESVIRUS;INSULIN RESISTANCE;KIDNEY TRANSPLANTATION;PROSTATE CANCER;RELATIVE RISK;RESEARCH METHODOLOGY;WAIST;21-HYDROXYLASE;ABDOMINAL AORTIC ANEURYSM;ABORTION;ACUTE TUBULAR NECROSIS;AMPULLA OF VATER;ANDROGEN;ANGIOTENSIN-CONVERTING ENZYME;ANTITHROMBIN;APOLIPOPROTEIN B;ATYPICAL HYPERPLASIA;AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE;BASAL CELL CARCINOMA;BETA THALASSEMIA;BLEOMYCIN;BRAIN ACTIVITY AND MEDITATION;BRONCHOALVEOLAR LAVAGE;CALCINEURIN;CARCINOGENESIS;CARDIAC FUNCTION CURVE;CARDIOVERSION;CD34;CERVIX;CHELATION THERAPY;COHORT EFFECT;COMMON ILIAC ARTERY;CONTRAST-ENHANCED ULTRASOUND;CUMULATIVE INCIDENCE;CYSTIC KIDNEY DISEASE;CYTOPENIA;DAMAGE CONTROL SURGERY;DEFERASIROX;DEFERIPRONE;DIABETIC NEPHROPATHY;DIASTOLE;DIFFUSE LARGE B-CELL LYMPHOMA;DILATED CARDIOMYOPATHY;EPIDERMAL GROWTH FACTOR RECEPTOR;EXON;EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY;FIXATION (POPULATION GENETICS);FLUCONAZOLE;FRESH FROZEN PLASMA;GALACTOMANNAN;GESTATION;GROWTH FACTOR RECEPTOR;HAZARD RATIO;HEALTH SERVICES;HEART RATE;HEPATOCYTE GROWTH FACTOR;ILOPROST;IMMUNOGLOBULIN G;INFRATEMPORAL FOSSA;INTERFERON GAMMA;INTERSTITIAL LUNG DISEASE;INVESTIGATIONAL DEVICE EXEMPTION;ITRACONAZOLE;LIPID PROFILE;LIVER BIOPSY;LIVER CANCER;LIVER TRANSPLANTATION;LYTIC CYCLE;MASTOIDECTOMY;METABOLIC SYNDROME;MISCARRIAGE;MITOCHONDRIAL DNA;MONOCLONAL ANTIBODY;MUTATION;MYOCARDIAL INFARCTION DIAGNOSIS;NEONATAL SEPSIS;NEPHROSTOMY;NEURILEMOMA;NEUTROPENIA;OBSTETRICS AND GYNAECOLOGY;ODDS;PHASED ARRAY;PLACEBO;PLEOMORPHISM (CYTOLOGY);POLYCYSTIC KIDNEY DISEASE;PREECLAMPSIA;PREFRONTAL CORTEX;PROSTANOID;PROSTATE;PTERYGOPALATINE FOSSA;REAL-TIME POLYMERASE CHAIN REACTION;RENAL BIOPSY;SCLERODERMA (FUNGUS);SIGNAL-AVERAGED ELECTROCARDIOGRAM;SINUS (BOTANY);SINUS RHYTHM;SODIUM NITROPRUSSIDE;SOFT TISSUE SARCOMA;STAPHYLOCOCCUS AUREUS;STEREOTACTIC BIOPSY;STREPTOCOCCUS;TELOMERASE;TENOFOVIR;THROMBOCYTOPENIC PURPURA;THYROID CARCINOMA;TROPONIN;TROPONIN I;TROPONIN T;VIRAL DISEASE;VIRULENCE;VORICONAZOLE","5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIRETROVIRAL THERAPY;ELISPOT;FAMILY PLANNING;KAPOSI'S SARCOMA;MAMMOGRAPHY;TRANSITIONAL CELL CARCINOMA;ADENOCARCINOMA OF THE LUNG;ANDROGEN DEFICIENCY;ATYPICAL ADENOMATOUS HYPERPLASIA;BASILIXIMAB;BREAST CARCINOMA;C-MET;CASPOFUNGIN;CHLORMADINONE ACETATE;DISTANT METASTASIS;ELECTROCHEMOTHERAPY;ENDOVASCULAR ANEURYSM REPAIR;EOSINOPHILIC PNEUMONIA;ETHINYLESTRADIOL;FUNCTIONAL MITRAL REGURGITATION;FUNCTIONAL NEAR-INFRARED SPECTROSCOPY;HAPLOTYPE;HEART RATE VARIABILITY;HERPESVIRIDAE;IDIOPATHIC INTERSTITIAL PNEUMONIA;IMMUNOGLOBULIN A;MASTECTOMY;MONOCLONAL;PANCREAS TRANSPLANTATION;PAPILLARY CARCINOMA;PILUS;PKD1;POINT MUTATION;POLYCYSTIC OVARY;PRENATAL DIAGNOSIS;PROSTATECTOMY;RIGHT HEMICOLECTOMY;SENTINEL LYMPH NODE;SENTINEL NODE;SINGLE-NUCLEOTIDE POLYMORPHISM;SOLITARY FIBROUS TUMOR;STREPTOCOCCUS AGALACTIAE;STREPTOCOCCUS PYOGENES;TELOMERASE REVERSE TRANSCRIPTASE;UNDIFFERENTIATED PLEOMORPHIC SARCOMA;USUAL INTERSTITIAL PNEUMONIA","4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MIDDLE AGED;MALE;ADULT;AGED;;LUNG NEOPLASMS;BREAST NEOPLASMS;ITALY;ADENOCARCINOMA;TREATMENT OUTCOME;AGED, 80 AND OVER;BLOOD PRESSURE;HIV-ASSOCIATED LIPODYSTROPHY SYNDROME;MYOCARDIAL INFARCTION;POSTOPERATIVE COMPLICATIONS;ABDOMINAL NEOPLASMS;ADOLESCENT;CARDIOVASCULAR DISEASES","51;38;28;25;20;20;14;12;10;10;9;9;8;8;7;7;7;6;6;6","ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;KIDNEY TRANSPLANTATION;LYMPHOID NEOPLASMS;NEUROFIBROMATOSIS TYPE 1 AND TYPE 2;OBSTETRIC VESICOVAGINAL FISTULA AND URETERAL INJURIES;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ADVANCEMENTS IN LUNG CANCER RESEARCH;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;ATRIAL FIBRILLATION;BIOLOGICAL EFFECTS OF ELECTROMAGNETIC FIELDS;BIOMEDICAL OPTICAL IMAGING AND SPECTROSCOPY;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CANCER OF UNKNOWN PRIMARY SITE;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHRONIC RHINOSINUSITIS AND NASAL POLYPS;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","KAPOSI'S SARCOMA;ELISPOT;IMMUNOSUPPRESSION;TRANSPLANTATION;ANTIRETROVIRAL THERAPY;BRACHIAL ARTERY;BREAST MRI;CANCER INCIDENCE;CARDIOVASCULAR MRI;CONCOMITANT;CONTRACEPTION;DILATED CARDIOMYOPATHY;EMERGENCY CONTRACEPTION;EVEROLIMUS;HEMATOLOGICAL MALIGNANCIES;HUMAN HERPESVIRUS 8;LEVONORGESTREL;LIPODYSTROPHY;METASTATIC TUMORS;OPEN SURGERY","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CELL CARCINOMA;HEART FAILURE;DE NOVO;ACTIVE ANTIRETROVIRAL;BREAST CANCER;CARDIOVASCULAR RISK;CLINICAL EXPERIENCE;HIGHLY ACTIVE;HUMAN HERPESVIRUS-;HUMAN IMMUNODEFICIENCY;MAGNETIC RESONANCE;MIDDLE TURBINATE;NON-HODGKINS LYMPHOMA;NOVO RENAL;POSTMENOPAUSAL WOMEN;RANDOMIZED TRIAL;RESONANCE IMAGING;TRANSITIONAL CELL;TUMOR SEEDING;URETERAL TRANSITIONAL;ABDOMINAL BLEEDING;ABSTRACT PRETREATMENT;ACQUIRED CHOLESTEATOMA;ACTIVATED FACTOR;ACUTE REJECTION;ADENOCARCINOID TUMOR;ADENOMATOUS HYPERPLASIAASSOCIATED;ADVERSE PREGNANCY;AFFECTS CARDIOVASCULAR;AGENT THERAPY","4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","DI CARDIOLOGIA;CHARITÉ VIRCHOW;INCIDENCE RATIO;METABOLIC SYNDROME;OBSTETRICS CHARITÉ;VIRCHOW CLINIC;BERLIN GERMANYSEARCH;BREAST CANCER;CLINIC BERLIN;NON-HODGKINS LYMPHOMA;ARTERIOVENOUS MALFORMATION;DRUG-ELUTING STENTS;ECTOPIC PREGNANCY;HENRICH MD;LD SEVERITY;RESPONSE RATE;TIME FREE;WOLFGANG HENRICH;BLASI MD;BOLOGNA ITALY;BOLOGNA POLICLINICO;CARDIOLOGIA UNIVERSITÀ;CARDIOVASCULAR RISK;DI BOLOGNA;DUDENHAUSEN MD;ISTITUTO DI;MD DEPARTMENT;OBSTET GYNECOL;OPERATIVA DI;ORSOLA-MALPIGHI ITALY","10;7;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4",9,0.14,6,2,0,0,0,3,7.75,0,1.75,2,0,0,0,0,1,0,0,0,0,0,0,109,109,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,6.61,513.28,14.81,4,0.2,55.75,0,2,3,1,4,0,3,7,0,13,5,0,0,0,0,0,0,16,4,0,17,2,0,1,0,0,0,0,0,0,"Italy;United States;Germany","3;3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3215 REPRODUCTIVE MEDICINE;3203 DENTISTRY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;44 HUMAN SOCIETY","19;7;5;4;3;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;INFECTIOUS DISEASES;CANCER;HIV/AIDS;RARE DISEASES;BIOTECHNOLOGY;DIGESTIVE DISEASES;PREVENTION;BREAST CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;LIVER DISEASE;PATIENT SAFETY;CARDIOVASCULAR;HEART DISEASE;HEMATOLOGY;IMMUNIZATION;LUNG;TRANSPLANTATION;AGING","18;9;6;5;5;5;4;4;4;3;3;3;3;2;2;2;2;2;2;1","CANCER;INFECTION;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY","6;5;2;2;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.7 PHYSICAL","12;4;3;2;1;1;1","BREAST CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER;LUNG CANCER;MELANOMA;MYELOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER","3;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;3.3 CHEMOPREVENTION;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","6;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_MODENA",2009,71,9.50704225352113,3.7887323943662,0.535211267605634,0.507042253521127,0.563380281690141,1.43085106382979,1.1875,1.38461538461538,1.21212121212121,0.394366197183099,2,39,13,11,4,0.55,0.18,0.15,0.06,44.01,0.951507297511212,NA,0.253521126760563,0.732394366197183,0.371,0.343,0.338,0.339,"FABIO RUMPIANESI;MATTEO ALICANDRI‐CIUFELLI;MARIO LUPPI;MONICA PECORARI;GIULIO ROSSI;GABRIELE MOLTENI;LIVIO PRESUTTI;MARIA GRAZIA MODENA;ALBERTO CAVAZZA;ROBERTO D’AMICO;LUCA RICHELDI;ROSARIO ROSSI;GIUSEPPE TORELLI;NATHALIE VAISSIÈRE;SARA TAGLIAZUCCHI;C. DANIELLI;GIORGIO ENRICO GERUNDA;LEONARDO M. FABBRI;BARBARA MECCUGNI;ALESSANDRO MARCHIONI","7;5;5;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3","CRISTINA MUSSINI;GIULIANO FRANCO;MATTEO ALICANDRI‐CIUFELLI;GABRIELE MOLTENI;LIVIO PRESUTTI;MARIA GRAZIA MODENA;ANNIBALE VOLPE;GIULIO ROSSI;ALBERTO CAVAZZA;FABIO RUMPIANESI;ELISABETTA GENOVESE;ANGELO CAGNACCI;ANTONIO LANDI;SILVIO TOCCO;PAOLO BOCCOLARI;ANTONELLO PIETRANGELO;CHIARA VECCHI;GIULIANA MONTOSI;MARIO LUPPI;ROSARIO ROSSI","1.12;1;0.89;0.89;0.89;0.88;0.73;0.66;0.57;0.57;0.54;0.53;0.53;0.5;0.5;0.48;0.48;0.48;0.47;0.45","FABIO RUMPIANESI;MATTEO ALICANDRI‐CIUFELLI;MARIO LUPPI;MONICA PECORARI;GIULIO ROSSI;GABRIELE MOLTENI;LIVIO PRESUTTI;MARIA GRAZIA MODENA;LUCA RICHELDI;ROSARIO ROSSI;GIUSEPPE TORELLI;NATHALIE VAISSIÈRE;SARA TAGLIAZUCCHI;C. DANIELLI;GIORGIO ENRICO GERUNDA;BARBARA MECCUGNI;M. MORAND;PIERFRANCO CONTÉ;ELISABETTA GENOVESE;ANTONELLA GROTTOLA","7;5;5;5;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3","CRISTINA MUSSINI;GIULIANO FRANCO;MATTEO ALICANDRI‐CIUFELLI;GABRIELE MOLTENI;LIVIO PRESUTTI;MARIA GRAZIA MODENA;ANNIBALE VOLPE;GIULIO ROSSI;FABIO RUMPIANESI;ELISABETTA GENOVESE;ANGELO CAGNACCI;ANTONIO LANDI;PAOLO BOCCOLARI;ANTONELLO PIETRANGELO;CHIARA VECCHI;GIULIANA MONTOSI;MARIO LUPPI;ROSARIO ROSSI;GIUSEPPE SANGIORGI;MONICA PECORARI","1.12;1;0.89;0.89;0.89;0.88;0.73;0.66;0.57;0.54;0.53;0.53;0.5;0.48;0.48;0.48;0.47;0.45;0.44;0.42","CRISTINA MUSSINI;FABIO RUMPIANESI;ROSARIO ROSSI;MARIA GRAZIA MODENA;ALESSANDRO COZZI‐LEPRI;AMALIO TELENTI;ANDREA DE LUCA;ANDREW J. MCMICHAEL;ANTONELLA CASTAGNA;BARTON F. HAYNES;BRUNO LEDERGERBER;CURTIS GUMBS;DAVID B. GOLDSTEIN;DONGLIANG GE;ELIZABETH T. CIRULLI;HULDRYCH F. GÜNTHARD;J. BECKMANN;JACQUES FELLAY;JASON P. SMITH;JAVIER MARTÍNEZ‐PICADO","576;566;426;422;413;413;413;413;413;413;413;413;413;413;413;413;413;413;413;413","FABIO RUMPIANESI;ROSARIO ROSSI;CRISTINA MUSSINI;MARIA GRAZIA MODENA;ANNIBALE VOLPE;GIUSEPPE SANGIORGI;CHIARA LEUZZI;DANIEL MONOPOLI;E GUERRI;FABIO SGURA;FRANCESCA BURSI;ANTONELLO PIETRANGELO;CHIARA VECCHI;GIULIANA MONTOSI;BARBARA MECCUGNI;MARISA MEACCI;ANTONIO LA MARCA;IGOR LAMBERTI;MONICA PECORARI;A.M.T. SABBATINI","566;426;425;418;382;376;365;365;365;365;365;344;344;344;313;313;306;297;253;250","FABIO RUMPIANESI;GABRIELE MOLTENI;GIULIO ROSSI;LIVIO PRESUTTI;MATTEO ALICANDRI‐CIUFELLI;MONICA PECORARI;ROSARIO ROSSI;BARBARA MECCUGNI;MARISA MEACCI;PIERFRANCO CONTÉ;ANNIBALE VOLPE;CRISTINA MUSSINI;ELISABETTA GENOVESE;MASSIMINO MESSINÒ;ANTONELLA GROTTOLA;MARIA GRAZIA MODENA;WILLIAM GENNARI;A ALBERTAZZI;A CHAN;ANGELO CAGNACCI","7;5;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;ART;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;BUSINESS;HISTORY;MATERIALS SCIENCE;PSYCHOLOGY;SOCIOLOGY","66;18;6;4;4;3;2;2;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;RADIOLOGY;ONCOLOGY;CARDIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GENETICS;BIOCHEMISTRY;CANCER RESEARCH;DERMATOLOGY;MEDICAL PHYSICS;NUCLEAR MEDICINE;OPTICS;PALEONTOLOGY;PEDIATRICS;ANESTHESIA;ARTIFICIAL INTELLIGENCE;CELL BIOLOGY;PHYSICAL MEDICINE AND REHABILITATION;VIROLOGY","49;28;17;13;12;10;9;8;7;7;7;5;5;4;4;4;4;4;4;3;3;3;3;3","CANCER;ADVERSE EFFECT;GENE;CHEMOTHERAPY;POPULATION;DISEASE;ARTERY;HEAD AND NECK;LYMPHOMA;MYOCARDIAL INFARCTION;RECEPTOR;REGIMEN;STAGE (STRATIGRAPHY);STENT;TRANSPLANTATION;ANGIOPLASTY;CLINICAL TRIAL;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;KIDNEY;LUNG;MAGNETIC RESONANCE IMAGING;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;TOXICITY;TUBERCULOSIS;VIRUS","14;8;8;7;7;6;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;COLORECTAL CANCER;GENOTYPE;TOLERABILITY;CISPLATIN;MUTATION;MYCOBACTERIUM TUBERCULOSIS;TUBERCULIN;16S RIBOSOMAL RNA;CLINICAL ENDPOINT;HEAD AND NECK SURGERY;HEPCIDIN;HEREDITARY HEMOCHROMATOSIS;IMAGE QUALITY;IMMUNOTHERAPY;MYCOBACTERIUM;MYCOSIS FUNGOIDES;NEUTROPENIA;PERCUTANEOUS CORONARY INTERVENTION;PROTEINURIA;RADIATION TREATMENT PLANNING;SKIN CANCER;T CELL;TOMOTHERAPY;TYROSINE KINASE;VIRAL LOAD","7;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","METASTATIC BREAST CANCER;CAPECITABINE;LATENT TUBERCULOSIS;VINORELBINE;ANTHRACYCLINE;ANTIRETROVIRAL THERAPY;MACE;MAMMOGRAPHY;NONTUBERCULOUS MYCOBACTERIA;ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY;ARTERY DISSECTION;CD137;CD38;COMPUTED RADIOGRAPHY;COPY-NUMBER VARIATION;CORONAVIRUS DISEASE 2019 (COVID-19);DASATINIB;DETECTIVE QUANTUM EFFICIENCY;DRUG-ELUTING STENT;ESTROGEN RECEPTOR;ETHINYLESTRADIOL;FAMILY PLANNING;FEBRILE NEUTROPENIA;FERROPORTIN;FLUORESCENCE IN SITU HYBRIDIZATION;FOLLICULOGENESIS;GENOTYPING;GLOMERULOPATHY;HIATAL HERNIA;HUMAN GENOME;INTERFERON Γ;KARYOTYPE;LDL APHERESIS;LYMPHOBLASTIC LYMPHOMA;MISSENSE MUTATION;MUTANT PROTEIN;MYCOBACTERIUM KANSASII;OPPORTUNISTIC INFECTION;OVARIAN RESERVE;PARVOVIRIDAE;PD-L1;POLYCYSTIC OVARY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIGHT CORONARY ARTERY;SINGLE-NUCLEOTIDE POLYMORPHISM;SOLID ORGAN;TAXANE;TETRAPLEGIA;TRASTUZUMAB;TRIPLE-NEGATIVE BREAST CANCER;VINCRISTINE;WILD TYPE","5;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADOLESCENT;HIV INFECTIONS;ITALY;TREATMENT OUTCOME;LUNG NEOPLASMS;YOUNG ADULT;AGED, 80 AND OVER;ANGIOPLASTY, BALLOON, CORONARY;MELANOMA;SKIN NEOPLASMS;T-LYMPHOCYTES;TUBERCULOSIS, PULMONARY","53;35;34;34;24;24;18;14;13;12;12;12;11;11;9;9;8;8;8;8","CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;TUBERCULOSIS;BREAST CANCER SCREENING TECHNOLOGY;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;DIAGNOSIS AND TREATMENT OF VOICE DISORDERS;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;KIDNEY TRANSPLANTATION;LYMPHOID NEOPLASMS;MELANOMA;REGULATION OF IRON METABOLISM AND ANEMIA;TREATMENT AND OUTCOMES OF HAND INJURIES;ADVANCEMENTS IN LUNG CANCER RESEARCH;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;BRANCHIAL ANOMALIES AND THYROID ABNORMALITIES;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CANCER IMMUNOTHERAPY;CHOLESTEROL-LOWERING TREATMENT;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES","4;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","BREAST CANCER;CORONARY STENTS;METASTATIC BREAST CANCER;REGIMEN;TOLERABILITY;TREATMENT;HIV;QUANTIFERON;VINORELBINE;ANTIRETROVIRAL THERAPY;CLINICAL ENDPOINT;DIAGNOSTIC CRITERIA;DIGITAL MAMMOGRAPHY;DRUG-ELUTING STENTS;HEMATOLOGY;HEREDITARY HEMOCHROMATOSIS;HOMEOSTASIS;IMMUNOCOMPROMISED PATIENTS;INTERPHALANGEAL JOINT;INTRAVASCULAR ULTRASOUND","4;4;4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;METASTATIC BREAST;PHASE II;II TRIAL;INTERNATIONAL PHASE;ORAL VINORELBINE;AIRTUM STUDY;ALL-ORAL COMBINATION;ALLOGENEIC STEM;CANCER MBC;CANCER REGISTRIES;CARDIAC EVENTS;CONTROLLED TRIAL;CORONARY ARTERY;HER-NEGATIVE METASTATIC;ITALIAN NETWORK;LATENT TUBERCULOSIS;MULTICENTER INTERNATIONAL;MYOCARDIAL INFARCTION;NONTUBERCULOUS MYCOBACTERIA;RANDOMIZED CONTROLLED;REGISTRIES AIRTUM;SKIN MELANOMA;STEM CELL;STRONG SEASONALITY;VINORELBINE NVBO;ABDOMINAL AORTIC;ACCIDENTAL ASA;ACTIVE ANTIRETROVIRAL;ACTIVITY DIRECTED","5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","PUBMED SCOPUS;CROSSREF PUBMED;REGGIO EMILIA;MODENA ITALYSEARCH;AZIENDA OSPEDALIERA-UNIVERSITARIA;EMILIA AZIENDA;HUMAN HERPESVIRUS;OSPEDALIERA-UNIVERSITARIA POLICLINICO;POLICLINICO MODENA;STEM CELL;INFECT DIS;BONE MARROW;CLARK DA;HUMAN HERPESVIRUS-;DIS -CROSSREF;ONCOLOGY HEMATOLOGY;RESPIRATORY DISEASES;INTEGRATED HUMAN;LEONG HN;DISEASES SECTION;HEMATOLOGY UNIVERSITY;VIROL -CROSSREF;HHV- DNA;HHV- LOADS;MED VIROL;NECK SURGERY;GRIFFITHS PD;NACHEVA EP;CHROMOSOMALLY INTEGRATED;DI MODENA","53;49;32;28;22;22;22;22;22;22;20;19;17;17;16;16;16;15;15;14;14;14;13;13;13;12;11;11;10;10",10,0.14,3,2.75,0,1,0,1,1.5,0,2,3.75,0,0,1,0,5,0,0,1,0,0,0,127.25,128.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,5.17,383.27,10.06,3,0.18,41.12,0,0,5,0,4,0,5,3,0,9,2,0,0,0,0,0,0,14,1,2,11,6,0,0,0,0,0,0,0,0,"United States;Italy;Japan","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3009 VETERINARY SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;49 MATHEMATICAL SCIENCES","15;9;4;4;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;LYMPHOMA;ORPHAN DRUG;RARE DISEASES;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;BIOENGINEERING;INFECTIOUS DISEASES;PEDIATRIC;AGING;BIOMEDICAL IMAGING;BREAST CANCER;CHILDHOOD LEUKEMIA","12;11;5;4;3;3;3;3;3;3;3;2;2;2;2;2;1;1;1;1","CANCER;INFECTION;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;GENERIC HEALTH RELEVANCE;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE","5;4;2;2;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;5.4 SURGERY;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","7;3;1;1;1;1;1;1;1","LIVER CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;PROSTATE CANCER","3;2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","5;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_MODENA",2010,92,10.25,3.51086956521739,0.532608695652174,0.434782608695652,0.66304347826087,1.40434782608696,1.225,1.42857142857143,1.17307692307692,0.456521739130435,2,50,19,14,1,0.54,0.21,0.15,0.01,32.57,0.720619376295315,NA,0.184782608695652,0.684782608695652,0.457,0.311,0.416,0.37,"MARIA GRAZIA MODENA;GIULIO ROSSI;GIUSEPPE SANGIORGI;GIORGIO ENRICO GERUNDA;ROBERTO MONTALTI;FABRIZIO DI BENEDETTO;STEFANO SACCHI;MARCELLO PINTI;ANDREA COSSARIZZA;GIANLUCA ROMPIANESI;MILENA NASI;FRANCESCO DI RAIMONDO;GIORGIO LA NASA;PELLEGRINO MUSTO;FRANCESCO MERLI;LUIGI POLITI;LUCA BALDINI;MASSIMO GIRARDIS;CRISTINA MUSSINI;GIOVANNA CUTRONA","11;7;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;3","MARIA GRAZIA MODENA;ANGELO CAGNACCI;GIUSEPPE SANGIORGI;GIULIO ROSSI;PAOLO BOCCOLARI;MASSIMO GIRARDIS;TRACY FAIRPLAY;SILVANA SARTINI;LUIGI POLITI;L POLITI;ANDRÉA BARBIERI;DANIEL MONOPOLI;S FERRARI;ALBERTO CAVAZZA;NAZARENA NANNINI;MARIA CECILIA MENGOLI;GIORGIO ENRICO GERUNDA;ROBERTO MONTALTI;ALFREDO CACCIARI;FABRIZIO DI BENEDETTO","2.32;1.67;1.58;1.09;1;0.95;0.83;0.83;0.77;0.67;0.6;0.52;0.5;0.5;0.48;0.48;0.48;0.48;0.45;0.45","MARIA GRAZIA MODENA;GIULIO ROSSI;GIUSEPPE SANGIORGI;GIORGIO ENRICO GERUNDA;ROBERTO MONTALTI;FABRIZIO DI BENEDETTO;STEFANO SACCHI;GIANLUCA ROMPIANESI;LUIGI POLITI;MASSIMO GIRARDIS;CRISTINA MUSSINI;FABIO RUMPIANESI;GIAN PIERO GUERRINI;B. BEGLIOMINI;ANTONELLA GROTTOLA;ALFREDO CACCIARI;DANIEL MONOPOLI;ANGELO CAGNACCI;LAURA CORTESI;NAZARENA NANNINI","11;7;7;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3","MARIA GRAZIA MODENA;ANGELO CAGNACCI;GIUSEPPE SANGIORGI;GIULIO ROSSI;PAOLO BOCCOLARI;MASSIMO GIRARDIS;TRACY FAIRPLAY;SILVANA SARTINI;LUIGI POLITI;L POLITI;ANDRÉA BARBIERI;DANIEL MONOPOLI;NAZARENA NANNINI;MARIA CECILIA MENGOLI;GIORGIO ENRICO GERUNDA;ROBERTO MONTALTI;ALFREDO CACCIARI;FABRIZIO DI BENEDETTO;ELISABETTA GENOVESE;FRANCESCA BURSI","2.32;1.67;1.58;1.09;1;0.95;0.83;0.83;0.77;0.67;0.6;0.52;0.48;0.48;0.48;0.48;0.45;0.45;0.45;0.44","MASSIMO OFFIDANI;FRANCESCO DI RAIMONDO;GIORGIO LA NASA;A LEDDA;ANTONIO PALUMBO;ANTONIO SPADANO;CLAUDIA CELLINI;CLAUDIA CRIPPA;ELENA ZAMAGNI;FRANCESCA PATRIARCA;FRANCO NARNI;LUCIA PANTANI;MARIA TERESA PETRUCCI;MICHELE BACCARANI;MICHÈLE CAVO;MÓNICA GALLI;NORBERT PESCOSTA;PAOLA TACCHETTI;PAOLO CORRADINI;PATRIZIA TOSI","835;817;817;815;815;815;815;815;815;815;815;815;815;815;815;815;815;815;815;815","FRANCO NARNI;MICHÈLE ZOLI;CRISTINA MUSSINI;FRANCESCA BURSI;B. BEGLIOMINI;MARIA GRAZIA MODENA;GIULIO ROSSI;ANDRÉA BARBIERI;CATERINA RICCI;CHIARA LEUZZI;LETIZIA REGGIANINI;VERA ZANASI;MAURO CODELUPPI;GABRIELE MOLTENI;LIVIO PRESUTTI;MATTEO ALICANDRI‐CIUFELLI;CLAUDIA CIRILLI;FABRIZIO DI BENEDETTO;GIORGIO ENRICO GERUNDA;ROBERTO MONTALTI","815;275;245;231;227;204;157;142;141;141;141;141;133;116;116;116;107;106;106;106","MARIA GRAZIA MODENA;GIUSEPPE SANGIORGI;CRISTINA MUSSINI;GIULIO ROSSI;GIORGIO ENRICO GERUNDA;ROBERTO MONTALTI;STEFANO SACCHI;FABRIZIO DI BENEDETTO;MASSIMO GIRARDIS;LUIGI POLITI;B. BEGLIOMINI;DANIEL MONOPOLI;FRANCESCA BURSI;GIAN PIERO GUERRINI;GIANLUCA ROMPIANESI;LAURA CORTESI;ROSARIO ROSSI;ANGELO CAGNACCI;ALBERTO BERARDI;ALBERTO PASETTO","9;7;7;6;5;5;5;4;4;3;3;3;3;3;3;3;3;3;2;2","MEDICINE;BIOLOGY;PHYSICS;MATHEMATICS;SOCIOLOGY;CHEMISTRY;ENGINEERING;POLITICAL SCIENCE;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;PHILOSOPHY;MATERIALS SCIENCE","87;28;6;4;4;3;3;3;3;2;2;2;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;CARDIOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;PHARMACOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;INTENSIVE CARE MEDICINE;MICROBIOLOGY;VIROLOGY;BOTANY;EMERGENCY MEDICINE;GYNECOLOGY;OPTICS;RADIOLOGY","68;27;19;19;15;14;13;11;9;8;7;7;6;6;6;5;5;5;5;5","GENE;MYOCARDIAL INFARCTION;CANCER;TRANSPLANTATION;ALTERNATIVE MEDICINE;ANTIBODY;POPULATION;HORMONE;IMMUNOHISTOCHEMISTRY;INCIDENCE (GEOMETRY);SEPSIS;VIRUS;ADVERSE EFFECT;ARTERY;BLOOD PRESSURE;CHEMOTHERAPY;DISEASE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IDENTIFICATION (BIOLOGY);IMMUNE SYSTEM;IN VITRO;LUNG;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;RENAL FUNCTION","13;10;9;8;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4","BREAST CANCER;LIVER TRANSPLANTATION;VIRAL LOAD;CD34;CD8;DIASTOLE;PERCUTANEOUS CORONARY INTERVENTION;SEPTIC SHOCK;CALCINEURIN;CHRONIC LYMPHOCYTIC LEUKEMIA;COMPLEMENT SYSTEM;CONTRAINDICATION;CYTOTOXIC T CELL;EJECTION FRACTION;HAZARD RATIO;INSULIN RESISTANCE;MITOCHONDRIAL DNA;PERIPHERAL BLOOD MONONUCLEAR CELL;PLACEBO;PROGESTIN;PROGRESSIVE DISEASE;RESEARCH METHODOLOGY;STREPTOCOCCUS;T CELL;VIRAL DISEASE","5;5;5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;CD38;FAMILY PLANNING;SEVERE SEPSIS;TAMOXIFEN;ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS;ALTERNATIVE COMPLEMENT PATHWAY;ANTIVIRAL THERAPY;ATYPICAL HEMOLYTIC UREMIC SYNDROME;BASILIXIMAB;BONE MARROW TRANSPLANT;BRONCHIOLITIS OBLITERANS;CHLORMADINONE ACETATE;COMPLEMENTARITY DETERMINING REGION;CORONARY STENT;CREB;CYP2D6;DRUG-ELUTING STENT;DYSTROGLYCAN;ECULIZUMAB;EOSINOPHILIC PNEUMONIA;ETHINYLESTRADIOL;FACTOR H;FUNCTIONAL MITRAL REGURGITATION;GLOMERULOPATHY;HOMEOSTATIC MODEL ASSESSMENT;IGHV@;KARYOTYPE;LAMIVUDINE;LEGIONNAIRES' DISEASE;LENTIVIRUS;LIVING DONOR LIVER TRANSPLANTATION;MACE;MAMMOGRAPHY;MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;MONOCLONAL;MYCOBACTERIUM BOVIS;NEOADJUVANT THERAPY;ORTHOTOPIC LIVER TRANSPLANTATION;OVARIAN RESERVE;PAPILLARY THYROID CANCER;PARAPNEUMONIC EFFUSION;POLYCYSTIC OVARY;PULMONARY EOSINOPHILIA;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIBAVIRIN;SIDA;SIGMA-1 RECEPTOR;SOLID ORGAN;SUPERANTIGEN;VENTRAL TEGMENTAL AREA;VIRILIZATION;WAIST–HIP RATIO","4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;HIV INFECTIONS;AGED;MYOCARDIAL INFARCTION;ITALY;LUNG NEOPLASMS;TREATMENT OUTCOME;HIV-1;STREPTOCOCCAL INFECTIONS;AGED, 80 AND OVER;CD4-POSITIVE T-LYMPHOCYTES;LIVER TRANSPLANTATION;TIME FACTORS;ANGIOPLASTY, BALLOON, CORONARY;CARCINOID TUMOR","58;44;38;31;28;25;21;19;17;14;12;11;10;10;9;9;9;9;8;8","EPIDEMIOLOGY AND MANAGEMENT OF SEPSIS AND SEPTIC SHOCK;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;STRUCTURE AND FUNCTION OF NICOTINIC RECEPTORS;ADVANCEMENTS IN LUNG CANCER RESEARCH;AMOEBIASIS: PATHOGENESIS AND CLINICAL MANAGEMENT;ANALYSIS OF ELECTROCARDIOGRAM SIGNALS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CLASSIFICATION AND TREATMENT OF HISTIOCYTIC DISORDERS;CONGENITAL CORONARY ARTERY ANOMALIES AND THEIR MANAGEMENT;CONTRACEPTION AND UNINTENDED PREGNANCY PREVENTION","4;4;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","HIV;ANTIRETROVIRAL THERAPY;IDENTIFICATION (BIOLOGY);MYOCARDIAL REVASCULARIZATION;GROUP B;LIVER TRANSPLANTATION;SEPSIS;AIDS;BRAIN REWARD AREAS;BREAST CANCER;CANCER INCIDENCE;CARDIAC IMAGING;CARDIOVASCULAR EVALUATION;CARDIOVASCULAR RISK ASSESSMENT;CONTRAINDICATION;CORONARY ARTERY ANOMALIES;CORONARY STENTS;DIAGNOSIS;ECHOCARDIOGRAPHY;EVEROLIMUS","7;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","MYOCARDIAL INFARCTION;LIVER TRANSPLANTATION;ACUTE MYOCARDIAL;BREAST CANCER;CHRONIC LYMPHOCYTIC;CIRRHOTIC PATIENTS;CORONARY ARTERY;DE NOVO;GENE SEQUENCING;LYMPHOCYTIC LEUKEMIA;MULTICENTER STUDY;MULTIMODALITY IMAGING;NEUROENDOCRINE TUMOR;NEWLY DIAGNOSED;PHASE II;RENAL FUNCTION;SEPTIC SHOCK;ACCURATE IDENTIFICATION;ACETATE-ETHINYLESTRADIOL ORAL;ACETYLCHOLINE RECEPTORS;ACRAL MYXOINFLAMMATORY;ACTIVITY INSPECTION;ACUTE MYELOID;ADL AIDES;AGEPERIODCOHORT EFFECTS;AL POLICLINICO;ALCOHOL MICROSPHERES;ALTERNATIVE SPLINTING;ANALYSES BASED;ANALYSIS MOLECULAR","5;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CD CELL;MUCINOUS BAC;MITRAL REGURGITATION;NONMUCINOUS BAC;RISK FACTORS;CELL COUNT;CELL DECLINE;CIRRHOTIC PATIENTS;HIV INFECTION;IMPLANT RATES;CRP LEVEL;CRP LEVELS;DIASTOLIC DYSFUNCTION;MAJOR PD;MELD SCORE;MITOCHONDRIAL TOXICITY;MTDNA CONTENT;PAPILLARY TC;PRE-CART CD;PROTEIN CRP;SEVENTY-FIFTH PERCENTILE;SEVERE MITRAL;ANTIRETROVIRAL REGIMENS;BACTERIAL INFECTION;CD T-CELLS;CELL SLOPE;CLINICAL PRACTICE;CONFORMAL RADIOTHERAPY;DA NEURONS;DIMENSIONAL CONFORMAL","11;7;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3",10,0.11,6.12,2,0,0,0,1,1,0,2,4.25,0,1,1,0,2,1,1,1,1,0,0,78.5,78.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,5,902.88,4.46,4,0.4,45.2,0,0,4,0,5,0,1,0,0,8,0,0,0,0,0,0,0,8,2,0,8,2,0,0,0,0,0,0,0,0,"Canada;Germany;Switzerland;United States","1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","10;5;4;3;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;RARE DISEASES;CARDIOVASCULAR;BREAST CANCER;ORPHAN DRUG;AGING;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;BIOENGINEERING;BIOMEDICAL IMAGING;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;DENTAL/ORAL AND CRANIOFACIAL DISEASE;DIGESTIVE DISEASES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;INFECTIOUS DISEASES;LUNG","8;6;6;4;4;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY","4;2;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;6.4 SURGERY;7.3 MANAGEMENT AND DECISION MAKING","6;3;1;1;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;HEAD AND NECK CANCER;LARYNGEAL CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","2;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","5;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_MODENA",2011,106,10.0471698113208,3.08490566037736,0.405660377358491,0.330188679245283,0.433962264150943,1.35833333333333,1.16216216216216,1.52173913043478,1.17948717948718,0.443396226415094,1,47,21,19,9,0.44,0.2,0.18,0.08,42.34,0.995423354882811,NA,0.264150943396226,0.839622641509434,0.382,0.315,0.268,0.324,"GIULIO ROSSI;ALBERTO CAVAZZA;MILENA NASI;MONICA PECORARI;PIERFRANCO CONTÉ;PAOLO GRAZIANO;GIUSEPPE PELOSI;LINDA BERTONCELLI;MARCO PIGNATTI;MATTIA BARBARESCHI;ANDREA COSSARIZZA;MAURO PAPOTTI;MATTEO ALICANDRI‐CIUFELLI;GIOVANNI GUARALDI;FABIO RUMPIANESI;ALBERTO BERARDI;ALESSIA BARI;FABIO CATANI;CARMELA DI GREGORIO;BENIAMINO PALMIERI","8;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","MARCO PIGNATTI;BENIAMINO PALMIERI;GIULIO ROSSI;ALESSANDRO GHIDDI;PAOLA PEDRAZZI;MARCO MARIETTA;LUCA RICHELDI;MARIA TERESA MASCIA;FABIO CATANI;CLAUDIO FERRI;STEFANIA CAPONE;ALBERTO CAVAZZA;M BOLONDI;Y. UZUNHAN;ALBERTO FARINETTI;CLODOVEO FERRI;ROSARIO ROSSI;MARIA GRAZIA MODENA;ALESSIA BARI;STEFANO SACCHI","1.54;0.87;0.85;0.67;0.67;0.67;0.64;0.57;0.56;0.54;0.53;0.53;0.5;0.5;0.5;0.49;0.45;0.45;0.42;0.42","GIULIO ROSSI;MILENA NASI;MONICA PECORARI;PIERFRANCO CONTÉ;PAOLO GRAZIANO;MARCO PIGNATTI;MATTEO ALICANDRI‐CIUFELLI;GIOVANNI GUARALDI;FABIO RUMPIANESI;ALBERTO BERARDI;ALESSIA BARI;FABIO CATANI;CARMELA DI GREGORIO;BENIAMINO PALMIERI;ANTONELLA GROTTOLA;STEFANO SACCHI;CLAUDIO FERRI;VANNI BORGHI;GIUSEPPE SANGIORGI;CINZIA DEL GIOVANE","8;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","MARCO PIGNATTI;BENIAMINO PALMIERI;GIULIO ROSSI;ALESSANDRO GHIDDI;PAOLA PEDRAZZI;LUCA RICHELDI;MARIA TERESA MASCIA;FABIO CATANI;CLAUDIO FERRI;M BOLONDI;CLODOVEO FERRI;ROSARIO ROSSI;MARIA GRAZIA MODENA;ALESSIA BARI;STEFANO SACCHI;MATTEO ALICANDRI‐CIUFELLI;LIVIO PRESUTTI;MILENA NASI;PIERFRANCO CONTÉ;GIOVANNI GUARALDI","1.54;0.87;0.85;0.67;0.67;0.64;0.57;0.56;0.54;0.5;0.49;0.45;0.45;0.42;0.42;0.39;0.39;0.38;0.37;0.37","ANTONIO LA MARCA;ANNA PIA FERRARETTI;BART C.J.M. FAUSER;BASIL C. TARLATZIS;GEETA NARGUND;LUCA GIANAROLI;GIULIO ROSSI;ALBERTO CAVAZZA;GIUSEPPE PELOSI;MATTIA BARBARESCHI;MAURO PAPOTTI;PAOLO GRAZIANO;MONICA PECORARI;VANNI BORGHI;FABRIZIO BIANCHI;PATRICK MAISONNEUVE;LUCA NOCETTI;ANNALISA BARGELLINI;ISABELLA MARCHESI;PAOLA BORELLA","1582;1580;1580;1580;1580;1580;363;288;288;288;288;288;251;238;191;191;184;173;173;173","ANTONIO LA MARCA;GIULIO ROSSI;VANNI BORGHI;LUCA NOCETTI;S. CENCETTI;CRISTINA MUSSINI;MARCO PIGNATTI;G MALMUSI;MONICA PECORARI;ANTONIO FRASSOLDATI;LISA MANZINI;ADRIANA CORDOVA;FRANCESCO MOSCHELLA;SALVATORE D’ARPA;T. COSTI;MONICA CELLINI;LIVIO PRESUTTI;MATTEO ALICANDRI‐CIUFELLI;ALBERTO GRAMMATICA;CLAUDIA VENTURELLI","1582;363;238;184;173;164;149;141;127;123;113;109;109;109;99;98;96;96;93;93","GIULIO ROSSI;CRISTINA MUSSINI;CLAUDIA VENTURELLI;MARCO PIGNATTI;PIERFRANCO CONTÉ;ALBERTO BERARDI;ANTONELLA GROTTOLA;BENIAMINO PALMIERI;CARMELA DI GREGORIO;FABIO CATANI;FABIO RUMPIANESI;FEDERICA BERTOLINI;GABRIELE LUPPI;LIVIO PRESUTTI;MATTEO ALICANDRI‐CIUFELLI;MONICA PECORARI;VANNI BORGHI;ALBERTO GRAMMATICA;ALDO ROSSI;ALESSIA BARI","8;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;CHEMISTRY;MATHEMATICS;PSYCHOLOGY;ECONOMICS;PHILOSOPHY;BUSINESS;GEOGRAPHY;MATERIALS SCIENCE;SOCIOLOGY","98;33;10;9;6;4;4;4;3;3;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GENETICS;IMMUNOLOGY;ONCOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;ANATOMY;BIOCHEMISTRY;CARDIOLOGY;ENDOCRINOLOGY;PEDIATRICS;INTENSIVE CARE MEDICINE;MICROBIOLOGY;PSYCHIATRY;VIROLOGY;DERMATOLOGY;OPTICS","61;31;22;21;18;17;12;11;9;8;8;8;8;8;7;7;7;7;6;6","CANCER;GENE;POPULATION;BACTERIA;VIRUS;COHORT;ALTERNATIVE MEDICINE;CHEMOTHERAPY;TRANSPLANTATION;BIOPSY;BLOOD PRESSURE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNOHISTOCHEMISTRY;INCIDENCE (GEOMETRY);RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;REGIMEN;ANTIBIOTICS;ANTIGEN;CARCINOMA;CONFIDENCE INTERVAL;IMMUNE SYSTEM;PREGNANCY;PROSPECTIVE COHORT STUDY;QUALITY OF LIFE (HEALTHCARE);RETROSPECTIVE COHORT STUDY","22;13;11;8;8;7;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","COLORECTAL CANCER;BREAST CANCER;LIVER TRANSPLANTATION;VIRAL LOAD;ADENOCARCINOMA;CYCLOPHOSPHAMIDE;METASTASIS;STAPHYLOCOCCUS AUREUS;GENOTYPE;HAZARD RATIO;BRACHIAL ARTERY;CARCINOGENESIS;CARDIAC FUNCTION CURVE;CERVICAL CANCER;CISPLATIN;GENE EXPRESSION;HUMAN CYTOMEGALOVIRUS;HUMAN LEUKOCYTE ANTIGEN;HYPERPHOSPHATEMIA;IN VITRO FERTILISATION;INFERTILITY;INNATE IMMUNE SYSTEM;LEGIONELLA;LEGIONELLA PNEUMOPHILA;MUTATION;OSTEOARTHRITIS;PERCUTANEOUS CORONARY INTERVENTION;PHENOTYPE;PROINFLAMMATORY CYTOKINE;SUPEROXIDE DISMUTASE;VIRAL DISEASE","8;6;5;5;4;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;CAPECITABINE;ADENOSQUAMOUS CARCINOMA;DNA MISMATCH REPAIR;GERMLINE MUTATION;HERPESVIRIDAE;HPV INFECTION;MICROCOCCACEAE;PRIMARY TUMOR;THYROID TRANSCRIPTION FACTOR 1;VANCOMYCIN;VINCRISTINE;VINORELBINE;ACINETOBACTER BAUMANNII;ACUTE ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;ANTIVIRAL TREATMENT;AROMATASE;AXILLA;CD38;CD40;CETUXIMAB;COMET ASSAY;COMPLEMENTARITY DETERMINING REGION;CYP2D6;CYTOMEGALOVIRUS INFECTION;DNA METHYLATION;DRUG-ELUTING STENT;ENTEROCOCCUS FAECALIS;FOLLICULAR FLUID;FOVEOLAR CELL;HAPLOTYPE;HLA-B27;HORMONAL THERAPY;IGHV@;IN UTERO;LARGE CELL;LATENT TUBERCULOSIS;LYMPHOVASCULAR INVASION;MACE;MALE INFERTILITY;MEN WHO HAVE SEX WITH MEN;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;METHYLTRANSFERASE;MICROARRAY;MICROMETASTASIS;MICROSATELLITE;MILAN CRITERIA;MUCOSA-ASSOCIATED LYMPHOID TISSUE;MULTILOCUS SEQUENCE TYPING;NKG2D;OLIGOARTHRITIS;OSTEONECROSIS OF THE JAW;OVARIAN RESERVE;OVULATION INDUCTION;OXALIPLATIN;PAPILLOMAVIRIDAE;PHOSPHATE BINDER;PRIMARY ANGIOPLASTY;PROBAND;PROSTATE BIOPSY;PULSED-FIELD GEL ELECTROPHORESIS;RIBAVIRIN;SECONDARY HYPERPARATHYROIDISM;SENTINEL LYMPH NODE;SEVELAMER;SEVERE SEPSIS;STAPHYLOCOCCAL INFECTIONS;STROKE VOLUME;TAMOXIFEN;TRANSORAL LASER MICROSURGERY;TRIPLE-NEGATIVE BREAST CANCER;VERY LOW CALORIE DIET","3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;;ITALY;HIV INFECTIONS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;TREATMENT OUTCOME;LUNG NEOPLASMS;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;CARCINOMA, NON-SMALL-CELL LUNG;ADRENAL CORTEX NEOPLASMS;BIOMARKERS, TUMOR;CARCINOMA, SQUAMOUS CELL;CARCINOSARCOMA;NEOPLASMS, MULTIPLE PRIMARY","75;54;48;42;32;30;28;27;22;16;16;15;15;14;11;10;10;10;10;10","HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;LYMPHOID NEOPLASMS;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;FACIAL FILLERS AND REJUVENATION TECHNIQUES;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;INTERACTIONS OF LEGIONELLA AND AMOEBAE IN DISEASE;MANAGEMENT AND EPIDEMIOLOGY OF PNEUMONIA;MANAGEMENT AND PATHOPHYSIOLOGY OF INTRACEREBRAL HEMORRHAGE;MINERAL METABOLISM IN CHRONIC KIDNEY DISEASE;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;RHEUMATOID ARTHRITIS;RNA METHYLATION AND MODIFICATION IN GENE EXPRESSION;TREATMENT AND OUTCOMES OF HAND INJURIES","5;5;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","REGIMEN;FACIAL REJUVENATION;HIV;HIV INFECTION;LIVER BIOPSY;TREATMENT;ADENOSQUAMOUS CARCINOMA;ANTICOAGULANT THERAPY;ANTIRETROVIRAL THERAPY;BIOMARKER ANALYSIS;BRACHIAL ARTERY;BREAST CANCER;CELL DIFFERENTIATION;CHEEK;CHRONIC KIDNEY DISEASE;CLINICAL SIGNIFICANCE;CONCOMITANT;CYTOMEGALOVIRUS;DERMAL FILLERS;DIAGNOSIS","5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LIVER TRANSPLANTATION;RECTAL CANCER;CELL LUNG;ADRENAL GLAND;B-CELL LYMPHOMA;BREAST CANCER;CAP PRELIMINARY;COLLISION TUMOR;CYTOMEGALOVIRUS INFECTION;ENDOTHELIAL FUNCTION;FACIAL LIPOATROPHY;FAILCAP STUDY;GLAND CARCINOSARCOMA;HITHERTO UNREPORTED;HOSPITALIZED PATIENTS;INTRACEREBRAL HAEMORRHAGE;ITALIAN SOCIETY;ITALIAN SURVEY;LEGIONELLA CONTAMINATION;LUNG CANCER;LYMPH NODE;LYNCH SYNDROME;METASTATIC RECTAL;METRONOMIC CHEMOTHERAPY;NATIONAL ITALIAN;NON-SMALL CELL;NORTHERN ITALIAN;ONCOLOGY RESULTS;PERCUTANEOUS CORONARY;PNEUMONIA CAP","4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","TREATMENT INTERRUPTION;ANTIVIRAL TREATMENT;CONFIDENCE INTERVAL;ENDOTHELIAL FUNCTION;DELAYED ZOL;INTRASEPTAL DISSECTION;MUTATION CARRIERS;POSTMENOPAUSAL WOMEN;SURGICAL SPECIMENS;ADVANCED AGE;AIDS EVENT;BLOOD PRESSURE;CANCER ONSET;CLINICAL PARAMETERS;CLINICAL PROGRESSION;DECOMPENSATED PATIENTS;DONOR AGE;HPV INFECTION;HYPERTENSIVE POSTMENOPAUSAL;LIVER DONORS;LIVER TRANSPLANT;LUNG CANCER;MULTIVARIATE ANALYSIS;NORTH EASTERN;PERCUTANEOUS VERTEBROPLASTY;PERFORATOR FLAPS;PHOSPHATE LEVELS;POSTERIOR TIBIAL;SQUAMOUS CELL;SSC PATIENTS","8;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",22,0.21,3.94,3,1,2,0,4,2.5,0,1,4,0,0,2,0,0,1,1,2.25,1,0,0,76.25,77,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,4.69,363.57,6.61,6,0.4,62.13,1,0,4,0,7,0,0,3,0,13,1,0,0,0,0,0,0,13,2,0,14,1,0,0,0,0,0,0,0,0,"Italy;Switzerland;United Kingdom","5;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","15;6;5;4;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;HEMATOLOGY;AGING;LYMPHOMA;PREVENTION;AUTOIMMUNE DISEASE;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;INFECTIOUS DISEASES;LIVER DISEASE;NEUROSCIENCES;PEDIATRIC;BIOTECHNOLOGY;BRAIN DISORDERS;CARDIOVASCULAR;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;EMERGING INFECTIOUS DISEASES","14;11;7;6;5;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1","CANCER;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY","5;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;3.4 VACCINES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;6.7 PHYSICAL;7.3 MANAGEMENT AND DECISION MAKING","10;2;1;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;NEUROBLASTOMA;OVARIAN CANCER","3;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","4",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,"AMERICAN CHEMICAL SOCIETY","9","31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES","9;9;9","CANCER;CLINICAL RESEARCH;DIGESTIVE DISEASES;PANCREATIC CANCER;RARE DISEASES","9;9;9;9;9","CANCER","9","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","9;9","BIOMEDICAL","9","CLINICAL MEDICINE AND SCIENCE","9","PANCREATIC CANCER","9",NA,NA
"AOU_MODENA",2012,88,11.6022727272727,2.31818181818182,0.295454545454545,0.284090909090909,0.352272727272727,1.36912751677852,1.08333333333333,1.08695652173913,1.06896551724138,0.534090909090909,2,54,18,9,1,0.61,0.2,0.1,0.01,34.5,0.825984568052557,5.08373205741627,0.284090909090909,0.875,0.391,0.335,0.348,0.326,"GIULIO ROSSI;CRISTINA MUSSINI;ANDREA COSSARIZZA;ALBERTO CAVAZZA;MARIO MIGALDI;CHRISTOPH STEPHAN;MASSIMO FEDERICO;GIULIANA SARTORI;MARCELLO PINTI;VANNI BORGHI;FRANCESCO MERLI;VERONICA BERNABUCCI;GIOVANNI GUARALDI;GIORGIO ENRICO GERUNDA;ANNA MARIA CESINARO;MILENA NASI;CALOGERO CAMMÀ;FRANCO AVERSA;NICOLA DE MARIA;CHIARA CORIANI","8;6;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","ANNA MARIA CESINARO;GIULIO ROSSI;RICCARDO MAGISTRONI;ANDREA COSSARIZZA;GIORGIO DE SANTIS;CRISTINA MUSSINI;MARCELLO PINTI;VANNI BORGHI;FRANCESCO MERLI;MARCO PIGNATTI;MASSIMO FEDERICO;MARIO MIGALDI;CHIARA CORIANI;M. BERGONZI;EMILIO MARIA BASSI;PAOLO G. GOBBI;FABIO CATANI;ALBERTO CAVAZZA;GIULIANA SARTORI;GIOVANNI GUARALDI","1.48;1.16;1;0.77;0.67;0.6;0.57;0.54;0.53;0.5;0.45;0.4;0.4;0.4;0.4;0.4;0.4;0.39;0.38;0.36","GIULIO ROSSI;CRISTINA MUSSINI;MARIO MIGALDI;MASSIMO FEDERICO;GIULIANA SARTORI;VANNI BORGHI;GIOVANNI GUARALDI;GIORGIO ENRICO GERUNDA;ANNA MARIA CESINARO;PIERFRANCO CONTÉ;MARIA CECILIA MENGOLI;ROBERTO SABBATINI;ANTONINO MAIORANA;MARIO LUPPI;ANTONIO LA MARCA;VIVIANA DURANTE;ANJEZA XHOLLI;MONICA PECORARI;A. SCARCELLI;DIEGO BIONDINI","8;6;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","ANNA MARIA CESINARO;GIULIO ROSSI;RICCARDO MAGISTRONI;GIORGIO DE SANTIS;CRISTINA MUSSINI;VANNI BORGHI;MARCO PIGNATTI;MASSIMO FEDERICO;MARIO MIGALDI;FABIO CATANI;GIULIANA SARTORI;GIOVANNI GUARALDI;C.U. MANZINI;PIETRO ROVERSI;BIANCA BEGHÉ;CLAUDIO FERRI;ELISA MANZINI;FABRIZIO LUPPI;PIERFRANCO CONTÉ;ANJEZA XHOLLI","1.48;1.16;1;0.67;0.6;0.54;0.5;0.45;0.4;0.4;0.38;0.36;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.31","AIMILIA KARAMPATOU;CALOGERO CAMMÀ;ERICA VILLA;NICOLA DE MARIA;RANKA VUKOTIC;STEFANO GITTO;VERONICA BERNABUCCI;ELENA TUROLA;SALVATORE PETTA;ANNA FERRARI;BARBARA LEI;BEATRICE ZAMBOTTO;C. TATA;CRISTIAN CAPORALI;DOMINIQUE VALLA;FILIPPO SCHEPIS;GIOVANNI FORNACIARI;LUISA SIMONI;MARCO MARIETTA;MARIAGRAZIA DEL BUONO","768;768;768;768;768;768;768;759;759;682;682;673;673;673;673;673;673;673;673;673","C. TATA;CRISTIAN CAPORALI;LUISA SIMONI;MARCO MARIETTA;STEFANO COLOPI;MARIA GRAZIA MODENA;ANJEZA XHOLLI;GIOVANNI GRANDI;MARIANNA CANNOLETTA;GIULIO ROSSI;FERRARI;PALMA;VOLPE;GIULIANA SARTORI;A. BERTANI;A. SCARCELLI;CLAUDIA CIRILLI;ANTONIO LA MARCA;ANTONIO LANDI;MARIO MIGALDI","673;673;673;673;673;303;206;206;206;178;177;177;177;167;155;155;142;141;118;116","GIULIO ROSSI;CRISTINA MUSSINI;GIULIANA SARTORI;VANNI BORGHI;GIORGIO ENRICO GERUNDA;MARIO MIGALDI;GIOVANNI GUARALDI;MASSIMO FEDERICO;ANNA MARIA CESINARO;A. BERTANI;A. SCARCELLI;ALFREDO CACCIARI;ANJEZA XHOLLI;ANNIBALE VOLPE;ANTONINO MAIORANA;ANTONIO LA MARCA;CLAUDIA CIRILLI;CRISTINA MASINI;DIEGO BIONDINI;EMANUELA BIAGIONI","7;7;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;PHYSICS;CHEMISTRY;MATHEMATICS;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;ENGINEERING;HISTORY","83;32;6;5;4;3;3;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GENETICS;ONCOLOGY;IMMUNOLOGY;GASTROENTEROLOGY;CANCER RESEARCH;RADIOLOGY;ENVIRONMENTAL HEALTH;PALEONTOLOGY;VIROLOGY;BIOCHEMISTRY;CARDIOLOGY;DERMATOLOGY;INTENSIVE CARE MEDICINE;NEUROSCIENCE;CELL BIOLOGY;FAMILY MEDICINE;GYNECOLOGY;NURSING;PHYSICAL THERAPY","65;26;21;17;17;16;12;11;9;8;7;7;6;6;6;5;5;4;4;4;4;4","CANCER;GENE;CHEMOTHERAPY;POPULATION;CONFIDENCE INTERVAL;HUMAN IMMUNODEFICIENCY VIRUS (HIV);LUNG;RADIATION THERAPY;DISEASE;CONCOMITANT;MAGNETIC RESONANCE IMAGING;STAGE (STRATIGRAPHY);VIRUS;CLINICAL TRIAL;COHORT;RANDOMIZED CONTROLLED TRIAL;STEM CELL;ANTIFUNGAL;CARCINOMA;CONTEXT (ARCHAEOLOGY);HEPATOCELLULAR CARCINOMA;IMMUNE SYSTEM;IMMUNOHISTOCHEMISTRY;INCIDENCE (GEOMETRY);LUNG CANCER;MELANOMA;PATHOGENESIS;PROPORTIONAL HAZARDS MODEL;RENAL CELL CARCINOMA;TOXICITY;TRANSPLANTATION","16;13;12;8;7;7;7;7;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","VIRAL LOAD;BREAST CANCER;CLINICAL ENDPOINT;COLORECTAL CANCER;HAZARD RATIO;CISPLATIN;HEPATITIS C VIRUS;PI3K/AKT/MTOR PATHWAY;CD34;CD8;CHEMORADIOTHERAPY;CYCLOPHOSPHAMIDE;DIFFUSION MRI;DOCETAXEL;FLUCONAZOLE;FLUOROURACIL;GENE EXPRESSION;GENOTYPE;HEAD AND NECK CANCER;INDUCTION CHEMOTHERAPY;INFERTILITY;INTERSTITIAL LUNG DISEASE;METHYLATION;MITOCHONDRIAL DNA;NEUTROPENIA;PHENOTYPE;PROGENITOR CELL;PROINFLAMMATORY CYTOKINE;PROSTATE CANCER;RELATIVE RISK;SORAFENIB;T CELL","8;4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;CETUXIMAB;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;KRAS;VINCRISTINE;ANAPLASTIC LYMPHOMA KINASE;ANDROGEN DEPRIVATION THERAPY;ANEMIA OF CHRONIC DISEASE;ANGIOTENSIN RECEPTOR BLOCKERS;ANTIFOLATE;BLASTOMYCES;BREAST PAIN;BRONCHIOLITIS OBLITERANS;CARBOPLATIN;CD24;CD38;CHEMOKINE RECEPTOR;CORONAVIRUS DISEASE 2019 (COVID-19);CRIZOTINIB;DACLIZUMAB;DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING;DUCTAL CARCINOMA;DYSPLASTIC NEVUS;ECULIZUMAB;ENOXAPARIN SODIUM;EXTERNAL BEAM RADIOTHERAPY;FIBER TRACT;FLUORESCENCE IN SITU HYBRIDIZATION;FONDAPARINUX;FRAMESHIFT MUTATION;GENE DOSAGE;HAPLOINSUFFICIENCY;HAPLOTYPE;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HISTONE DEACETYLASE;HOMEOBOX;HOMEOTIC GENE;HPV INFECTION;IMPELLA;INTERNATIONAL PROGNOSTIC INDEX;IPILIMUMAB;LENTIVIRUS;MASTECTOMY;MEGAKARYOCYTE;MELANOCYTIC NEVUS;METASTATIC BREAST CANCER;METHYLENETETRAHYDROFOLATE REDUCTASE;MICROSATELLITE;MYELOPOIESIS;OSTEOPENIA;OVARIAN RESERVE;PAPILLOMAVIRIDAE;PEMETREXED;PLATELET-DERIVED GROWTH FACTOR RECEPTOR;POSACONAZOLE;PROMOTER;PROSTATE-SPECIFIC ANTIGEN;PTEN;RELATIVE SURVIVAL;RENAL STEM CELL;RIBAVIRIN;SANGER SEQUENCING;TASK-POSITIVE NETWORK;THYMIDYLATE SYNTHASE;TRACTOGRAPHY;UNICOMPARTMENTAL KNEE ARTHROPLASTY;USUAL INTERSTITIAL PNEUMONIA;VANCOMYCIN;VOXEL-BASED MORPHOMETRY","6;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;;ITALY;HIV INFECTIONS;AGED;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ADOLESCENT;MYCOSES;LUNG NEOPLASMS;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOPLASM RECURRENCE, LOCAL;YOUNG ADULT;HODGKIN DISEASE;ANTIFUNGAL AGENTS","59;42;41;30;30;28;25;23;18;13;13;12;12;11;10;10;10;10;9;8","DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;LYMPHOID NEOPLASMS;RENAL CELL CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;CLINICAL AND MOLECULAR ASPECTS OF NOCARDIOSIS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;HEPATITIS C INFECTION AND TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;MELANOMA;MENSTRUAL HEALTH AND DISORDERS;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ANALYSIS OF BRAIN FUNCTIONAL CONNECTIVITY NETWORKS;BIOACTIVITY OF STEROIDAL SAPONINS IN MEDICINAL PLANTS","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","CLINICAL ENDPOINT;CONCOMITANT;TREATMENT;ANTIRETROVIRAL THERAPY;HIV;BREAST CANCER SCREENING;PATHOGENESIS;RADIOTHERAPY;ACTINOMYCOSIS;ANTIFUNGAL RESISTANCE;ANTIFUNGAL THERAPY;CHEMORADIOTHERAPY;CROSS-SECTIONAL STUDY;DIAGNOSIS;DISCONTINUATION;DYSMENORRHEA;HEMATOLOGY;HEPATITIS C;INDUCTION CHEMOTHERAPY;INFLAMMATION","5;5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","HIV INFECTION;ANTIRETROVIRAL THERAPY;BREAST CANCER;CELL CARCINOMA;CROHNS DISEASE;EUROPEAN COUNTRIES;FACTORIAL PHASE;HIV-INFECTED PATIENTS;HODGKIN LYMPHOMA;ICU DOCTORS;II-III STUDY;LASCCHN PRELIMINARY;LOCALLY ADVANCED;LYMPHOMA TREATED;MAGNETIC RESONANCE;MITOCHONDRIAL DNA;NEWLY DIAGNOSED;PAIN MANAGEMENT;PATIENTS RECEIVING;PHASE II-III;RESONANCE IMAGING;STUDY NCT;TUMOUR BURDEN;ABSTRACT LB-;ACCELERATES BONE;ACID TRIGGERS;ACTION OBSERVATION;ACTIVATING C-KIT;ACUTE CARDIOGENIC;ACUTE MYELOID","4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","MENSTRUAL PAIN;CD T-CELL;PELVIC PAIN;VIRAL LOAD;MYOCARDIAL INFARCTION;INTERMENSTRUAL PELVIC;CCHT RT;MEDIAN AGE;POLYACRYLAMIDE GEL;ACUTE MYOCARDIAL;BREAST CANCER;CET RT;G- IN-FIELD;HUMAN IMMUNODEFICIENCY;ADVERSE EVENTS;PATIENTS PTS;SURVIVAL OS;T-CELL COUNTS;VISITING POLICIES;CARDIOGENIC SHOCK;ESTRADIOLTESTOSTERONE RATIO;HCV RECURRENCE;HOSPITAL STAFF;IN-FIELD TOXICITY;INDUCTION TPF;LINE CHEMOTHERAPY;LUNG CANCER;MO CI;PATIENTS RECEIVED;PRIMARY ENDPOINT","11;10;10;10;9;8;7;7;7;6;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4",32,0.36,4.09,4.25,2,1.5,0,52,2,0,1,5,0,1,3,2,1.25,2,2.25,3,1.75,0,0,53.5,53.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,6.21,420.93,11.81,6,0.35,54.71,0,0,7,0,4,0,1,5,0,13,1,0,0,0,0,0,0,14,3,0,14,3,0,0,0,0,0,0,0,0,"United States;Italy","4;3","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;3215 REPRODUCTIVE MEDICINE;34 CHEMICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","17;8;6;5;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;DIGESTIVE DISEASES;LIVER DISEASE;CHRONIC LIVER DISEASE AND CIRRHOSIS;HEMATOLOGY;HEPATITIS;INFECTIOUS DISEASES;LYMPHOMA;AGING;BIOMEDICAL IMAGING;BREAST CANCER;PREVENTION;CHRONIC PAIN;CONTRACEPTION/REPRODUCTION;COOLEY'S ANEMIA;DIABETES;EMERGING INFECTIOUS DISEASES","16;12;7;7;6;6;4;4;4;3;3;2;2;2;2;1;1;1;1;1","CANCER;INFECTION;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;ORAL AND GASTROINTESTINAL","7;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;5.1 PHARMACEUTICALS","13;3;2;2;1;1;1;1","NON-HODGKIN'S LYMPHOMA;BREAST CANCER;HODGKIN'S DISEASE;LIVER CANCER;OVARIAN CANCER","4;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","7;2;1",1,0,0,5,2,2,1,0,0,0,"HEIDELBERG UNIVERSITY;POLICLINICO DI MODENA","1;1","DEUTSCHE FORSCHUNGSGEMEINSCHAFT","1",NA,NA,"RESEARCH GRANTS (DFG PROGRAMME)","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;51 PHYSICAL SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS","1;1;1;1;1","BIOENGINEERING;BIOMEDICAL IMAGING;CANCER;CLINICAL RESEARCH;LUNG;LUNG CANCER","1;1;1;1;1;1",NA,NA,"4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1","LUNG CANCER","1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","1;1;1","A01 CLINICAL MEDICINE","1",NA,NA,8,"PUBLIC LIBRARY OF SCIENCE","8","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3105 GENETICS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3215 REPRODUCTIVE MEDICINE","10;7;3;2;2;1;1","CANCER;CONTRACEPTION/REPRODUCTION;GENETICS;LUNG;LUNG CANCER","1;1;1;1;1","CANCER","1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.2 CELLULAR AND GENE THERAPIES","1;1;1","BIOMEDICAL","1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","2;1","LUNG CANCER;KIDNEY CANCER","2;1",NA,NA
"AOU_MODENA",2013,100,12.32,2.92,0.36,0.31,0.51,1.3394495412844,1.2,1.29166666666667,1.18604651162791,0.46,2,58,18,16,4,0.58,0.18,0.16,0.04,26.72,0.765779192129695,5.18777292576419,0.27,0.88,0.418,0.249,0.323,0.286,"GIULIO ROSSI;FABIO CATANI;GIORGIO ENRICO GERUNDA;ALBERTO BERARDI;ROBERTA CRETI;ROBERTO SABBATINI;MAURO CODELUPPI;MARIO LUPPI;FABRIZIO FERRARI;ROBERTO MONTALTI;RAFFAELE MUGNAI;TEODORO SAVA;CRISTINA GOZZI;GIOVANNI LO RE;CECILIA ROSSI;GIUSEPPE PROCOPIO;LUCIO BRUGIONI;PAOLA BRESCIANI;GUIDO LIGABUE;CLAUDIA VENTURELLI","7;6;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","FABIO CATANI;RICCARDO MAGISTRONI;ELISABETTA BERARDI;GIULIO ROSSI;CRISTINA GOZZI;LUCIO BRUGIONI;RAFFAELE MUGNAI;GORETTA BONACORSI;AMBRA PAOLINI;ANTONINA MIKOCKA‐WALUS;J ANDREWS;LUIGI TARALLO;ROBERTO ADANI;GIORGIO ENRICO GERUNDA;ALBERTO BERARDI;ROBERTA CRETI;GABRIELE CAMPOCHIARO;FRANCESCO ZAMBIANCHI;PAOLO BAUDI;MANUELA REBUZZI","1.18;1;1;0.73;0.67;0.67;0.65;0.64;0.5;0.5;0.5;0.45;0.45;0.41;0.4;0.4;0.37;0.37;0.37;0.37","GIULIO ROSSI;FABIO CATANI;GIORGIO ENRICO GERUNDA;ALBERTO BERARDI;ROBERTO SABBATINI;MAURO CODELUPPI;MARIO LUPPI;FABRIZIO FERRARI;ROBERTO MONTALTI;RAFFAELE MUGNAI;CRISTINA GOZZI;CECILIA ROSSI;LUCIO BRUGIONI;PAOLA BRESCIANI;GUIDO LIGABUE;CLAUDIA VENTURELLI;CRISTINA MUSSINI;LUCREZIA PACCHIONI;GIOVANNI GUARALDI;GABRIELE CAMPOCHIARO","7;6;5;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2","FABIO CATANI;RICCARDO MAGISTRONI;ELISABETTA BERARDI;GIULIO ROSSI;CRISTINA GOZZI;LUCIO BRUGIONI;RAFFAELE MUGNAI;GORETTA BONACORSI;AMBRA PAOLINI;J ANDREWS;LUIGI TARALLO;GIORGIO ENRICO GERUNDA;ALBERTO BERARDI;GABRIELE CAMPOCHIARO;FRANCESCO ZAMBIANCHI;PAOLO BAUDI;MANUELA REBUZZI;ANJEZA XHOLLI;R ZANDOMENEGHI;ANDREA LETI ACCIARO","1.18;1;1;0.73;0.67;0.67;0.65;0.64;0.5;0.5;0.45;0.41;0.4;0.37;0.37;0.37;0.37;0.33;0.33;0.33","PAOLA BRESCIANI;ALBERTO BERARDI;ROBERTA CRETI;CATERINA DE BENEDITTIS;CLAUDIA VENTURI;CRISTINA PAPAYANNIDIS;DOMENICO RUSSO;GIOVANNI MARTINELLI;ILARIA IACOBUCCI;MICHELE BACCARANI;MICHÈLE CAVO;SIMONA SOVERINI;CECILIA ROSSI;FABRIZIO FERRARI;GIULIO ROSSI;CLAUDIA VENTURELLI;GIOVANNI DELLA CASA;GUIDO LIGABUE;RICCARDO FALETTI;FABIO CATANI","381;291;291;287;287;287;287;287;287;287;287;287;282;282;269;262;247;247;238;231","PAOLA BRESCIANI;CLAUDIA VENTURELLI;GIOVANNI DELLA CASA;GUIDO LIGABUE;FABIO CATANI;ANDRÉA BARBIERI;FRANCESCA MANTOVANI;ALBERTO BERARDI;MARIO LUPPI;ALESSANDRA CHINAGLIA;ANTONIO BRUCATO;DAVIDE CUMETTI;F. BONOMI;FRANCESCA FERRONI;MARIA GRAZIA MODENA;MASSIMO IMAZIO;PAOLA DI CORATO;R. LUGLI;RICCARDO BELLI;RICCARDO FALETTI","381;262;247;247;231;229;229;224;224;218;218;218;218;218;218;218;218;218;218;218","FABIO CATANI;CRISTINA MUSSINI;GIORGIO ENRICO GERUNDA;MAURO CODELUPPI;ALBERTO BERARDI;CLAUDIA VENTURELLI;GIULIO ROSSI;GUIDO LIGABUE;PAOLA BRESCIANI;RAFFAELE MUGNAI;ROBERTO MONTALTI;CRISTINA GOZZI;LUCIO BRUGIONI;MARIO LUPPI;ROBERTO SABBATINI;ANDRÉA BARBIERI;ANNA LASAGNI;CARMELA DI GREGORIO;CECILIA ROSSI;CLODOVEO FERRI","6;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;MATHEMATICS;CHEMISTRY;COMPUTER SCIENCE;HISTORY;PSYCHOLOGY;ENGINEERING;PHILOSOPHY;SOCIOLOGY;BUSINESS;ECONOMICS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;MATERIALS SCIENCE;POLITICAL SCIENCE","93;32;9;5;4;4;3;3;2;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;ENVIRONMENTAL HEALTH;PATHOLOGY;ONCOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;PEDIATRICS;CANCER RESEARCH;BIOCHEMISTRY;OPTICS;RADIOLOGY;ANESTHESIA;CARDIOLOGY;PSYCHIATRY;ANATOMY;MICROBIOLOGY;OBSTETRICS;PALEONTOLOGY;PHYSICAL THERAPY","74;36;19;18;18;17;15;13;11;10;7;6;6;6;5;5;5;4;4;4;4;4","CANCER;POPULATION;DISEASE;GENE;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;CHEMOTHERAPY;BACTERIA;PROSPECTIVE COHORT STUDY;RETROSPECTIVE COHORT STUDY;TRANSPLANTATION;ALTERNATIVE MEDICINE;INCIDENCE (GEOMETRY);LUNG CANCER;PREGNANCY;RENAL CELL CARCINOMA;GROUP B;HEPATOCELLULAR CARCINOMA;IMMUNOHISTOCHEMISTRY;MULTIVARIATE ANALYSIS;ODDS RATIO","18;18;14;11;10;10;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4","BREAST CANCER;COLORECTAL CANCER;HAZARD RATIO;LIVER TRANSPLANTATION;MULTICENTER STUDY;MUTATION;SORAFENIB;ADENOCARCINOMA;FIXATION (POPULATION GENETICS);GENOTYPE;GESTATION;MALIGNANT PLEURAL EFFUSION;AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE;CHROMOSOME;CHRONIC LYMPHOCYTIC LEUKEMIA;CLINICAL ENDPOINT;DISTAL PANCREATECTOMY;DISTAL RADIUS FRACTURE;EJECTION FRACTION;HEPATITIS C VIRUS;IMATINIB;NEPHRECTOMY;NEUTROPENIA;OSTEOARTHRITIS;PANCREATECTOMY;PANCREATIC CANCER;POLYCYSTIC KIDNEY DISEASE;PROGRAMMED CELL DEATH;PROGRESSION-FREE SURVIVAL;STREPTOCOCCUS;SUNITINIB;TARGETED THERAPY;TOLERABILITY;TYROSINE KINASE;UNIVARIATE ANALYSIS;VIRAL LOAD;WARFARIN","4;4;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANAPLASTIC LYMPHOMA KINASE;CRIZOTINIB;SINGLE-NUCLEOTIDE POLYMORPHISM;ABL;ANTIRETROVIRAL THERAPY;BREAST RECONSTRUCTION;FLUORESCENCE IN SITU HYBRIDIZATION;KRAS;SANGER SEQUENCING;AJCC STAGING SYSTEM;ANDROGEN RECEPTOR;ARTICULAR CARTILAGE;BENDAMUSTINE;BLASTOID;BURKHOLDERIA CEPACIA COMPLEX;CARDIAC RESYNCHRONIZATION THERAPY;CETUXIMAB;CHLORAMINATION;CHORIOAMNIONITIS;COLONOSCOPY;CORONAVIRUS DISEASE 2019 (COVID-19);CYCLIN D1;DASATINIB;DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;DYSKINESIA;ERLOTINIB;FAS LIGAND;FEBRILE NEUTROPENIA;FOLLICLE-STIMULATING HORMONE;GENETIC STRUCTURE;GENOTYPING;GERMLINE MUTATION;HAPLOTYPE;IGHV@;IMATINIB MESYLATE;INDUCED PLURIPOTENT STEM CELL;INHIBITOR OF APOPTOSIS;MASTECTOMY;METASTATIC BREAST CANCER;MIGRAINE WITH AURA;MILAN CRITERIA;NILOTINIB;NON-SMALL CELL LUNG CANCER (NSCLC);NUMBER NEEDED TO TREAT;OFATUMUMAB;OPISTHORCHIS;PDGFRA;PERCUTANEOUS ETHANOL INJECTION;PHILADELPHIA CHROMOSOME;PKD1;PLASMA CELL NEOPLASM;POINT MUTATION;PRAZIQUANTEL;PRENATAL DIAGNOSIS;PROTEIN KINASE DOMAIN;RENAL MASS;RETINOPATHY OF PREMATURITY;RIBAVIRIN;SDHA;SERINE PROTEASE;SIDA;STREPTOCOCCUS AGALACTIAE;SUICIDE ATTEMPT;SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION;TESTIS DETERMINING FACTOR;WECHSLER INTELLIGENCE SCALE FOR CHILDREN;WOMAC","3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;ADULT;MIDDLE AGED;AGED;ITALY;STREPTOCOCCAL INFECTIONS;ADOLESCENT;HIV INFECTIONS;PROSPECTIVE STUDIES;TREATMENT OUTCOME;YOUNG ADULT;PROTEIN KINASE INHIBITORS;CARCINOMA, NON-SMALL-CELL LUNG;AGED, 80 AND OVER;BIOMARKERS, TUMOR;CROSS INFECTION;LUNG NEOPLASMS","59;52;43;40;37;31;30;25;17;14;14;14;14;13;11;10;9;9;9;9","RENAL CELL CARCINOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;PANCREATIC CANCER RESEARCH AND TREATMENT;TREATMENT AND OUTCOMES OF HAND INJURIES;ADVANCEMENTS IN LUNG CANCER RESEARCH;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;EFFICACY AND RESISTANCE IN CML TREATMENT;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MOLECULAR BIOLOGY OF STEROIDOGENESIS AND DISORDERS;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;PEDIATRIC PAIN ASSESSMENT AND MANAGEMENT;SHOULDER PATHOLOGY AND TREATMENT OUTCOMES;;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ANTERIOR CRUCIATE LIGAMENT INJURIES IN ATHLETES;CANCER OF UNKNOWN PRIMARY SITE;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE","5;4;4;4;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1","TREATMENT;GROUP B;ALK INHIBITORS;GROUP B STREPTOCOCCUS;LIVER CIRRHOSIS;LIVER TRANSPLANTATION;LIVING DONOR LIVER TRANSPLANTATION;ABL;ALK INHIBITOR;ANTIRETROVIRAL THERAPY;BREAST RECONSTRUCTION;CLINICAL ENDPOINT;COLORECTAL CANCER;CONCOMITANT;DIAGNOSIS;DISTAL HUMERUS FRACTURES;DISTAL PANCREATECTOMY;DISTAL RADIUS FRACTURE;DISTAL RADIUS FRACTURES;ETIOLOGY","8;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","PHASE II;CANCER PATIENTS;CARDIAC RESYNCHRONIZATION;CELL CARCINOMA;CIRRHOTIC PATIENTS;LIVER TRANSPLANTATION;METASTATIC RENAL;RENAL CELL;BREAST CANCER;CARCINOMA MRCC;CHRONIC LYMPHOCYTIC;CLINICAL OUTCOME;CONTROLLED TRIAL;DIGITAL ULCERS;DISEASE PATIENTS;DISTAL PANCREATECTOMY;DISTAL RADIUS;EFFICACY RESULTS;II STUDY;ITALIAN REGISTRY;KINASE DOMAIN;LYMPHOCYTIC LEUKEMIA;MULTICENTER SURVEY;PATIENTS PTS;PREDICT RESPONSE;PROCEDURAL PAIN;RANDOMIZED CONTROLLED;RETROSPECTIVE ANALYSIS;THERAPY DATA;TYROSINE KINASE","5;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HTGW PHENOTYPE;SHR IC;STENT GRAFT;DE NOVO;ADVERSE EVENTS;CHLORINE DIOXIDE;KITPDGFRA WILD-TYPE;PATIENTS TREATED;RELAY STENT;TB-CT SCAN;ABNORMAL MOTION;AORTIC INJURY;DISTAL RADIUS;ENROLLED PATIENTS;HYPOANOSMIC NORMOSMIC;IPS CELLS;NOVO DSA;WILD-TYPE GIST;AORTIC REPAIR;COMPUTED TOMOGRAPHY;CONFIDENCE INTERVAL;ENDOVASCULAR AORTIC;HEART FAILURE;INTELLECTUAL FUNCTION;LIST DROP-OUT;MOVEMENT ABNORMALITIES;MULTIVARIATE ANALYSIS;MYOCARDIAL FIBROSIS;PRENATAL DIAGNOSIS;PROTEIN EXPRESSION","10;10;8;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4",21,0.21,5.2,3,1,1,0,3.25,1.75,0,1,4,0,1,3,1,2.5,1,1,2,1,0,0,99,99,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,5.53,524.79,8.76,9,0.47,90.42,0,0,4,0,8,0,0,7,0,14,5,0,0,0,0,0,0,14,4,1,19,0,0,0,0,0,0,0,0,0,"United States;Italy;United Kingdom;Israel;Japan","5;3;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","19;11;7;3;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;AGING;HEMATOLOGY;PATIENT SAFETY;BREAST CANCER;LUNG;LYMPHOMA;ORPHAN DRUG;BIOTECHNOLOGY;ESTROGEN;GENETICS;INFECTIOUS DISEASES;ACUTE RESPIRATORY DISTRESS SYNDROME;ANTIMICROBIAL RESISTANCE;ARTHRITIS;ASTHMA;AUTOIMMUNE DISEASE","18;13;13;8;6;5;5;3;3;3;3;2;2;2;2;1;1;1;1;1","CANCER;INFECTION;MUSCULOSKELETAL;RESPIRATORY","10;1;1;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","12;1;1;1","BREAST CANCER;NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;ENDOMETRIAL CANCER;LIVER CANCER;MELANOMA;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;PROSTATE CANCER","3;3;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","9;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"PUBLIC LIBRARY OF SCIENCE","2","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;4613 THEORY OF COMPUTATION","2;1;1;1;1",NA,NA,NA,NA,NA,NA,NA,NA,"BASIC SCIENCE","1","MELANOMA;SKIN CANCER","2;1",NA,NA
"AOU_MODENA",2014,118,11.9322033898305,2.93220338983051,0.398305084745763,0.38135593220339,0.449152542372881,1.57534246575342,1.30555555555556,1.55172413793103,1.26190476190476,0.449152542372881,1,53,27,13,13,0.45,0.23,0.11,0.11,23.41,0.619362955255655,5.25984251968504,0.271186440677966,0.822033898305085,0.393,0.377,0.368,0.354,"GIULIO ROSSI;GIUSEPPE PROCOPIO;ANGELO CAGNACCI;ROBERTO SABBATINI;GIOVANNI GUARALDI;UGO DE GIORGI;CRISTINA MUSSINI;STEFANO ZONA;ALBERTO CAVAZZA;CINZIA ORTEGA;ALBERTO BERARDI;FABIO CATANI;GIAMPAOLO BIANCHI;ILARIA PIACENTI;DONATELLO GASPARRO;UMBERTO BASSO;DANIELE SANTINI;CHIARA STENTARELLI;CAMILLO PORTA;MATTEO SANTONI","10;8;7;6;6;6;6;5;5;5;5;5;5;5;5;5;5;4;4;4","VERONICA BERNABUCCI;ANGELO CAGNACCI;ILARIA PIACENTI;GIULIO ROSSI;FABIO CATANI;A. RUSSOMANDO;GIOVANNI GUARALDI;CRISTINA MUSSINI;HAKAN ÖZBEN;ERICA VILLA;STEFANO ZONA;GIOVANNI GRANDI;ALBERTO CAVAZZA;A. MARCUZZI;ANTONIO LANDI;ANJEZA XHOLLI;ANTONELLO PIETRANGELO;DILIA GIUGGIOLI;ANDREINA MANFREDI;CLODOVEO FERRI","1.5;1.36;1.03;1.01;0.79;0.75;0.71;0.7;0.67;0.62;0.62;0.62;0.58;0.58;0.58;0.57;0.56;0.53;0.53;0.53","GIULIO ROSSI;ANGELO CAGNACCI;ROBERTO SABBATINI;GIOVANNI GUARALDI;CRISTINA MUSSINI;STEFANO ZONA;ALBERTO BERARDI;FABIO CATANI;GIAMPAOLO BIANCHI;ILARIA PIACENTI;CHIARA STENTARELLI;ANTONELLO PIETRANGELO;VANNI BORGHI;ANJEZA XHOLLI;FABRIZIO FERRARI;VITANTONIO DIGENNARO;HAKAN ÖZBEN;FAUSTO BARBIERI;FRANCESCO ZAMBIANCHI;ANDREA CONTI","10;7;6;6;6;5;5;5;5;5;4;4;4;3;3;3;3;3;3;3","VERONICA BERNABUCCI;ANGELO CAGNACCI;ILARIA PIACENTI;GIULIO ROSSI;FABIO CATANI;A. RUSSOMANDO;GIOVANNI GUARALDI;CRISTINA MUSSINI;HAKAN ÖZBEN;ERICA VILLA;STEFANO ZONA;GIOVANNI GRANDI;A. MARCUZZI;ANTONIO LANDI;ANJEZA XHOLLI;ANTONELLO PIETRANGELO;DILIA GIUGGIOLI;ANDREINA MANFREDI;CLODOVEO FERRI;MARCO SEBASTIANI","1.5;1.36;1.03;1.01;0.79;0.75;0.71;0.7;0.67;0.62;0.62;0.62;0.58;0.58;0.57;0.56;0.53;0.53;0.53;0.53","ALBERTO BERARDI;CLAIRE POYART;PIERRETTE MELIN;GIULIO ROSSI;ALBERTO CAVAZZA;FABIO CATANI;ANDROULLA EFSTRATIOU;ANNA BÜCHELE;ANTOANETA DECHEVA;BAHARAK AFSHAR;BENEDETTA ROMI;BOGDAN PETRUNOV;CARMEN BUCHRIESER;CHRISTIANE BOUCHIER;DAVID J. MCMILLAN;DOMENICO MAIONE;DOMINIQUE CLERMONT;ELISABETH SAUVAGE;ERIKA SOUCHE;GORDAN DOUGAN","497;384;384;373;315;296;215;215;215;215;215;215;215;215;215;215;215;215;215;215","ALBERTO BERARDI;GIULIO ROSSI;FABIO CATANI;GIAMPAOLO BIANCHI;ANGELO CAGNACCI;FRANCESCO ZAMBIANCHI;VITANTONIO DIGENNARO;FRANCESCO FIACCHI;RAFFAELE MUGNAI;ANDREA CONTI;CRISTINA MUSSINI;MARIO MIGALDI;ROBERTO SABBATINI;FABRIZIO FERRARI;FILIPPO FERRARI;ANNALISA FONTANA;GABRIELE LUPPI;ANTONIO LANDI;GIOVANNI GRANDI;ALESSANDRO MARCHIONI","497;342;296;170;159;144;144;133;133;123;123;121;115;113;110;103;103;100;95;90","GIULIO ROSSI;CRISTINA MUSSINI;ANGELO CAGNACCI;GIOVANNI GUARALDI;ROBERTO SABBATINI;GIAMPAOLO BIANCHI;FABIO CATANI;STEFANO ZONA;ALBERTO BERARDI;ANTONELLO PIETRANGELO;ANTONIO LANDI;VANNI BORGHI;FABRIZIO FERRARI;FAUSTO BARBIERI;A. RUSSOMANDO;ANDREA CONTI;ANJEZA XHOLLI;ANTONELLA SANTORO;FEDERICA CARLI;ILARIA PIACENTI","9;8;6;6;6;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;MATHEMATICS;PSYCHOLOGY;ENGINEERING;GEOLOGY;PHILOSOPHY;POLITICAL SCIENCE;ART;HISTORY;MATERIALS SCIENCE;SOCIOLOGY","112;31;12;7;6;4;3;3;2;2;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;PATHOLOGY;IMMUNOLOGY;GASTROENTEROLOGY;ONCOLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;ANESTHESIA;BIOCHEMISTRY;RADIOLOGY;CANCER RESEARCH;DERMATOLOGY;ANATOMY;FAMILY MEDICINE;OPTICS;PSYCHIATRY;VIROLOGY","84;40;24;21;19;18;17;15;14;9;9;8;8;8;7;7;6;6;6;6;6","CANCER;GENE;POPULATION;DISEASE;RETROSPECTIVE COHORT STUDY;COHORT;HUMAN IMMUNODEFICIENCY VIRUS (HIV);PREGNANCY;RENAL CELL CARCINOMA;ADVERSE EFFECT;CHEMOTHERAPY;ESTROGEN;IMMUNOHISTOCHEMISTRY;LUNG;LUNG CANCER;MULTIVARIATE ANALYSIS;PROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;INCIDENCE (GEOMETRY);KIDNEY;LOGISTIC REGRESSION;TRANSPLANTATION;VIRUS","20;16;14;13;10;8;8;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5","MUTATION;COLORECTAL CANCER;VIRAL LOAD;NEPHRECTOMY;UNIVARIATE ANALYSIS;LIVER TRANSPLANTATION;PROSTATE CANCER;RESEARCH METHODOLOGY;ADENOCARCINOMA;DIENOGEST;DOCETAXEL;EPIDERMAL GROWTH FACTOR RECEPTOR;ESTRADIOL VALERATE;EXON;GENE EXPRESSION;GENOME;HEPATITIS C VIRUS;METASTASIS;PHENOTYPE;PROGESTIN;TOLERABILITY","8;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;FAMILY PLANNING;ANAPLASTIC LYMPHOMA KINASE;ANDROGEN DEPRIVATION THERAPY;ETHINYLESTRADIOL;FERROPORTIN;KRAS;RIBAVIRIN;WHOLE GENOME SEQUENCING;ACUTE LYMPHOCYTIC LEUKEMIA;ADENOCARCINOMA OF THE LUNG;ADENOMATOUS POLYPOSIS COLI;ADJUVANT CHEMOTHERAPY;ANDROGEN RECEPTOR;CD90;CHLORMADINONE ACETATE;COLECTOMY;CONDOM;CRIZOTINIB;CUTANEOUS VASCULITIS;DECORIN;DNA METHYLATION;DNA MISMATCH REPAIR;ERLOTINIB;FAMILIAL ADENOMATOUS POLYPOSIS;FIBRINOID NECROSIS;FUSION TRANSCRIPT;HEPACIVIRUS;HOUSEKEEPING GENE;IGHV@;IMATINIB MESYLATE;INSULIN SENSITIVITY;LAMIVUDINE;LOSS FUNCTION;LYMPHOCYTE SUBSETS;MODEL FOR END-STAGE LIVER DISEASE;MONOCLONAL;MYCOLIC ACID;MYELOPROLIFERATIVE NEOPLASM;NILOTINIB;OMIM : ONLINE MENDELIAN INHERITANCE IN MAN;PDGFRA;PHOSPHATIDYLCHOLINE;PHYLOGENESIS;POINT MUTATION;PORPHOBILINOGEN DEAMINASE;PRIMARY TUMOR;PROBAND;PROSTATE BIOPSY;PROSTATECTOMY;REGORAFENIB;RUNX1;RUPTURE OF MEMBRANES;SANGER SEQUENCING;SIGNET RING CELL;STREPTOCOCCUS AGALACTIAE;SYSTEMIC THERAPY;TLR2;TRANSIENT ELASTOGRAPHY;UNICOMPARTMENTAL KNEE ARTHROPLASTY;USTEKINUMAB;WERNICKE'S ENCEPHALOPATHY","5;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;HIV INFECTIONS;RETROSPECTIVE STUDIES;ITALY;LUNG NEOPLASMS;TREATMENT OUTCOME;KIDNEY NEOPLASMS;STREPTOCOCCAL INFECTIONS;AGED, 80 AND OVER;BIOMARKERS, TUMOR;COHORT STUDIES;CARCINOMA, RENAL CELL;CONTRACEPTIVES, ORAL, COMBINED;ANTI-BACTERIAL AGENTS","79;59;53;39;35;32;28;20;20;18;17;17;13;12;11;11;11;10;10;9","RENAL CELL CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;PROJECTIONS AND OUTCOMES OF ARTHROPLASTY SURGERY IN THE US;TREATMENT AND OUTCOMES OF HAND INJURIES;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HEPATITIS C INFECTION AND TREATMENT;REGULATION OF IRON METABOLISM AND ANEMIA;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;CONTRACEPTION AND UNINTENDED PREGNANCY PREVENTION;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEPATOCELLULAR CARCINOMA;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;LYMPHOID NEOPLASMS;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH","8;6;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;1","HIV;TREATMENT;EGFR MUTATIONS;HIV INFECTION;UNIVARIATE ANALYSIS;CONTRACEPTION;DIENOGEST;ESTRADIOL VALERATE;HEPATITIS C;KNEE BIOMECHANICS;PROGESTIN;REGIMEN;SUBCLINICAL INFECTION;TOLERABILITY;WRIST ARTHROSCOPY;ANTIRETROVIRAL THERAPY;BIOMARKER ANALYSIS;CABAZITAXEL;CLINICAL ENDPOINT;CONCOMITANT","7;6;5;5;5;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","CELL CARCINOMA;RENAL CELL;PROSTATE CANCER;CASTRATION-RESISTANT PROSTATE;LUNG CANCER;ORAL CONTRACEPTIVE;PROSPECTIVE MULTICENTER;CANCER MCRPC;CANCER PATIENTS;CLINICAL OUTCOMES;COMPARATIVE STUDY;DIAMOND PROJECT;DOC FAILURE;DRUGS NDS;EGFR MUTATION-SPECIFIC;HIGHLY EFFECTIVE;HIV PATIENTS;IMMUNOHISTOCHEMICAL SCREENING;ITALIAN EXPERIENCE;ITALIAN PATIENTS;ITALIAN PROJECT;LIVER TRANSPLANTATION;LUNG ADENOCARCINOMAS;MCRPC PATIENTS;METASTATIC CASTRATION-RESISTANT;METASTATIC RENAL;MULTICENTER EVALUATION;MULTICENTER ITALIAN;MUTATION-SPECIFIC ANTIBODIES;NEPHRON-SPARING SURGERY","5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","EGFR MUTATIONS;MONTHS CI;PATIENTS TREATED;VIRAL LOAD;HIV-INFECTED PATIENTS;IRON EXPORT;LOWER RISK;RENAL BIOPSY;RETROSPECTIVE STUDY;ANTIRETROVIRAL THERAPY;BONE METASTASES;CD COUNT;HIV INFECTION;INCREASED RISK;LT CPΜL;MEDIAN AGE;MULTIVARIABLE ANALYSIS;RISK SCORE;BLOOD LOSS;CI -P;COMBINATION THERAPY;CT SCANS;CVD RISK;EXPORT FUNCTION;GENE EXPRESSION;GENUS MYCOBACTERIUM;HCV RNA;INTENSIVE CARE;INTERMENSTRUAL PAIN;ITALIAN CENTERS","8;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4",38,0.32,4.19,3,1,1.25,1,6.25,3,0,1,4,0,1,3,0,1,1,1,3,1.75,0,0,80.25,80.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,6.86,306.33,9.86,13,0.62,60.05,0,0,9,0,7,0,0,5,0,20,1,0,0,0,0,0,0,19,2,0,20,0,0,1,0,0,0,0,0,0,"United States;Italy;Belgium","4;3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS;4204 MIDWIFERY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","21;14;8;6;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;ORPHAN DRUG;LYMPHOMA;DIGESTIVE DISEASES;GENETICS;PEDIATRIC;TRANSPLANTATION;CHILDHOOD LEUKEMIA;PEDIATRIC CANCER;PREVENTION;AUTOIMMUNE DISEASE;INFLAMMATORY BOWEL DISEASE;NUTRITION;PANCREATIC CANCER;REGENERATIVE MEDICINE;STEM CELL RESEARCH","21;18;15;14;10;8;6;5;5;4;4;3;3;3;2;2;2;2;2;2","CANCER;ORAL AND GASTROINTESTINAL;BLOOD;GENERIC HEALTH RELEVANCE;REPRODUCTIVE HEALTH AND CHILDBIRTH","13;2;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","15;6;2;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;PANCREATIC CANCER;BLOOD CANCER;BREAST CANCER;COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;LUNG CANCER;ORAL CAVITY AND LIP CANCER;OVARIAN CANCER;PHARYNGEAL CANCER;STOMACH CANCER","6;5;2;1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","11;2;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_MODENA",2015,128,12.625,3.25,0.390625,0.34375,0.4296875,1.48920863309353,1.08695652173913,1.375,1.05769230769231,0.5390625,5,68,19,18,11,0.53,0.15,0.14,0.09,23.95,0.642722748574665,4.81399317406143,0.3515625,0.8515625,0.408,0.318,0.387,0.341,"GIULIO ROSSI;ERICA VILLA;G. GUIDI;FILIPPO BERTONI;ROBERTO SABBATINI;ALBERTO CAVAZZA;N. MAFFEI;GLORIA MONTANARI;A. CIARMATORI;ROBERTO MARASCA;LUCA REGGIANI BONETTI;FABIO FORGHIERI;VINCENZO MONTESARCHIO;T. COSTI;A. BENEDETTI;DOMENICO SANSONNO;COSTANTINO DI CARLO;ANTONIO GASBARRINI;FABIO CATANI;C. BONI","13;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","LESLEY DE PIETRI;GIULIO ROSSI;ALESSANDRO LANDI;MARCO MARIETTA;PAOLO VENTURA;LUCIA PALMIERI;FABIO CATANI;FILIPPO BERTONI;G. GUIDI;LUCA REGGIANI BONETTI;N. MAFFEI;GLORIA MONTANARI;COSTANTINO DI CARLO;ANGELO CAGNACCI;T. COSTI;C. VECCHI;ERICA VILLA;GIANNI CAPPELLI;GIOVANNI GOTTARDI;A. CIARMATORI","1.4;1.1;1;1;1;1;0.72;0.71;0.69;0.67;0.6;0.58;0.56;0.56;0.5;0.5;0.49;0.45;0.43;0.43","GIULIO ROSSI;ERICA VILLA;G. GUIDI;FILIPPO BERTONI;ROBERTO SABBATINI;N. MAFFEI;GLORIA MONTANARI;A. CIARMATORI;ROBERTO MARASCA;LUCA REGGIANI BONETTI;FABIO FORGHIERI;T. COSTI;FABIO CATANI;GIOVANNI GOTTARDI;ANGELO CAGNACCI;FEDERICA BERTOLINI;LESLEY DE PIETRI;GABRIELE LUPPI;ERCOLE MAZZEO;C. VECCHI","13;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","LESLEY DE PIETRI;GIULIO ROSSI;ALESSANDRO LANDI;MARCO MARIETTA;PAOLO VENTURA;LUCIA PALMIERI;FABIO CATANI;FILIPPO BERTONI;G. GUIDI;LUCA REGGIANI BONETTI;N. MAFFEI;GLORIA MONTANARI;ANGELO CAGNACCI;T. COSTI;C. VECCHI;ERICA VILLA;GIANNI CAPPELLI;GIOVANNI GOTTARDI;A. CIARMATORI;ALESSANDRA TIRELLI","1.4;1.1;1;1;1;1;0.72;0.71;0.69;0.67;0.6;0.58;0.56;0.5;0.5;0.49;0.45;0.43;0.43;0.41","GIULIO ROSSI;ALBERTO CAVAZZA;LESLEY DE PIETRI;B. BEGLIOMINI;FABRIZIO DI BENEDETTO;GIORGIO ENRICO GERUNDA;ROBERTO MONTALTI;ERICA VILLA;GUADALUPE GARCÍA‐TSAO;MARCELLO BIANCHINI;NICOLA DE MARIA;TOMMASO DI MAIRA;ALESSANDRA DUBINI;ANGELO CARLONI;ATHOL U. WELLS;CHRISTIAN GURIOLI;CLAUDIA RAVAGLIA;ELISA CARRETTA;JAY H. RYU;MATTEO BUCCIOLI","667;639;452;417;401;401;401;378;375;375;375;375;312;312;312;312;312;312;312;312","GIULIO ROSSI;LESLEY DE PIETRI;B. BEGLIOMINI;FABRIZIO DI BENEDETTO;GIORGIO ENRICO GERUNDA;ERICA VILLA;GUADALUPE GARCÍA‐TSAO;MARCELLO BIANCHINI;NICOLA DE MARIA;TOMMASO DI MAIRA;FABIO CATANI;A. CIARMATORI;GIAN MARIA CAVALLINI;MATTEO FORLINI;ROBERTO SABBATINI;FRANCESCO FIDANZA;GIAMPAOLO BIANCHI;LUCA REGGIANI BONETTI;CRISTINA MUSSINI;GIOVANNI PALAZZI","664;452;417;401;401;378;375;375;375;375;135;128;114;114;107;106;106;100;96;93","GIULIO ROSSI;ERICA VILLA;FILIPPO BERTONI;ROBERTO SABBATINI;A. CIARMATORI;G. GUIDI;N. MAFFEI;ROBERTO MARASCA;ANGELO CAGNACCI;CRISTINA MUSSINI;FABIO CATANI;FABIO FORGHIERI;GABRIELE LUPPI;GIOVANNI GOTTARDI;GLORIA MONTANARI;LESLEY DE PIETRI;LUCA REGGIANI BONETTI;T. COSTI;ERCOLE MAZZEO;FRANCO NARNI","12;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;MATHEMATICS;ENGINEERING;CHEMISTRY;PSYCHOLOGY;POLITICAL SCIENCE;SOCIOLOGY;BUSINESS;GEOGRAPHY;MATERIALS SCIENCE;PHILOSOPHY;ECONOMICS;GEOLOGY","125;26;13;12;8;6;5;5;4;4;3;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;GASTROENTEROLOGY;PSYCHIATRY;CANCER RESEARCH;IMMUNOLOGY;CARDIOLOGY;GENETICS;INTENSIVE CARE MEDICINE;PALEONTOLOGY;ARTIFICIAL INTELLIGENCE;ANESTHESIA;PHYSICAL THERAPY;ANATOMY;BIOCHEMISTRY;DERMATOLOGY;ENDOCRINOLOGY;NUCLEAR MEDICINE;OPTICS;PEDIATRICS;UROLOGY","96;40;29;27;20;19;18;12;11;11;10;10;9;9;8;7;7;6;6;6;6;6;6;6;6","CANCER;POPULATION;CHEMOTHERAPY;DISEASE;ADVERSE EFFECT;IMMUNOHISTOCHEMISTRY;GENE;ALTERNATIVE MEDICINE;CLINICAL TRIAL;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;HEPATOCELLULAR CARCINOMA;INCIDENCE (GEOMETRY);MAGNETIC RESONANCE IMAGING;STAGE (STRATIGRAPHY);TRANSPLANTATION;ANTIBODY;KIDNEY;OBSERVATIONAL STUDY;PROSPECTIVE COHORT STUDY;RETROSPECTIVE COHORT STUDY","33;19;15;13;11;10;9;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5","COLORECTAL CANCER;PROSTATE CANCER;HEAD AND NECK CANCER;SORAFENIB;BREAST CANCER;PLACEBO;PROGRESSION-FREE SURVIVAL;TOLERABILITY;ADENOCARCINOMA;BEVACIZUMAB;CARDIAC MAGNETIC RESONANCE;CARDIAC MAGNETIC RESONANCE IMAGING;CLINICAL ENDPOINT;CLONE (JAVA METHOD);DOCETAXEL;GESTATIONAL AGE;INFLAMMATORY BOWEL DISEASE;KIDNEY TRANSPLANTATION;PHASES OF CLINICAL RESEARCH;TOMOTHERAPY;UNIVARIATE ANALYSIS;VIRAL LOAD","9;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","KRAS;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ANTIRETROVIRAL THERAPY;CETUXIMAB;CROSSOVER STUDY;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;DNA METHYLATION;PROSTATECTOMY;TRABECTEDIN;ANAPLASTIC LYMPHOMA KINASE;ANTIVIRAL THERAPY;AROMATASE;AXITINIB;BENDAMUSTINE;BRAIN METASTASIS;BRCA MUTATION;CAPECITABINE;CARBOPLATIN;CARPOMETACARPAL JOINT;CELL COUNTING;CHEMOIMMUNOTHERAPY;CHILDHOOD LEUKEMIA;CHLORMADINONE ACETATE;CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME;CHROMOSOME INSTABILITY;CRITICAL LIMB ISCHEMIA;CRIZOTINIB;DABIGATRAN;DNA MISMATCH REPAIR;DOPPLER ECHOCARDIOGRAPHY;ERLOTINIB;FAMILY PLANNING;FLUDARABINE;FOLLICLE-STIMULATING HORMONE;GERMINAL CENTER;GROUND-GLASS OPACITY;HEME OXYGENASE;HERPESVIRIDAE;HIV VACCINE;HOMOCYSTINURIA;INTRA ARTICULAR;INTRAEPITHELIAL NEOPLASIA;IRINOTECAN;LENTIVIRUS;LYMPHOVASCULAR INVASION;MAMMOGRAPHY;MASTECTOMY;MECAMYLAMINE;MICROSATELLITE;NEOADJUVANT THERAPY;NIVOLUMAB;OFATUMUMAB;PAZOPANIB;PCA3;PEMETREXED;PLACENTA;PORTOPULMONARY HYPERTENSION;PRENATAL DIAGNOSIS;PROSTATE BIOPSY;PROSTATE-SPECIFIC ANTIGEN;REGORAFENIB;RENAL ISCHEMIA;SF-36;SINGLE-NUCLEOTIDE POLYMORPHISM;STEATOHEPATITIS;T-TYPE CALCIUM CHANNEL;TENSION BAND WIRING;THYMIDYLATE SYNTHASE;THYMOGLOBULIN;TRASTUZUMAB;TRIPLE-NEGATIVE BREAST CANCER;USUAL INTERSTITIAL PNEUMONIA;VINCRISTINE;VOXEL-BASED MORPHOMETRY","5;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;ITALY;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;LUNG NEOPLASMS;TREATMENT OUTCOME;YOUNG ADULT;TOMOGRAPHY, X-RAY COMPUTED;ADOLESCENT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BRONCHIAL NEOPLASMS;ESTRADIOL;RISK FACTORS;FOLLOW-UP STUDIES","67;58;54;49;43;31;31;26;17;17;14;14;12;10;9;9;9;9;9;8","ADVANCEMENTS IN LUNG CANCER RESEARCH;RENAL CELL CARCINOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;HEPATOCELLULAR CARCINOMA;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;TREATMENT AND OUTCOMES OF HAND INJURIES;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;EFFECTS OF HORMONES ON MENOPAUSAL WOMEN'S HEALTH;FLUID RESUSCITATION IN TRAUMA AND CRITICAL CARE;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE;PERIODONTAL DISEASES AND ORAL MICROBIOME","4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","EVEROLIMUS;PROGRESSION-FREE SURVIVAL;REGIMEN;TOLERABILITY;TREATMENT;CARDIAC IMAGING;CARDIAC MAGNETIC RESONANCE;CLINICAL ENDPOINT;CLONE (JAVA METHOD);ETIOLOGY;HIV;INTERVENTIONAL RADIOLOGY;METASTATIC PROSTATE CANCER;PROSTATE CANCER;RADIOTHERAPY;REFRACTORY (PLANETARY SCIENCE);SORAFENIB;TOMOTHERAPY;TREATMENT GUIDELINES;UNIVARIATE ANALYSIS","4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","COLORECTAL CANCER;RETROSPECTIVE ANALYSIS;FINAL RESULTS;PHASE II;RANDOMIZED PHASE;RISK FACTORS;ADVANCED HEAD;CANCER PATIENTS;CARDIAC MAGNETIC;CELL CARCINOMA;CHRONIC LYMPHOCYTIC;HEPATOCELLULAR CARCINOMA;LYMPHOCYTIC LEUKEMIA;MAGNETIC RESONANCE;MULTIPLE MYELOMA;PROSTATE CANCER;ADVANCED NEUROENDOCRINE;BOWEL DISEASE;BREAST CANCER;CANCER MCRPC;CASE-CONTROL STUDY;CENTRAL VENOUS;CLINICAL OUTCOMES;CLINICAL TRIAL;COMPUTED TOMOGRAPHY;CONFOCAL MICROSCOPY;CORONARY ATHEROSCLEROSIS;DIETARY SUPPLEMENT;ELDERLY PATIENTS;GIDEON GLOBAL","5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MEDIAN AGE;HR CI;CLINICAL PRACTICE;ADVERSE EVENTS;ITALIAN COHORT;PATIENTS PTS;PTS RECEIVED;SURVIVAL OS;BLOOD LOSS;GRADE AES;PROSTATE CANCER;RESPONSE RATE;SAFETY PROFILE;SIGNIFICANTLY LOWER;COLORECTAL CANCER;ELDERLY PTS;HIGH-VOLUME CENTERS;LINE THERAPY;LINE- HYPOMETHYLATION;MEDIAN OS;NEOADJUVANT CT;THYMIC CARCINOMAS;ECOG PS;OBSERVATIONAL STUDY;CD COUNT;CYFLOW MINIPOC;E-CIG VAPOUR;ESTIMATED BLOOD;HAND ECZEMA;MEDIAN PFS","15;14;12;11;10;10;10;10;9;9;9;9;9;9;8;8;8;8;8;8;8;8;7;7;6;6;6;6;6;6",43,0.34,4.54,4.5,1,2,1,2,1.25,1,1,5,0,1,4,1,1,1,4.5,3,3,0,0,66,66,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,4.08,1245.28,9.51,13,0.52,135,0,0,6,0,10,0,3,6,0,20,5,0,0,0,0,0,0,23,2,0,25,0,0,0,0,0,0,0,0,0,"United States;Japan;Italy;Canada;Germany;Israel;Netherlands;Spain;United Kingdom","10;3;2;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH","24;14;8;4;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;DIGESTIVE DISEASES;AUTOIMMUNE DISEASE;PATIENT SAFETY;RARE DISEASES;HEMATOLOGY;INFLAMMATORY BOWEL DISEASE;LUNG;BREAST CANCER;CROHN'S DISEASE;HIV/AIDS;CARDIOVASCULAR;EMERGING INFECTIOUS DISEASES;HEART DISEASE;INFECTIOUS DISEASES;LYMPHOMA;ORPHAN DRUG;PEDIATRIC","23;16;8;7;6;6;6;5;4;4;3;3;3;2;2;2;2;2;2;2","CANCER;INFECTION;ORAL AND GASTROINTESTINAL;CARDIOVASCULAR;RESPIRATORY;STROKE","7;4;3;2;2;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING","21;3;2;1;1","BREAST CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;GASTROINTESTINAL TRACT;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;PANCREATIC CANCER","3;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","9",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;TAYLOR & FRANCIS GROUP","10;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;49 MATHEMATICAL SCIENCES;3202 CLINICAL SCIENCES;4206 PUBLIC HEALTH;31 BIOLOGICAL SCIENCES;3105 GENETICS;3213 PAEDIATRICS;4904 PURE MATHEMATICS;4905 STATISTICS","14;5;5;3;2;2;1;1;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BREAST CANCER;COLO-RECTAL CANCER;DIGESTIVE DISEASES;HEMATOLOGY;INFECTIOUS DISEASES;SEPSIS","3;2;2;1;1;1;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM;INFECTION","5;3;2","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.2 CELLULAR AND GENE THERAPIES","4;1;1","CLINICAL","2","CLINICAL MEDICINE AND SCIENCE","3","COLON AND RECTAL CANCER;BLOOD CANCER;BREAST CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;GENITAL SYSTEM, MALE;HEAD AND NECK CANCER;HODGKIN'S DISEASE;KIDNEY CANCER;LIVER CANCER;LUNG CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;RESPIRATORY SYSTEM;STOMACH CANCER;THYMOMA, MALIGNANT;URINARY SYSTEM","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","2"
"AOU_MODENA",2016,186,13.2741935483871,2.94086021505376,0.365591397849462,0.338709677419355,0.365591397849462,1.98188405797101,1.47826086956522,1.53658536585366,1.47826086956522,0.629032258064516,1,122,31,16,7,0.66,0.17,0.09,0.04,19.53,0.601141385761948,4.45161290322581,0.258064516129032,0.913978494623656,0.483,0.506,0.513,0.506,"GIUSEPPE BORIANI;STEFANO CASCINU;T. COSTI;N. MAFFEI;G. GUIDI;A. CIARMATORI;GIULIO ROSSI;ANGELO CAGNACCI;ROBERTO SABBATINI;ERICA VILLA;GIOVANNI GRANDI;G. MISTRETTA;P. CERONI;P. GIACOBAZZI;VITTORINA ZAGONEL;GREGORY Y.H. LIP;ALDO P. MAGGIONI;BRUNO MEDURI;RENATO PIETRO RICCI;LUCA MOSCETTI","20;16;10;10;10;10;10;10;9;9;9;8;8;8;7;7;7;7;6;6","GIUSEPPE BORIANI;ANGELO CAGNACCI;GIOVANNI GRANDI;STEFANO CASCINU;GIULIO ROSSI;T. COSTI;A. CIARMATORI;GIOVANNA SPINZO;ERICA VILLA;GREGORY Y.H. LIP;LUCA NOCETTI;MARIA CECILIA MENGOLI;N. MAFFEI;G. GUIDI;G. MISTRETTA;ROBERTO SABBATINI;P. GIACOBAZZI;FILIPPO SCHEPIS;FILIPPO LOCOCO;P. CERONI","2.25;1.59;1.41;1.39;1.13;1;1;1;1;0.96;0.95;0.85;0.85;0.85;0.83;0.81;0.76;0.75;0.74;0.73","GIUSEPPE BORIANI;STEFANO CASCINU;T. COSTI;N. MAFFEI;G. GUIDI;A. CIARMATORI;GIULIO ROSSI;ANGELO CAGNACCI;ROBERTO SABBATINI;ERICA VILLA;GIOVANNI GRANDI;G. MISTRETTA;P. CERONI;P. GIACOBAZZI;BRUNO MEDURI;LUCA MOSCETTI;CLAUDIA OMARINI;ANNALISA GUIDA;VANNI BORGHI;MARIA CECILIA MENGOLI","20;16;10;10;10;10;10;10;9;9;9;8;8;8;7;6;5;5;5;5","GIUSEPPE BORIANI;ANGELO CAGNACCI;GIOVANNI GRANDI;STEFANO CASCINU;GIULIO ROSSI;T. COSTI;A. CIARMATORI;GIOVANNA SPINZO;ERICA VILLA;LUCA NOCETTI;MARIA CECILIA MENGOLI;N. MAFFEI;G. GUIDI;G. MISTRETTA;ROBERTO SABBATINI;P. GIACOBAZZI;FILIPPO SCHEPIS;P. CERONI;FEDERICA PALMA;FABIO CATANI","2.25;1.59;1.41;1.39;1.13;1;1;1;1;0.95;0.85;0.85;0.85;0.83;0.81;0.76;0.75;0.73;0.68;0.67","GIUSEPPE BORIANI;ANGELO MICHELE CARELLA;FRANCO NARNI;DOMENICO RUSSO;ANDREAS VÖLP;ANTONIO M. RISITANO;ARNON NAGLER;CARLOS SOLANO;CARMINE SELLERI;CHRISTELLE FERRÁ;CHRISTINE WOLSCHKE;DOMENICO PASTORE;ELISABETTA TERRUZZI;FABIO BENEDETTI;FRANCESCA BONIFAZI;FRANCESCA PATRIARCA;FRANCIS AYUK;GIUSEPPE BANDINI;GIUSEPPE MESSINA;GIUSEPPE MILONE","788;686;576;480;478;478;478;478;478;478;478;478;478;478;478;478;478;478;478;478","GIUSEPPE BORIANI;FRANCO NARNI;ROBERTO MARASCA;ANGELO CAGNACCI;GIOVANNI GRANDI;GIULIO ROSSI;FABIO FORGHIERI;P. MARCHEGIANO;MONICA CELLINI;STEFANO ZONA;MONICA MORSELLI;AMBRA PAOLINI;DANIELA VALLERINI;ELISABETTA COLACI;GIOVANNI RIVA;LEONARDO POTENZA;MARIO LUPPI;PATRIZIA BAROZZI;CRISTINA MUSSINI;LAURA CORTESI","788;576;306;248;210;176;163;122;107;101;99;98;98;98;98;98;98;98;95;87","GIUSEPPE BORIANI;STEFANO CASCINU;T. COSTI;A. CIARMATORI;ANGELO CAGNACCI;ERICA VILLA;P. GIACOBAZZI;ROBERTO SABBATINI;G. GUIDI;GIOVANNI GRANDI;N. MAFFEI;G. MISTRETTA;P. CERONI;GIULIO ROSSI;BRUNO MEDURI;LUCA MOSCETTI;CLAUDIA OMARINI;VANNI BORGHI;LUCA NOCETTI;MARIA CECILIA MENGOLI","20;14;11;10;10;9;9;9;9;9;9;8;8;7;7;6;6;5;5;5","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;MATHEMATICS;ECONOMICS;PHILOSOPHY;PSYCHOLOGY;GEOGRAPHY;MATERIALS SCIENCE;POLITICAL SCIENCE;BUSINESS;ART;SOCIOLOGY","183;36;27;17;14;10;10;6;5;4;3;3;3;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;GASTROENTEROLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;GENETICS;RADIOLOGY;IMMUNOLOGY;OPTICS;MEDICAL PHYSICS;NUCLEAR MEDICINE;BIOCHEMISTRY;GYNECOLOGY;PEDIATRICS;UROLOGY;CANCER RESEARCH;ENDOCRINOLOGY;FAMILY MEDICINE;MECHANICAL ENGINEERING;VIROLOGY","136;51;49;33;30;27;25;21;19;18;14;13;13;12;12;10;10;9;9;9;9;9","CANCER;POPULATION;CLINICAL TRIAL;GENE;ATRIAL FIBRILLATION;RADIATION THERAPY;ADVERSE EFFECT;CHEMOTHERAPY;DISEASE;CONFIDENCE INTERVAL;ALTERNATIVE MEDICINE;RANDOMIZED CONTROLLED TRIAL;COHORT;HEART FAILURE;OBSERVATIONAL STUDY;INCIDENCE (GEOMETRY);PREGNANCY;RENAL CELL CARCINOMA;STROKE (ENGINE);LUNG CANCER;PROPORTIONAL HAZARDS MODEL;REGIMEN;TRANSPLANTATION;VIRUS","53;25;20;16;15;15;14;14;13;12;11;11;10;10;10;9;8;8;8;7;7;7;7;7","BREAST CANCER;COLORECTAL CANCER;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;HAZARD RATIO;TOLERABILITY;PHASES OF CLINICAL RESEARCH;ADENOCARCINOMA;NEUTROPENIA;PACLITAXEL;PI3K/AKT/MTOR PATHWAY;PROSTATE CANCER;BEVACIZUMAB;MALIGNANT PLEURAL EFFUSION;METASTASIS;VASCULAR ENDOTHELIAL GROWTH FACTOR;CHROMOSOME;CUMULATIVE INCIDENCE;DOCETAXEL;EJECTION FRACTION;HEPATITIS C VIRUS;KIDNEY TRANSPLANTATION;MULTICENTER STUDY;MUTATION;PANCREATIC CANCER;PLACEBO;PROGESTIN;RANDOMIZATION;SORAFENIB;SUNITINIB;TOMOTHERAPY;VIRAL LOAD","20;13;12;9;8;8;7;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","METASTATIC BREAST CANCER;TRASTUZUMAB;ANAPLASTIC LYMPHOMA KINASE;ANDROGEN DEPRIVATION THERAPY;CAPECITABINE;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;OXALIPLATIN;RIBAVIRIN;TAMOXIFEN;ACUTE PROMYELOCYTIC LEUKEMIA;ANDROGEN RECEPTOR;ANTIRETROVIRAL THERAPY;AROMATASE;BRCA MUTATION;CARDIAC RESYNCHRONIZATION THERAPY;FEBRILE NEUTROPENIA;FLUORESCENCE IN SITU HYBRIDIZATION;HERPESVIRIDAE;IRINOTECAN;KRAS;MISSENSE MUTATION;NAB-PACLITAXEL;ONCOGENE;PAZOPANIB;PDGFRA;PLACENTAL GROWTH FACTOR;REGORAFENIB;ROS1;SINGLE-NUCLEOTIDE POLYMORPHISM;THERMOLUMINESCENT DOSIMETER","10;6;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MALE;MIDDLE AGED;ATRIAL FIBRILLATION;AGED;ITALY;ADULT;AGED, 80 AND OVER;STROKE;LUNG NEOPLASMS;RISK FACTORS;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;BREAST NEOPLASMS;ARRHYTHMIAS, CARDIAC;PROSPECTIVE STUDIES;EUROPE;ADOLESCENT","96;90;73;60;54;46;45;41;40;24;22;21;21;18;17;16;15;15;13;12","ATRIAL FIBRILLATION;RADIOTHERAPY PHYSICS AND TECHNOLOGY;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HER2 SIGNALING IN BREAST CANCER TREATMENT;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;RENAL CELL CARCINOMA;COLORECTAL CANCER RESEARCH AND TREATMENT;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;PANCREATIC CANCER RESEARCH AND TREATMENT;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLINICAL AND PATHOLOGICAL ASPECTS OF URACHAL CARCINOMA;EFFECTS OF HORMONES ON MENOPAUSAL WOMEN'S HEALTH;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;EPILEPSY AND SEIZURES","9;9;7;6;5;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2","BREAST CANCER;CLINICAL ENDPOINT;ATRIAL FIBRILLATION;PROGRESSION-FREE SURVIVAL;STROKE (ENGINE);TOLERABILITY;TREATMENT;METASTATIC COLORECTAL CANCER;REGIMEN;EVEROLIMUS;CONCOMITANT;DISCONTINUATION;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;METASTATIC BREAST CANCER;REFRACTORY (PLANETARY SCIENCE);TRASTUZUMAB;ANGIOGENIC SIGNALING;CABAZITAXEL;CARDIAC RESYNCHRONIZATION THERAPY;CARDIOVASCULAR RISK ASSESSMENT","12;12;10;9;8;8;8;7;7;5;4;4;4;4;4;4;3;3;3;3","BREAST CANCER;ATRIAL FIBRILLATION;METASTATIC BREAST;PATIENTS PTS;CANCER PATIENTS;CELL CARCINOMA;RENAL CELL;EUROBSERVATIONAL RESEARCH;PRELIMINARY RESULTS;PROSTATE CANCER;RANDOMIZED PHASE;ADVANCED BREAST;CASTRATION-RESISTANT PROSTATE;LOCALLY ADVANCED;MULTICENTER ITALIAN;OBSERVATIONAL STUDY;PROSPECTIVE STUDY;RETROSPECTIVE ANALYSIS;ADAPTIVE RT;ADVANCED RECTAL;CANCER MCRPC;CLINICAL PRACTICE;COLORECTAL CANCER;COMPARING PREOPERATIVE;FIBRILLATION EORP-AF;FINAL RESULTS;III TRIAL;ITALIAN EXPERIENCE;ITALIAN STUDY;LUNG CANCER","17;15;9;9;8;8;6;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","MEDIAN AGE;BREAST CANCER;HR CI;MEDIAN PFS;FGF- LEVELS;MO CI;SURVIVAL OS;ADVERSE EVENTS;ATRIAL FIBRILLATION;MEDIAN OS;CLINICAL PRACTICE;PATIENTS PTS;PHYSICAL ACTIVITY;PTS RECEIVED;PTS TREATED;SURVIVAL PFS;INKT CELLS;PATIENTS TREATED;GROWTH FACTOR;NORMOGLYCEMIC PTS;RESPONSE RATE;ECOG PS;FIBRILLATION AF;PHASE III;AF PATIENTS;MEDIAN FOLLOW-UP;MULTIVARIATE ANALYSIS;PRIMARY ENDPOINT;PROGRESSION-FREE SURVIVAL;CLINICAL TRIAL","23;21;19;18;16;16;16;15;15;14;13;13;13;13;13;13;12;12;11;11;11;10;10;10;9;9;9;9;9;8",53,0.28,7,4,1,2,0,2,1,1,1,6,0,1,5.5,1,0,3,3,4,2,0,0,61,59,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,5.19,573.38,9.77,16,0.62,99.38,3,0,4,0,11,0,1,7,0,20,6,0,0,0,0,0,0,26,0,0,26,0,0,0,0,0,0,0,0,0,"Japan;United States;Italy;Germany","6;5;3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","26;15;14;6;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;LYMPHOMA;DIGESTIVE DISEASES;PREVENTION;LUNG;ORPHAN DRUG;PATIENT SAFETY;AUTOIMMUNE DISEASE;BEHAVIORAL AND SOCIAL SCIENCE;BIOMEDICAL IMAGING;BREAST CANCER;COLO-RECTAL CANCER;DENTAL/ORAL AND CRANIOFACIAL DISEASE;INFECTIOUS DISEASES;KIDNEY DISEASE;LUNG CANCER","26;21;17;10;6;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;INFECTION","12;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES","20;6;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;BREAST CANCER;COLON AND RECTAL CANCER;HEAD AND NECK CANCER;KIDNEY CANCER;LARYNGEAL CANCER;LUNG CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;NOT SITE-SPECIFIC CANCER;SARCOMA","4;3;2;2;2;2;2;2;2;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","15;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"PUBLIC LIBRARY OF SCIENCE","10","32 BIOMEDICAL AND CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;3202 CLINICAL SCIENCES;4904 PURE MATHEMATICS;3211 ONCOLOGY AND CARCINOGENESIS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;44 HUMAN SOCIETY","8;4;3;3;2;1;1;1","CANCER;CLINICAL RESEARCH;DIGESTIVE DISEASES;PANCREATIC CANCER;RARE DISEASES;BIOTECHNOLOGY;GENETICS;KIDNEY DISEASE;PREVENTION;REGENERATIVE MEDICINE;STEM CELL RESEARCH","2;2;2;2;2;1;1;1;1;1;1","CANCER;MUSCULOSKELETAL","3;1","5.2 CELLULAR AND GENE THERAPIES;5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","1;1","CLINICAL;BIOMEDICAL","2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","6;1","PANCREATIC CANCER;KIDNEY CANCER","2;1",NA,NA
"AOU_MODENA",2017,166,14.7168674698795,2.67469879518072,0.319277108433735,0.234939759036145,0.403614457831325,1.63837638376384,1.29268292682927,1.625,1.24074074074074,0.560240963855422,3,87,33,12,21,0.52,0.2,0.07,0.13,19.24,0.652788673974878,4.59914407988588,0.343373493975904,0.927710843373494,0.458,0.426,0.464,0.449,"GIUSEPPE BORIANI;FRANK LOHR;STEFANO CASCINU;LUCA MOSCETTI;FAUSTO BARBIERI;LUCIA MENTUCCIA;PATRIZIA VICI;TERESA GAMUCCI;ERICA VILLA;LAURA PIZZUTI;LORENZO LIVI;ALESSIO BRUNI;DANIELE SANTINI;MARIO LUPPI;DOMENICO GALETTA;GIULIO ROSSI;GIUSEPPE PROCOPIO;ISABELLA SPERDUTI;PIETRO ANDREONÉ;CRISTINA MUSSINI","16;12;9;8;8;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5","GIUSEPPE BORIANI;FRANK LOHR;ANNA MARIA CESINARO;MARIA MARIANO;GIUSEPPE CASSONE;STEFANO CASCINU;MARIA CECILIA MENGOLI;FILIPPO LOCOCO;GIULIO ROSSI;FABIO CATANI;FAUSTO BARBIERI;FRANCESCO FONTANA;GIANNI CAPPELLI;FABRIZIO FERRARI;ALBERTO BERARDI;FRANCESCO FIACCHI;ANDREA LETI ACCIARO;MARIO LUPPI;MICHELE COLACI;MASSIMILIANO SALATI","1.54;1.4;1.17;1;1;0.95;0.74;0.7;0.67;0.65;0.6;0.54;0.54;0.54;0.54;0.51;0.5;0.49;0.49;0.48","GIUSEPPE BORIANI;FRANK LOHR;STEFANO CASCINU;LUCA MOSCETTI;FAUSTO BARBIERI;ERICA VILLA;ALESSIO BRUNI;MARIO LUPPI;GIULIO ROSSI;PIETRO ANDREONÉ;CRISTINA MUSSINI;LEONARDO POTENZA;CLODOVEO FERRI;ROBERTO SABBATINI;FABRIZIO FERRARI;FRANCESCO FONTANA;ALBERTO BERARDI;FABIO CATANI;ANDREINA MANFREDI;VANNI BORGHI","16;12;9;8;8;7;6;5;5;5;5;5;5;4;4;4;4;4;4;4","GIUSEPPE BORIANI;FRANK LOHR;ANNA MARIA CESINARO;MARIA MARIANO;GIUSEPPE CASSONE;STEFANO CASCINU;MARIA CECILIA MENGOLI;GIULIO ROSSI;FABIO CATANI;FAUSTO BARBIERI;FRANCESCO FONTANA;GIANNI CAPPELLI;FABRIZIO FERRARI;ALBERTO BERARDI;FRANCESCO FIACCHI;ANDREA LETI ACCIARO;MARIO LUPPI;MICHELE COLACI;MASSIMILIANO SALATI;CHIARA CAVATORTA","1.54;1.4;1.17;1;1;0.95;0.74;0.67;0.65;0.6;0.54;0.54;0.54;0.54;0.51;0.5;0.49;0.49;0.48;0.48","GIUSEPPE BORIANI;MONICA PECORARI;ANNA FABIO;ANTONELLA GROTTOLA;CLOTILDE BETTUA;CONOR J. MEEHAN;ELISABETTA GIACOBAZZI;ENRICO TORTOLI;GIULIA FREGNI SERPINI;NICOLA SEGATA;OLIVIER JOUSSON;ROBERTO BERTORELLI;SARA TAGLIAZUCCHI;TARCISIO FEDRIZZI;VERONICA DE SANCTIS;ALDO P. MAGGIONI;A GODA;FRANCISCO MARÍN;G Y H LIP;G-A DAN","651;324;321;321;321;321;321;321;321;321;321;321;321;321;321;272;262;262;262;262","GIUSEPPE BORIANI;MONICA PECORARI;ANNA FABIO;ANTONELLA GROTTOLA;GIULIA FREGNI SERPINI;SARA TAGLIAZUCCHI;FRANK LOHR;STEFANO CASCINU;FABIO RUMPIANESI;ALESSIO BRUNI;FAUSTO BARBIERI;FRANCESCA FRASCARO;ROBERTO SABBATINI;MASSIMO GIRARDIS;PAOLO NICHELLI;CLODOVEO FERRI;LUCA MOSCETTI;ILARIA MARIOTTI;LUIGI MARCHESELLI;ERICA VILLA","651;324;321;321;321;321;232;230;185;171;159;136;104;89;87;84;84;80;79;73","GIUSEPPE BORIANI;FRANK LOHR;STEFANO CASCINU;FAUSTO BARBIERI;LUCA MOSCETTI;ERICA VILLA;ALESSIO BRUNI;CLODOVEO FERRI;CRISTINA MUSSINI;ALBERTO BERARDI;FABIO CATANI;FABRIZIO FERRARI;FABRIZIO LUPPI;GIOVANNI GRANDI;LEONARDO POTENZA;MARIO LUPPI;MASSIMO GIRARDIS;ROBERTO SABBATINI;STEFANIA CERRI;ANDREINA MANFREDI","16;12;9;8;8;6;6;6;5;4;4;4;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;PSYCHOLOGY;SOCIOLOGY;CHEMISTRY;POLITICAL SCIENCE;MATHEMATICS;MATERIALS SCIENCE;ECONOMICS;GEOGRAPHY","161;28;18;8;7;7;7;5;4;3;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;INTENSIVE CARE MEDICINE;CARDIOLOGY;GENETICS;OPTICS;DERMATOLOGY;PEDIATRICS;VIROLOGY;ANESTHESIA;PALEONTOLOGY;BIOCHEMISTRY;NUCLEAR MEDICINE;PSYCHIATRY;UROLOGY","132;45;44;30;24;22;21;19;16;15;15;15;13;12;10;8;8;7;7;7;7","CANCER;POPULATION;DISEASE;ADVERSE EFFECT;CONFIDENCE INTERVAL;CHEMOTHERAPY;RADIATION THERAPY;GENE;LUNG CANCER;RANDOMIZED CONTROLLED TRIAL;INCIDENCE (GEOMETRY);LUNG;ATRIAL FIBRILLATION;RETROSPECTIVE COHORT STUDY;ANTIBODY;CLINICAL TRIAL;VIRUS;COHORT;LYMPHOMA;HEART FAILURE;PROSPECTIVE COHORT STUDY","46;20;17;15;14;13;13;11;11;11;10;10;9;9;8;8;8;7;7;6;6","BREAST CANCER;COLORECTAL CANCER;ADENOCARCINOMA;CLINICAL ENDPOINT;VIRAL LOAD;EJECTION FRACTION;HAZARD RATIO;IMMUNOTHERAPY;INTERSTITIAL LUNG DISEASE;MALIGNANT PLEURAL EFFUSION;MULTICENTER STUDY;OVARIAN CANCER;SORAFENIB;TOLERABILITY;CHRONIC HEPATITIS;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;DOCETAXEL;EPIDERMAL GROWTH FACTOR RECEPTOR;GENOTYPE;PROGRESSION-FREE SURVIVAL;PROSTATE CANCER;RADIOSURGERY;RITUXIMAB;SCLERODERMA (FUNGUS);SEROLOGY;SUNITINIB;VENTILATOR-ASSOCIATED PNEUMONIA;VISCERAL LEISHMANIASIS","14;9;7;6;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","METASTATIC BREAST CANCER;CARDIAC RESYNCHRONIZATION THERAPY;NIVOLUMAB;CRIZOTINIB;ROS1;ANTIRETROVIRAL THERAPY;ESTROGEN RECEPTOR;LEISHMANIA INFANTUM;OXALIPLATIN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TAXANE;TRASTUZUMAB;ANDROGEN DEPRIVATION THERAPY;ANTISYNTHETASE SYNDROME;AROMATASE;BRCA MUTATION;COLONOSCOPY;CONNECTIVE TISSUE DISEASE;DIFFUSING CAPACITY;ERLOTINIB;FAMILY PLANNING;GEFITINIB;GENOTYPING;KRAS;LAMIVUDINE;MOLECULAR EPIDEMIOLOGY;PAZOPANIB;PIRFENIDONE;POLY ADP RIBOSE POLYMERASE;RIBAVIRIN;TAMOXIFEN","6;5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;MIDDLE AGED;;AGED;ADULT;ITALY;AGED, 80 AND OVER;ATRIAL FIBRILLATION;BREAST NEOPLASMS;TREATMENT OUTCOME;RISK FACTORS;HIV INFECTIONS;RETROSPECTIVE STUDIES;PROSPECTIVE STUDIES;FOLLOW-UP STUDIES;YOUNG ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;DEFIBRILLATORS, IMPLANTABLE","101;75;69;68;65;57;44;44;27;26;24;22;20;19;19;18;17;16;15;15","ADVANCEMENTS IN LUNG CANCER RESEARCH;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;ATRIAL FIBRILLATION;RADIOTHERAPY PHYSICS AND TECHNOLOGY;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;RENAL CELL CARCINOMA;GLOBAL BURDEN OF LEISHMANIASIS INCIDENCE AND TREATMENT;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;TREATMENT AND OUTCOMES OF HAND INJURIES;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ANKLE INJURIES AND DISORDERS IN SPORTS MEDICINE;CANCER IMMUNOTHERAPY;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;DIAGNOSIS AND TREATMENT OF LUNG CANCER","8;7;6;6;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2","TREATMENT;BREAST CANCER;CLINICAL ENDPOINT;IMAGE-GUIDED RADIOTHERAPY;ATRIAL FIBRILLATION;EVEROLIMUS;INTENSITY-MODULATED RADIOTHERAPY;REGIMEN;CARDIAC RESYNCHRONIZATION THERAPY;EXPANDED ACCESS;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;METASTATIC BREAST CANCER;NON-SMALL CELL LUNG CANCER;RADIOTHERAPY PHYSICS;STROKE (ENGINE);TOLERABILITY;ARRHYTHMIAS;CANCER SUSCEPTIBILITY;CROSS-SECTIONAL STUDY;DIAGNOSIS","14;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3","ATRIAL FIBRILLATION;BREAST CANCER;CANCER PATIENTS;LUNG CANCER;CELL CARCINOMA;EXPANDED ACCESS;METASTATIC RENAL;RENAL CELL;ACCESS PROGRAM;METASTATIC BREAST;NON-SMALL-CELL LUNG;OBSERVATIONAL STUDY;OVARIAN CANCER;RETROSPECTIVE ANALYSIS;ADVANCED BREAST;BODY POSITION;BODY RADIOTHERAPY;CANCER NSCLC;CARCINOMA MRCC;CARDIAC RESYNCHRONIZATION;CELL LUNG;CLINICAL OUTCOME;DEREGULATED NON-SMALL-CELL;EUROBSERVATIONAL RESEARCH;ITALIAN EXPANDED;MET DEREGULATED;METROS TRIAL;NORTHERN ITALY;PATIENTS PTS;PATIENTS TREATED","11;10;10;8;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","AF BURDEN;ADVERSE EVENTS;SURVIVAL OS;DAILY AF;ALL-CAUSE DEATH;MEDIAN AGE;MEDIAN FOLLOW-UP;COLORECTAL CANCER;PROGRESSION-FREE SURVIVAL;RESPONSE RATE;ATRIAL FIBRILLATION;BMI Z-SCORE;CLL CELLS;PEER VICTIMIZATION;PTS TREATED;RATE CONTROL;SURVIVAL PFS;AF PATIENTS;ANTI PL-;BREAST CANCER;LUNG CANCER;MONTHS NA;OVARIAN CANCER;PROGRESSION FREE;REAL WORLD;SSC PATIENTS;COLON CANCER;CONFIDENCE INTERVAL;DISEASE CONTROL;EMILIA-ROMAGNA REGION","16;15;14;12;11;11;11;10;10;10;9;9;9;9;9;9;9;8;8;8;8;8;8;8;8;8;7;7;7;7",63,0.38,6.15,7,1.75,1,1.5,2,1,0,1,8,1,1,6,1,1,1,2.25,4,3,0,0,72,72,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,4.82,685.59,14.29,19,0.51,107.22,0,0,12,0,16,0,0,9,0,26,8,0,0,0,0,0,0,34,3,0,34,3,0,0,0,0,0,0,0,0,"United States;Italy;Germany;Japan","12;5;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4205 NURSING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE","35;19;16;4;3;2;2;2;2;2;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;PATIENT SAFETY;DIGESTIVE DISEASES;LUNG;BREAST CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;HEMATOLOGY;AUTOIMMUNE DISEASE;LUNG CANCER;ASSISTIVE TECHNOLOGY;BIOENGINEERING;CARDIOVASCULAR;GENETICS;HEART DISEASE;INFLAMMATORY BOWEL DISEASE;ATHEROSCLEROSIS;CROHN'S DISEASE","31;23;22;16;9;7;7;6;5;5;4;4;3;3;3;3;3;3;2;2","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;RESPIRATORY","19;3;3;2","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;7.1 INDIVIDUAL CARE NEEDS;8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)","26;4;3;2;1;1;1","BREAST CANCER;LUNG CANCER;LEUKEMIA / LEUKAEMIA;MYELOMA;HODGKIN'S DISEASE;STOMACH CANCER;HEAD AND NECK CANCER;KIDNEY CANCER;LARYNGEAL CANCER;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;ORAL CAVITY AND LIP CANCER;OVARIAN CANCER;PANCREATIC CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","6;6;3;3;2;2;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","18;2;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,"PUBLIC LIBRARY OF SCIENCE","5","32 BIOMEDICAL AND CLINICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3009 VETERINARY SCIENCES;3103 ECOLOGY","4;2;2;2;1;1",NA,NA,"INFECTION","1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1",NA,NA,"CLINICAL MEDICINE AND SCIENCE","2",NA,NA,"3 GOOD HEALTH AND WELL BEING","2"
"AOU_MODENA",2018,218,16.4174311926606,2.54587155963303,0.311926605504587,0.321100917431193,0.426605504587156,1.72897196261682,1.33333333333333,1.59090909090909,1.29166666666667,0.559633027522936,2,123,46,20,12,0.56,0.21,0.09,0.06,19.07,0.625037642816392,4.50121951219512,0.293577981651376,0.926605504587156,0.421,0.419,0.452,0.433,"GIUSEPPE BORIANI;STEFANO CASCINU;FRANK LOHR;VANNI BORGHI;JUDIT BODA‐HEGGEMANN;WILLIAM GENNARI;FAUSTO BARBIERI;IGOR DIEMBERGER;GREGORY Y.H. LIP;MAURO BIFFI;MATTEO ZIACCHI;L.N. MAZZONI;MAURIZIO ZAZZI;C. GORI;FREDERIK WENZ;A. CICCARONE;FLORIAN STIELER;R. TARDUCCI;L. FEDELI;GIACOMO BELLI","23;15;10;9;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6","GIUSEPPE BORIANI;FRANK LOHR;LUCA MOSCETTI;STEFANO CASCINU;GIOVANNI MEROLLA;GIUSEPPE PORCELLINI;JUDIT BODA‐HEGGEMANN;IGOR DIEMBERGER;ROBERTA GELMINI;GREGORY Y.H. LIP;VANNI BORGHI;GIULIA COLZANI;ANNA MARIA CESINARO;PAOLO PALADINI;MAURO BIFFI;MATTEO ZIACCHI;FREDERIK WENZ;E FANTECCHI;GIOVANNI GUARALDI;FRANCESCA CABRY","2.23;1.86;1.27;1.25;0.83;0.83;0.81;0.75;0.73;0.72;0.7;0.7;0.67;0.67;0.65;0.63;0.6;0.57;0.56;0.56","GIUSEPPE BORIANI;STEFANO CASCINU;FRANK LOHR;VANNI BORGHI;WILLIAM GENNARI;FAUSTO BARBIERI;ERICA VILLA;LUCA NOCETTI;CRISTINA MUSSINI;GIOVANNI GUARALDI;ROBERTA GELMINI;LORENA LOSI;FRANCO NARNI;PATRIZIA SOLA;FEDERICO PIACENTINI;E FANTECCHI;GIOVANNI PELLACANI;FABIO FORGHIERI;ROBERTO SABBATINI;DIANA FERRARO","23;15;10;9;8;7;6;6;6;5;5;5;5;5;5;5;4;4;4;4","GIUSEPPE BORIANI;FRANK LOHR;LUCA MOSCETTI;STEFANO CASCINU;GIUSEPPE PORCELLINI;ROBERTA GELMINI;VANNI BORGHI;GIULIA COLZANI;ANNA MARIA CESINARO;E FANTECCHI;GIOVANNI GUARALDI;FRANCESCA CABRY;LORENA SORRENTINO;FRANCESCO SERRA;GIOVANNI PELLACANI;CRISTINA MUSSINI;MANUELA SIMONI;PIETRO TORRICELLI;FAUSTO BARBIERI;GIACOMO PAVESI","2.23;1.86;1.27;1.25;0.83;0.73;0.7;0.7;0.67;0.57;0.56;0.56;0.56;0.56;0.55;0.53;0.53;0.53;0.52;0.52","GIUSEPPE BORIANI;IGOR DIEMBERGER;MATTEO ZIACCHI;MAURO BIFFI;CRISTIAN MARTIGNANI;MANUELA SIMONI;DANIELE SANTI;GIULIA MASSARO;ALESSANDRO CORZANI;ANTONIO MAZZOTTI;CINZIA VALZANIA;CLAUDIO RAPEZZI;MAURIZIO ZAZZI;ALEXANDRA ROHRACHER;CAROLINE NEURAY;CLAUDIA A. GRANBICHLER;CRISTINA FLOREA;EUGEN TRINKA;GEORG PILZ;GEORG ZIMMERMANN","640;363;326;305;289;256;241;241;220;220;220;220;204;188;188;188;188;188;188;188","GIUSEPPE BORIANI;MANUELA SIMONI;DANIELE SANTI;GIADA GIOVANNINI;STEFANO MELETTI;FEDERICO PIACENTINI;GIULIA BRIGANTE;VANNI BORGHI;LICIA LUGLI;MONICA PECORARI;ROBERTO D’AMICO;MASSIMILIANO SALATI;FRANK LOHR;ANNAMARIA FERRARESION;STEFANO CASCINU;WILLIAM GENNARI;ROBERTO SABBATINI;FABIO CATANI;ELISA MAGNANI;FABRIZIO LUPPI","640;256;241;188;188;160;153;150;145;145;139;135;131;129;118;112;105;99;97;97","GIUSEPPE BORIANI;STEFANO CASCINU;FRANK LOHR;CRISTINA MUSSINI;FAUSTO BARBIERI;VANNI BORGHI;WILLIAM GENNARI;LUCA NOCETTI;PATRIZIA SOLA;E FANTECCHI;ERICA VILLA;FEDERICO PIACENTINI;FRANCO NARNI;ANGELA TOSS;DIANA FERRARO;FABIO CATANI;FRANCESCO FONTANA;GIOVANNI GUARALDI;GIUSEPPE PORCELLINI;LAURA CORTESI","23;14;10;7;7;7;7;6;5;5;5;5;5;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;ENGINEERING;PSYCHOLOGY;CHEMISTRY;SOCIOLOGY;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY;GEOGRAPHY;ART;ENVIRONMENTAL SCIENCE;GEOLOGY;POLITICAL SCIENCE","209;50;24;15;13;12;11;7;6;5;5;3;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;ONCOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;IMMUNOLOGY;CARDIOLOGY;GENETICS;GASTROENTEROLOGY;NUCLEAR MEDICINE;PEDIATRICS;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;VIROLOGY;CANCER RESEARCH;ENDOCRINOLOGY;OPTICS;PHYSICAL THERAPY;STATISTICS","155;58;42;40;33;32;29;26;26;25;19;16;15;13;12;11;10;10;10;10","CANCER;POPULATION;CONFIDENCE INTERVAL;DISEASE;ATRIAL FIBRILLATION;GENE;COHORT;CHEMOTHERAPY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);RETROSPECTIVE COHORT STUDY;CLINICAL TRIAL;MAGNETIC RESONANCE IMAGING;VIRUS;HEART FAILURE;OBSERVATIONAL STUDY;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;ADVERSE EFFECT;IMAGING PHANTOM;LUNG CANCER;RADIATION THERAPY","50;31;19;19;18;18;17;13;12;12;11;11;11;10;10;10;10;9;8;8;8","BREAST CANCER;HAZARD RATIO;COLORECTAL CANCER;IMMUNOTHERAPY;CLINICAL ENDPOINT;VIRAL LOAD;HEPATITIS C VIRUS;MUTATION;EJECTION FRACTION;OVARIAN CANCER;PHASES OF CLINICAL RESEARCH;SPLENECTOMY;UNIVARIATE ANALYSIS;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;DIAPHRAGM (ACOUSTICS);EXPANDED DISABILITY STATUS SCALE;GEMCITABINE;GENOTYPE;HEART RATE;HEPATITIS B VIRUS;IDIOPATHIC PULMONARY FIBROSIS;ISOCENTER;KIDNEY CANCER;LIVER TRANSPLANTATION;METASTASIS;PANCREATIC CANCER;PROGRESSION-FREE SURVIVAL;QUALITY ASSURANCE;SINUS RHYTHM;SYPHILIS","12;10;9;9;8;8;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","NIVOLUMAB;ANTIRETROVIRAL THERAPY;CETUXIMAB;CARDIAC RESYNCHRONIZATION THERAPY;TRASTUZUMAB;BRADYCARDIA;METASTATIC BREAST CANCER;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;CARBOPLATIN;DEOXYCYTIDINE;DIFFUSING CAPACITY;ESTROGEN RECEPTOR;HISTOCOMPATIBILITY;IRINOTECAN;LAMIVUDINE;MICROSATELLITE;PIRFENIDONE;REVERSE TRANSCRIPTASE;STREPTOCOCCUS AGALACTIAE;TAXANE","8;7;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;ITALY;RETROSPECTIVE STUDIES;ATRIAL FIBRILLATION;HIV INFECTIONS;AGED, 80 AND OVER;TREATMENT OUTCOME;LUNG NEOPLASMS;HIV-1;PROSPECTIVE STUDIES;TIME FACTORS;YOUNG ADULT;ARRHYTHMIAS, CARDIAC;PROGNOSIS","129;100;92;86;74;59;58;54;42;39;36;32;28;24;18;16;16;16;15;15","ATRIAL FIBRILLATION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HEPATITIS C INFECTION AND TREATMENT;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CANCER IMMUNOTHERAPY;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;GASTRIC CANCER RESEARCH AND TREATMENT;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HER2 SIGNALING IN BREAST CANCER TREATMENT;LYMPHOID NEOPLASMS;MAGNETIC RESONANCE IMAGING APPLICATIONS IN MEDICINE;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MANAGEMENT OF SPLEEN TRAUMA IN POLYTRAUMA PATIENTS;MICROSURGICAL RECONSTRUCTION TECHNIQUES","9;7;6;6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3","TREATMENT;ATRIAL FIBRILLATION;CLINICAL ENDPOINT;HEPATITIS C;ANTIRETROVIRAL THERAPY;BREAST CANCER;HIV;PERFUSION IMAGING;DISCONTINUATION;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;METASTATIC GASTRIC CANCER;ANTICOAGULANT THERAPY;ARRHYTHMIAS;ATRIAL FLUTTER;CANCER IMAGING;DIAGNOSTIC ACCURACY;DIFFUSION-WEIGHTED IMAGING;EXPANDED ACCESS;IMAGE-GUIDED RADIOTHERAPY;INTERQUARTILE RANGE","10;8;8;7;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4","ATRIAL FIBRILLATION;BREAST CANCER;CELL CARCINOMA;METASTATIC RENAL;MULTIPLE SCLEROSIS;RENAL CELL;CANCER PATIENTS;EXPANDED ACCESS;GASTRIC CANCER;IDIOPATHIC PULMONARY;LUNG CANCER;MAGNETIC RESONANCE;PHASE II;ACCESS PROGRAM;CARCINOMA MRCC;CELL TRANSPLANTATION;CLINICAL OUTCOME;COLORECTAL CANCER;DE LA;FINAL RESULTS;HEART RHYTHM;METASTATIC COLORECTAL;MODENA ITALY;PATIENTS PTS;PULMONARY FIBROSIS;RETROSPECTIVE STUDY;RHEUMATOID ARTHRITIS;STEM CELL;ACTIVE MALIGNANCY;ADJUVANT TRASTUZUMAB","12;7;7;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2","ADVISORY COMMITTEES;ENTITYS BOARD;PUBMED SCOPUS;CROSSREF PUBMED;CONFIDENCE INTERVAL;RESEARCH FUNDING;HONORARIA MEMBERSHIP;ENTITY RESPONSIBLE;HR CI;LEGAL ENTITY;HR CI-;ADVISORY BOARD;LUNG CANCER;MEDIAN AGE;MULTIVARIATE ANALYSIS;ACCESS PROGRAM;BREAST CANCER;HAZARD RATIO;LECTURE FEES;PATIENTS RECEIVED;EXPANDED ACCESS;FUNDING DISCLOSURE;MEDIAN PFS;SPEAKERS BUREAU;ADVERSE EVENTS;CELL LUNG;EXOME SEQUENCING;GENET -ABSTRACT;GT COPIESML;HONORARIA RESEARCH","44;44;43;25;19;18;16;15;15;15;14;12;11;11;11;10;10;10;10;10;9;9;9;9;8;8;8;8;8;8",77,0.35,6.5,6,1,1,1,1,1.5,0,1,7,1,1,6,0,1,2,3,4,3,0,0,63,63,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,4.19,762.46,12.05,22,0.59,181.38,0,0,6,0,25,0,2,4,0,33,2,0,0,0,0,0,0,34,3,0,35,2,0,0,0,0,0,0,0,0,"United States;Italy;Japan;United Kingdom;Germany","15;3;3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3204 IMMUNOLOGY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3207 MEDICAL MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","37;23;14;6;4;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;DIGESTIVE DISEASES;PATIENT SAFETY;AUTOIMMUNE DISEASE;INFLAMMATORY BOWEL DISEASE;PEDIATRIC;BREAST CANCER;PREVENTION;INFECTIOUS DISEASES;NUTRITION;RARE DISEASES;AGING;BIOTECHNOLOGY;CROHN'S DISEASE;EMERGING INFECTIOUS DISEASES;HEMATOLOGY;PEDIATRIC CANCER;BIOMEDICAL IMAGING","33;27;15;9;8;7;7;7;5;5;4;4;4;3;3;3;3;3;3;2","CANCER;ORAL AND GASTROINTESTINAL;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","13;6;2;2;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","30;2;2","BREAST CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;BLADDER CANCER;MELANOMA;STOMACH CANCER","6;6;3;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","12;4;2;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,"PUBLIC LIBRARY OF SCIENCE","16","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3103 ECOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3502 BANKING, FINANCE AND INVESTMENT;3207 MEDICAL MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE;38 ECONOMICS;3801 APPLIED ECONOMICS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;49 MATHEMATICAL SCIENCES","18;7;6;2;2;2;1;1;1;1;1;1;1","AGING;BIOENGINEERING;BIOTECHNOLOGY;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIABETES;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HEPATITIS;HEPATITIS - C;HIV/AIDS;INFECTIOUS DISEASES;KIDNEY DISEASE;LIVER DISEASE;PATIENT SAFETY;PREVENTION","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;INFECTION;RENAL AND UROGENITAL","5;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","2;1;1;1","CLINICAL;BIOMEDICAL","4;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","6;1","LIVER CANCER;NOT SITE-SPECIFIC CANCER","1;1",NA,NA
"AOU_MODENA",2019,217,15.9953917050691,2.87557603686636,0.327188940092166,0.313364055299539,0.373271889400922,1.76271186440678,1.24561403508772,1.58139534883721,1.3728813559322,0.682027649769585,2,111,37,19,18,0.51,0.17,0.09,0.08,21.99,0.904152529195105,4.47784810126582,0.350230414746544,0.921658986175115,0.454,0.496,0.446,0.484,"GIUSEPPE BORIANI;STEFANO CASCINU;CARLO SALVARANI;STEFANIA CERRI;MARCO SEBASTIANI;ANDREINA MANFREDI;ANDREA CASADEI‐GARDINI;ROBERTA GELMINI;GIULIA CASSONE;FRANCESCO SERRA;FRANK LOHR;FABRIZIO LUPPI;VASSIL TRAYKOV;FEDERICO PIACENTINI;MANUELA SIMONI;CATERINA VACCHI;ANDREA SPALLANZANI;MARIO SCARTOZZI;GREGORY Y.H. LIP;VANNI BORGHI","22;16;10;10;10;9;9;8;8;7;7;7;7;7;7;6;6;6;6;6","LUCA RONCATI;GIUSEPPE BORIANI;ROBERTA GELMINI;CARLO SALVARANI;STEFANO CASCINU;MARCO SEBASTIANI;STEFANIA CERRI;FRANCESCO SERRA;ANDREINA MANFREDI;CATERINA VACCHI;GIORGIO DE SANTIS;FRANCESCA CABRY;FRANK LOHR;FRANCESCO MACCARRONE;GIULIA CASSONE;MATTEO ALICANDRI‐CIUFELLI;ROBERTO ADANI;MANUELA SIMONI;FABIO FACCHINETTI;LIVIO PRESUTTI","2.58;1.64;1.14;1.14;1.05;1.01;0.91;0.89;0.89;0.84;0.82;0.77;0.74;0.7;0.67;0.67;0.67;0.64;0.62;0.62","GIUSEPPE BORIANI;STEFANO CASCINU;CARLO SALVARANI;STEFANIA CERRI;MARCO SEBASTIANI;ANDREINA MANFREDI;ANDREA CASADEI‐GARDINI;ROBERTA GELMINI;GIULIA CASSONE;FRANCESCO SERRA;FRANK LOHR;FABRIZIO LUPPI;FEDERICO PIACENTINI;MANUELA SIMONI;CATERINA VACCHI;ANDREA SPALLANZANI;VANNI BORGHI;KALLIOPI ANDRIKOU;DANIELE SANTI;KATIA CAGOSSI","22;16;10;10;10;9;9;8;8;7;7;7;7;7;6;6;6;6;5;5","LUCA RONCATI;GIUSEPPE BORIANI;ROBERTA GELMINI;CARLO SALVARANI;STEFANO CASCINU;MARCO SEBASTIANI;STEFANIA CERRI;FRANCESCO SERRA;ANDREINA MANFREDI;CATERINA VACCHI;GIORGIO DE SANTIS;FRANCESCA CABRY;FRANK LOHR;FRANCESCO MACCARRONE;GIULIA CASSONE;MATTEO ALICANDRI‐CIUFELLI;ROBERTO ADANI;MANUELA SIMONI;FABIO FACCHINETTI;LIVIO PRESUTTI","2.58;1.64;1.14;1.14;1.05;1.01;0.91;0.89;0.89;0.84;0.82;0.77;0.74;0.7;0.67;0.67;0.67;0.64;0.62;0.62","GIUSEPPE BORIANI;VASSIL TRAYKOV;ZBIGNIEW KALARUS;NIKOLAOS DAGRES;JEAN‐CLAUDE DEHARO;SERGE BOVÉDA;HARAN BURRI;CARINA BLOMSTRÖM‐LUNDQVIST;CHRISTOPH STARCK;JEANNE E. POOLE;JENS COSEDIS NIELSEN;LAURENCE M. EPSTEIN;LÁSZLÓ SÁGHY;MARIA GRAZIA BONGIORNI;NEIL STRATHMORE;PAOLA ANNA ERBA;ROBERTO COSTA;ULRIKA SNYGG‐MARTIN;DIANA FERRARO;PATRIZIA SOLA","1095;840;774;749;730;671;639;592;592;592;592;592;592;592;592;592;592;592;583;583","GIUSEPPE BORIANI;DIANA FERRARO;PATRIZIA SOLA;MARCO SEBASTIANI;ANDREINA MANFREDI;STEFANIA CERRI;CARLO SALVARANI;GIOVANNI DELLA CASA;LAURA CORTESI;FAUSTO BARBIERI;GIULIA CASSONE;MASSIMO FEDERICO;FABRIZIO LUPPI;ROBERTO SABBATINI;ENZA DI PALMA;EMMA BERTUCCI;LUCA REGGIANI BONETTI;STEFANO CASCINU;VANNI BORGHI;ALBERTO BERARDI","1036;583;583;369;368;289;230;201;197;184;155;154;139;123;103;101;101;95;92;90","GIUSEPPE BORIANI;STEFANO CASCINU;CARLO SALVARANI;MARCO SEBASTIANI;STEFANIA CERRI;ANDREINA MANFREDI;FRANK LOHR;ROBERTA GELMINI;GIULIA CASSONE;CATERINA VACCHI;FRANCESCO SERRA;KALLIOPI ANDRIKOU;CRISTINA MUSSINI;DIANA FERRARO;FEDERICO PIACENTINI;FRANCESCA CABRY;GIOVANNI DELLA CASA;LAURA CORTESI;MANUELA SIMONI;PATRIZIA SOLA","21;15;12;10;10;9;7;7;7;6;6;6;5;5;5;5;5;5;5;5","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;PSYCHOLOGY;ENGINEERING;COMPUTER SCIENCE;PHILOSOPHY;ECONOMICS;MATHEMATICS;BUSINESS;POLITICAL SCIENCE;GEOLOGY;MATERIALS SCIENCE;SOCIOLOGY;ART;GEOGRAPHY;HISTORY","212;52;23;10;10;9;7;5;4;4;3;3;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;RADIOLOGY;CARDIOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;OPTICS;BIOCHEMISTRY;PEDIATRICS;DERMATOLOGY;CANCER RESEARCH;GYNECOLOGY;PALEONTOLOGY;INTENSIVE CARE MEDICINE;VIROLOGY;ENDOCRINOLOGY;UROLOGY","165;63;48;32;28;26;26;23;23;17;14;13;13;12;11;11;11;10;10;9;9","CANCER;DISEASE;COHORT;ADVERSE EFFECT;CONFIDENCE INTERVAL;GENE;POPULATION;CHEMOTHERAPY;LUNG;INCIDENCE (GEOMETRY);ATRIAL FIBRILLATION;RANDOMIZED CONTROLLED TRIAL;RADIATION THERAPY;PREGNANCY;RETROSPECTIVE COHORT STUDY;HORMONE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);PROPORTIONAL HAZARDS MODEL;PROSPECTIVE COHORT STUDY;CLINICAL TRIAL;MAGNETIC RESONANCE IMAGING;RENAL CELL CARCINOMA","51;28;20;19;18;17;17;16;16;13;12;12;11;10;10;9;9;9;9;8;8;8","BREAST CANCER;HAZARD RATIO;COLORECTAL CANCER;LUNG FUNCTION;IMMUNOTHERAPY;INTERSTITIAL LUNG DISEASE;CLINICAL ENDPOINT;IDIOPATHIC PULMONARY FIBROSIS;UNIVARIATE ANALYSIS;VASCULITIS;ADENOCARCINOMA;AMYOTROPHIC LATERAL SCLEROSIS;CD8;EJECTION FRACTION;PHASES OF CLINICAL RESEARCH;VIRAL LOAD;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CISPLATIN;CYCLOPHOSPHAMIDE;DIFFUSE LARGE B-CELL LYMPHOMA;GEMCITABINE;LUTEINIZING HORMONE;MUTATION;OVARIAN CANCER;PACLITAXEL;PLACEBO;PROSTATE CANCER;PSORIASIS AREA AND SEVERITY INDEX;RITUXIMAB;SALVAGE THERAPY;THYROID CARCINOMA","15;14;12;9;8;8;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","DIFFUSING CAPACITY;NIVOLUMAB;ANTIRETROVIRAL THERAPY;CARDIAC RESYNCHRONIZATION THERAPY;TAMOXIFEN;CARBOPLATIN;LAMIVUDINE;PIRFENIDONE;TRASTUZUMAB;CAPECITABINE;CHURG-STRAUSS SYNDROME;CONNECTIVE TISSUE DISEASE;DNA METHYLATION;DNA MISMATCH REPAIR;DUCTAL CARCINOMA;FOLLICLE-STIMULATING HORMONE;GRANULOMATOSIS WITH POLYANGIITIS;HORMONE RECEPTOR;METASTATIC BREAST CANCER;NEOADJUVANT THERAPY;NINTEDANIB;REGORAFENIB;REVERSE TRANSCRIPTASE;SECUKINUMAB;USUAL INTERSTITIAL PNEUMONIA","9;6;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;ATRIAL FIBRILLATION;TREATMENT OUTCOME;NEOPLASM RECURRENCE, LOCAL;BREAST NEOPLASMS;YOUNG ADULT;ARRHYTHMIAS, CARDIAC;DEFIBRILLATORS, IMPLANTABLE;PROGNOSIS;PYRIDONES;HIV INFECTIONS","109;107;81;76;63;56;46;41;34;28;19;19;18;17;17;15;15;15;15;14","IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;CANCER IMMUNOTHERAPY;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;ATRIAL FIBRILLATION;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;LYMPHOID NEOPLASMS;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;RADIOTHERAPY PHYSICS AND TECHNOLOGY;TREATMENT AND OUTCOMES OF HAND INJURIES;ADVANCEMENTS IN LUNG CANCER RESEARCH;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CHOLANGIOCARCINOMA;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;HER2 SIGNALING IN BREAST CANCER TREATMENT;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;RENAL CELL CARCINOMA","8;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","TREATMENT;BREAST CANCER;DLCO;HIV;CLINICAL ENDPOINT;DISCONTINUATION;ECHOCARDIOGRAPHY;HEART RHYTHM;REGIMEN;STROKE (ENGINE);UNIVARIATE ANALYSIS;ANTICOAGULANT THERAPY;ARRHYTHMIAS;ATRIAL FIBRILLATION;ENDOCARDITIS GUIDELINES;IMAGE-GUIDED RADIOTHERAPY;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;INTENSITY-MODULATED RADIOTHERAPY;INTERSTITIAL LUNG DISEASE;RENAL CELL CARCINOMA","13;7;7;7;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","HEART RHYTHM;RHYTHM SOCIETY;BREAST CANCER;PHASE II;CANCER PATIENTS;CARDIAC IMPLANTABLE;IMPLANTABLE ELECTRONIC;PATIENTS TREATED;ATRIAL FIBRILLATION;ELECTRONIC DEVICE;EUROPEAN HEART;INTERSTITIAL LUNG;ITALIAN ASSOCIATION;METASTATIC RENAL;PULMONARY FIBROSIS;RADIATION THERAPY;RENAL CELL;RHYTHM ASSOCIATION;AMYOTROPHIC LATERAL;ASSOCIATION EHRA;CELL CARCINOMA;COHORT STUDY;DE LA;IDIOPATHIC PULMONARY;INFECTIOUS DISEASES;LATERAL SCLEROSIS;LUNG DISEASE;MULTIPLE SCLEROSIS;RHEUMATOID ARTHRITIS;SOCIETY HRS","15;10;9;8;7;7;7;6;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","ADVISORY CONSULTANCY;ACCOMMODATION EXPENSES;TRAVEL ACCOMMODATION;ADVISORY COMMITTEES;ENTITYS BOARD;BUREAU EXPERT;EXPERT TESTIMONY;SPEAKER BUREAU;RESEARCH GRANT;GRANT FUNDING;FUNDING INSTITUTION;MEDIAN AGE;RESEARCH FUNDING;CONSULTANCY SPEAKER;PATIENTS TREATED;HR CI;CLINICAL TRIAL;MEDIAN FOLLOW-UP;ADVERSE EVENTS;BREAST CANCER;SPEAKERS BUREAU;HONORARIA MEMBERSHIP;ECOG PS;ENTITY RESPONSIBLE;LEGAL ENTITY;MULTIVARIATE ANALYSIS;PROGNOSTIC STAGE;INTERSTITIAL LUNG;SURVIVAL OS;HAZARD RATIO","78;41;41;30;30;29;29;29;26;25;22;20;20;18;18;16;15;15;14;14;14;13;12;12;12;12;12;11;11;10",90,0.41,8,8.75,2,1,2,2.25,1,0,1,9.75,1,1,10,1,2,2,4,6.75,4,0,0,62,62,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,5.62,664.34,13.36,22,0.54,115.51,0,0,10,0,19,0,1,11,0,28,10,0,0,0,0,0,0,37,4,0,38,3,0,0,0,0,0,0,0,0,"United States;Italy;Germany;Japan;Belgium;France;United Kingdom","13;7;2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","41;22;14;4;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;DIGESTIVE DISEASES;PATIENT SAFETY;AUTOIMMUNE DISEASE;LUNG;AGING;BIOENGINEERING;BREAST CANCER;HEMATOLOGY;INFLAMMATORY BOWEL DISEASE;LIVER DISEASE;ORPHAN DRUG;PREVENTION;ASSISTIVE TECHNOLOGY;GENETICS;INFECTIOUS DISEASES;NEUROSCIENCES","35;26;15;15;9;8;7;7;5;4;4;4;4;4;4;4;3;3;3;3","CANCER;ORAL AND GASTROINTESTINAL;RESPIRATORY;INFECTION;EYE;INFLAMMATORY AND IMMUNE SYSTEM;CARDIOVASCULAR;RENAL AND UROGENITAL","14;5;5;4;2;2;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;3.4 VACCINES;6.3 MEDICAL DEVICES","29;3;3;3;2;1;1","BREAST CANCER;LIVER CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;BLADDER CANCER;BLOOD CANCER;ENDOMETRIAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;HODGKIN'S DISEASE;LEUKEMIA / LEUKAEMIA;MYELOMA;NEUROBLASTOMA;OVARIAN CANCER;PANCREATIC CANCER;STOMACH CANCER","4;4;3;2;1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.1 INTERVENTIONS TO PREVENT CANCER: PERSONAL BEHAVIORS THAT AFFECT CANCER RISK;3.3 CHEMOPREVENTION;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.2 SURVEILLANCE","14;4;2;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"PUBLIC LIBRARY OF SCIENCE;MENDELEY DATA;FRONTIERS;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP","3;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3213 PAEDIATRICS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;38 ECONOMICS;3801 APPLIED ECONOMICS;46 INFORMATION AND COMPUTING SCIENCES;4605 DATA MANAGEMENT AND DATA SCIENCE","13;5;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;LUNG CANCER;PATIENT SAFETY;PSORIASIS;RARE DISEASES","3;1;1;1;1;1;1;1","GENERIC HEALTH RELEVANCE;MUSCULOSKELETAL;CANCER","2;2;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","2;1;1","CLINICAL;HEALTH SERVICES & SYSTEMS","2;1","CLINICAL MEDICINE AND SCIENCE","6","LUNG CANCER","1",NA,NA
"AOU_MODENA",2020,293,17.3447098976109,3.15358361774744,0.344709897610922,0.290102389078498,0.593856655290102,2.24817518248175,1.50746268656716,1.73469387755102,1.51304347826087,0.703071672354949,0,142,61,31,8,0.48,0.21,0.11,0.03,24.97,0.990900940140715,5.62117235345583,0.331058020477816,0.962457337883959,0.484,0.439,0.419,0.43,"GIUSEPPE BORIANI;GIOVANNI GUARALDI;MASSIMO GIRARDIS;MARIANNA MESCHIARI;ANDREA COSSARIZZA;ANDREINA MANFREDI;TOMMASO TRENTI;CRISTINA MUSSINI;GIANNI CAPPELLI;FRANCESCO FONTANA;FABIO FACCHINETTI;GAETANO ALFANO;CRISTINA MUSSINI;MANUELA SIMONI;MARCO SEBASTIANI;JOVANA MILIĆ;ANNALISA CHIARI;MARIANNA MENOZZI;ENRICO CLINI;CARLO SALVARANI","22;17;15;14;13;12;11;11;11;10;10;10;10;10;10;9;9;9;9;9","GIUSEPPE BORIANI;GIANNI CAPPELLI;FABIO FACCHINETTI;FRANCESCO FONTANA;GAETANO ALFANO;RICCARDO MAGISTRONI;ANDREINA MANFREDI;GIOVANNI GUARALDI;MARCO SEBASTIANI;CARLO SALVARANI;ANDREA COSSARIZZA;ANNALISA CHIARI;ANNA VITTORIA MATTIOLI;MASSIMO GIRARDIS;TOMMASO TRENTI;MANUELA SIMONI;CRISTINA MUSSINI;GIOVANNI GRANDI;GREGORY Y.H. LIP;GIULIA VINCETI","2.68;1.44;1.32;1.32;1.32;1.29;1.2;1.09;1.02;0.98;0.97;0.97;0.91;0.91;0.89;0.89;0.83;0.82;0.8;0.8","GIUSEPPE BORIANI;GIOVANNI GUARALDI;MASSIMO GIRARDIS;MARIANNA MESCHIARI;ANDREA COSSARIZZA;ANDREINA MANFREDI;TOMMASO TRENTI;CRISTINA MUSSINI;GIANNI CAPPELLI;FRANCESCO FONTANA;FABIO FACCHINETTI;GAETANO ALFANO;CRISTINA MUSSINI;MANUELA SIMONI;MARCO SEBASTIANI;JOVANA MILIĆ;ANNALISA CHIARI;MARIANNA MENOZZI;ENRICO CLINI;CARLO SALVARANI","22;17;15;14;13;12;11;11;11;10;10;10;10;10;10;9;9;9;9;9","GIUSEPPE BORIANI;GIANNI CAPPELLI;FABIO FACCHINETTI;FRANCESCO FONTANA;GAETANO ALFANO;RICCARDO MAGISTRONI;ANDREINA MANFREDI;GIOVANNI GUARALDI;MARCO SEBASTIANI;CARLO SALVARANI;ANDREA COSSARIZZA;ANNALISA CHIARI;ANNA VITTORIA MATTIOLI;MASSIMO GIRARDIS;TOMMASO TRENTI;MANUELA SIMONI;CRISTINA MUSSINI;GIOVANNI GRANDI;GIULIA VINCETI;JOVANA MILIĆ","2.68;1.44;1.32;1.32;1.32;1.29;1.2;1.09;1.02;0.98;0.97;0.97;0.91;0.91;0.89;0.89;0.83;0.82;0.8;0.79","GIOVANNI GUARALDI;CRISTINA MUSSINI;MASSIMO GIRARDIS;MARIANNA MESCHIARI;ENRICO CLINI;ANDREA COSSARIZZA;ROBERTO TONELLI;RICCARDO FANTINI;JOVANA MILIĆ;MARIANNA MENOZZI;ANTONELLO PIETRANGELO;LUCIO BRUGIONI;IVANA CASTANIERE;LUCA TABBÌ;CARLO SALVARANI;ERICA FRANCESCHINI;ANTONELLA SANTORO;SARA DE BIASI;ANDREA BEDINI;DOMENICO LO TARTARO","2513;2390;2346;2315;2211;2184;1974;1953;1938;1901;1664;1650;1253;1223;1204;1157;1112;1105;1096;1090","CRISTINA MUSSINI;MARIANNA MESCHIARI;GIOVANNI GUARALDI;MASSIMO GIRARDIS;MARIANNA MENOZZI;LUCIO BRUGIONI;ERICA FRANCESCHINI;ENRICO CLINI;ANDREA BEDINI;ROBERTO TONELLI;ANTONELLA SANTORO;VANNI BORGHI;IVANA CASTANIERE;RICCARDO FANTINI;GABRIELLA ORLANDO;CINZIA PUZZOLANTE;GIANLUCA CUOMO;FEDERICA CARLI;LUCA CORRADI;LUCA TABBÌ","2358;2315;2237;2164;1901;1650;1157;1146;1096;1086;1067;1060;1026;1020;1017;1004;1004;996;996;996","GIUSEPPE BORIANI;CRISTINA MUSSINI;MASSIMO GIRARDIS;MARIANNA MESCHIARI;GIOVANNI GUARALDI;ANDREINA MANFREDI;CARLO SALVARANI;LUCIO BRUGIONI;MARCO SEBASTIANI;FRANCESCO FONTANA;GAETANO ALFANO;GIANNI CAPPELLI;MARIANNA MENOZZI;PATRIZIA SOLA;MANUELA SIMONI;FABIO FACCHINETTI;DIANA FERRARO;RICCARDO MAGISTRONI;ANNALISA CHIARI;ROBERTA GELMINI","21;20;14;14;14;11;11;11;10;9;9;9;9;9;8;8;7;7;7;7","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;CHEMISTRY;ECONOMICS;PHILOSOPHY;SOCIOLOGY;POLITICAL SCIENCE;MATHEMATICS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;MATERIALS SCIENCE;ART;BUSINESS","283;64;17;15;15;11;10;10;7;7;6;5;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;INTENSIVE CARE MEDICINE;ONCOLOGY;PATHOLOGY;CARDIOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;GENETICS;ENVIRONMENTAL HEALTH;VIROLOGY;ENDOCRINOLOGY;RADIOLOGY;PEDIATRICS;EMERGENCY MEDICINE;PSYCHIATRY;ANESTHESIA;BIOCHEMISTRY;PHYSICAL THERAPY;UROLOGY","227;77;45;45;43;37;35;35;33;28;27;25;23;22;17;14;13;13;13;13","DISEASE;CANCER;OUTBREAK;POPULATION;RETROSPECTIVE COHORT STUDY;COHORT;GENE;CHEMOTHERAPY;CONFIDENCE INTERVAL;LUNG;PNEUMONIA;CLINICAL TRIAL;ADVERSE EFFECT;OBSERVATIONAL STUDY;ATRIAL FIBRILLATION;DIABETES MELLITUS;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;MULTIVARIATE ANALYSIS","72;51;26;26;23;22;21;17;16;16;16;14;13;13;12;11;11;11;11;10","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;BREAST CANCER;CLINICAL ENDPOINT;IMMUNOTHERAPY;INTERSTITIAL LUNG DISEASE;DEMENTIA;HAZARD RATIO;MUTATION;COLORECTAL CANCER;EJECTION FRACTION;UNIVARIATE ANALYSIS;OVARIAN CANCER;PROGRESSION-FREE SURVIVAL;LUTEINIZING HORMONE;PSORIATIC ARTHRITIS;TOCILIZUMAB;TOLERABILITY;IDIOPATHIC PULMONARY FIBROSIS;CHRONIC LYMPHOCYTIC LEUKEMIA;CYCLOPHOSPHAMIDE;HEAD AND NECK CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HIGH-RESOLUTION COMPUTED TOMOGRAPHY;INFLAMMATORY BOWEL DISEASE;LIVER TRANSPLANTATION;LUNG FUNCTION;OVERWEIGHT;PHENOTYPE;PLACEBO;RITUXIMAB;SPIROMETRY;T CELL;TELEMEDICINE","38;24;14;12;10;10;9;9;8;7;7;7;6;6;5;5;5;5;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);NIVOLUMAB;BRCA MUTATION;CARDIAC RESYNCHRONIZATION THERAPY;DIFFUSING CAPACITY;ESTROGEN RECEPTOR;FOLLICLE-STIMULATING HORMONE;HONEYCOMBING;NINTEDANIB;ANTIRETROVIRAL THERAPY;AROMATASE;CONNECTIVE TISSUE DISEASE;GERMLINE MUTATION;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;KLEBSIELLA PNEUMONIAE;METASTATIC BREAST CANCER;SECUKINUMAB;STROKE VOLUME;USTEKINUMAB;USUAL INTERSTITIAL PNEUMONIA","38;8;5;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;FEMALE;MALE;MIDDLE AGED;ITALY;ADULT;AGED;CORONAVIRUS INFECTIONS;PNEUMONIA, VIRAL;COVID-19;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;PROSPECTIVE STUDIES;SARS-COV-2;PANDEMICS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BETACORONAVIRUS;LUNG DISEASES, INTERSTITIAL;OVARIAN NEOPLASMS","174;118;74;65;56;51;48;42;33;32;28;22;20;18;18;17;16;16;16;16","CORONAVIRUS DISEASE 2019;ATRIAL FIBRILLATION;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;RENAL CELL CARCINOMA;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;RADIOMICS IN MEDICAL IMAGING ANALYSIS;TREATMENT AND OUTCOMES OF HAND INJURIES;CHOLANGIOCARCINOMA;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HEPATITIS C INFECTION AND TREATMENT;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH","14;10;10;8;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3","2019-20 CORONAVIRUS OUTBREAK;PANDEMIC;CLINICAL ENDPOINT;TREATMENT;CORONAVIRUS;ATRIAL FIBRILLATION;BREAST CANCER;INTERQUARTILE RANGE;UNIVARIATE ANALYSIS;BETACORONAVIRUS;CANCER RISK;DISCONTINUATION;INTERSTITIAL LUNG DISEASE;PROGRESSION-FREE SURVIVAL;CANCER SUSCEPTIBILITY;CARDIOVASCULAR RISK ASSESSMENT;CONCOMITANT;CORONAVIRUS INFECTIONS;ETIOLOGY;HIV","25;19;12;12;10;9;8;8;7;6;6;6;6;6;5;5;5;5;5;5","BREAST CANCER;ATRIAL FIBRILLATION;LUNG DISEASE;INTERSTITIAL LUNG;PATIENTS TREATED;CELL CARCINOMA;COHORT STUDY;MULTIPLE SCLEROSIS;RHEUMATOID ARTHRITIS;COVID- PANDEMIC;NORTHERN ITALY;CANCER PATIENTS;METASTATIC RENAL;OBSERVATIONAL STUDY;ONSET DEMENTIA;RENAL CELL;RISK FACTORS;SYSTEMIC SCLEROSIS;BOWEL DISEASE;CARCINOMA MRCC;CARDIAC PACING;CARDIOVASCULAR RISK;COVID- PNEUMONIA;HEART RHYTHM;INFLAMMATORY BOWEL;ITALIAN ASSOCIATION;ITALIAN SOCIETY;PHASE II;ACUTE LYMPHOBLASTIC;AMNIOTIC FLUID","10;9;9;8;8;7;7;7;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3","REGGIO EMILIA;MODENA ITALY;EMILIA MODENA;ITALY SEARCH;PATIENTS TREATED;COVID- PATIENTS;RISK FACTORS;MULTIPLE SCLEROSIS;SPEAKERS BUREAU;BREAST CANCER;COVID- PNEUMONIA;SEVERE COVID-;ADULTS UNIVERSITY;AOU POLICLINICO;SURGICAL SCIENCES;ACUTE RESPIRATORY;INTERSTITIAL LUNG;LUNG DISEASE;MEDIAN AGE;COHORT STUDY;CV RISK;MECHANICAL VENTILATION;PUBMED SCOPUS;COMPUTED TOMOGRAPHY;LOGISTIC REGRESSION;SEVERE ACUTE;HEALTHY CONTROLS;HR CI;INFECTIOUS DISEASES;MEDIAN FOLLOW-UP","42;41;38;34;27;25;25;24;24;20;19;19;17;17;17;16;16;16;16;15;15;15;15;14;14;13;12;12;12;12",130,0.44,12.37,12.75,2.5,1.5,0,9,2.5,1,1,16,2,1,11.75,2.5,1.75,2,5,10,6,0,0,74.25,74.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,49,3.49,667.09,13.24,26,0.53,86.67,0,2,6,1,25,0,0,15,0,35,10,0,0,0,0,0,0,42,5,2,45,4,0,0,0,0,0,0,0,0,"United States;Italy;United Kingdom;Japan;France;Germany;Netherlands;Switzerland","10;7;3;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;52 PSYCHOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;4204 MIDWIFERY;44 HUMAN SOCIETY;4403 DEMOGRAPHY;49 MATHEMATICAL SCIENCES","48;22;20;5;4;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;RARE DISEASES;LUNG;DIGESTIVE DISEASES;HEMATOLOGY;INFECTIOUS DISEASES;PREVENTION;AGING;PEDIATRIC;PNEUMONIA;PNEUMONIA & INFLUENZA;BIOMEDICAL IMAGING;BIOTECHNOLOGY;CARDIOVASCULAR;INFANT MORTALITY;LUNG CANCER;ORPHAN DRUG","45;34;21;15;15;12;7;7;6;5;4;4;4;4;3;3;3;3;3;3","CANCER;INFECTION;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;REPRODUCTIVE HEALTH AND CHILDBIRTH;ORAL AND GASTROINTESTINAL;BLOOD;EYE;NEUROLOGICAL;RESPIRATORY","15;7;3;3;3;2;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.2 CELLULAR AND GENE THERAPIES","34;3;3;2;2;1;1","LUNG CANCER;BREAST CANCER;COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;OVARIAN CANCER;PANCREATIC CANCER;PROSTATE CANCER;BLADDER CANCER;BLOOD CANCER;HEAD AND NECK CANCER;HODGKIN'S DISEASE;LARYNGEAL CANCER;MELANOMA;MYELOMA;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","5;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;3.3 CHEMOPREVENTION;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.2 SURVEILLANCE","15;4;3;2;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;SPRINGER NATURE","8;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;38 ECONOMICS;3801 APPLIED ECONOMICS;4203 HEALTH SERVICES AND SYSTEMS;44 HUMAN SOCIETY;4403 DEMOGRAPHY;46 INFORMATION AND COMPUTING SCIENCES;52 PSYCHOLOGY;5201 APPLIED AND DEVELOPMENTAL PSYCHOLOGY","8;3;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;ASTHMA;BRAIN DISORDERS;BREAST CANCER;CHILDHOOD LEUKEMIA;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;EPILEPSY;GENETICS;HEMATOLOGY;LUNG;NEURODEGENERATIVE;NEUROSCIENCES;PEDIATRIC;PEDIATRIC CANCER;PREVENTION;RARE DISEASES","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;RESPIRATORY","2;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","1;1;1",NA,NA,"CLINICAL MEDICINE AND SCIENCE","4","BREAST CANCER;LEUKEMIA / LEUKAEMIA","2;2",NA,NA
"AOU_MODENA",2021,341,18.049853372434,3.22873900293255,0.319648093841642,0.302052785923754,0.463343108504399,2.3454157782516,1.37974683544304,2.01960784313725,1.41071428571429,0.662756598240469,3,156,74,24,17,0.46,0.22,0.07,0.05,16,1.03775578644909,6.34929992630802,0.372434017595308,0.950146627565982,0.528,0.472,0.501,0.459,"GIUSEPPE BORIANI;STEFANO MELETTI;GIOVANNI GUARALDI;MARIANNA MESCHIARI;CRISTINA MUSSINI;GREGORY Y.H. LIP;MASSIMO GIRARDIS;TATJANA POTPARA;MARCO VITOLO;CRISTINA MUSSINI;FABIO FACCHINETTI;MARIO SARTI;ERICA FRANCESCHINI;JESSICA MANDRIOLI;LAURA CORTESI;VANNI BORGHI;GABRIELLA ORLANDO;MARIO LUPPI;MARIANNA MENOZZI;FRANCISCO MARÍN","45;20;18;18;16;15;15;14;13;13;12;11;11;11;11;11;11;10;10;10","GIUSEPPE BORIANI;STEFANO MELETTI;ROBERTO ADANI;GREGORY Y.H. LIP;GIANNI CAPPELLI;MARCO VITOLO;GAETANO ALFANO;ANDREA LETI ACCIARO;MARCO PROIETTI;ENRICO CLINI;ROBERTA DEPENNI;FABIO FACCHINETTI;CRISTINA MUSSINI;GIOVANNI GUARALDI;GIOVANNI GRANDI;AMEDEO LONARDO;JACOPO FRANCESCO IMBERTI;VANNI BORGHI;JESSICA MANDRIOLI;MASSIMO GIRARDIS","4.43;2.02;1.9;1.64;1.57;1.43;1.4;1.33;1.33;1.3;1.3;1.3;1.29;1.19;1.13;1.1;1.02;0.99;0.93;0.88","GIUSEPPE BORIANI;STEFANO MELETTI;GIOVANNI GUARALDI;MARIANNA MESCHIARI;CRISTINA MUSSINI;MASSIMO GIRARDIS;MARCO VITOLO;CRISTINA MUSSINI;FABIO FACCHINETTI;MARIO SARTI;ERICA FRANCESCHINI;JESSICA MANDRIOLI;LAURA CORTESI;VANNI BORGHI;GABRIELLA ORLANDO;MARIO LUPPI;MARIANNA MENOZZI;GIANLUCA CUOMO;ANGELA TOSS;MANUELA TONDELLI","45;20;18;18;16;15;13;13;12;11;11;11;11;11;11;10;10;10;9;9","GIUSEPPE BORIANI;STEFANO MELETTI;ROBERTO ADANI;GIANNI CAPPELLI;MARCO VITOLO;GAETANO ALFANO;ANDREA LETI ACCIARO;ENRICO CLINI;ROBERTA DEPENNI;FABIO FACCHINETTI;CRISTINA MUSSINI;GIOVANNI GUARALDI;GIOVANNI GRANDI;AMEDEO LONARDO;JACOPO FRANCESCO IMBERTI;VANNI BORGHI;JESSICA MANDRIOLI;MASSIMO GIRARDIS;FRANCESCO FONTANA;MARIANNA MESCHIARI","4.43;2.02;1.9;1.57;1.43;1.4;1.33;1.3;1.3;1.3;1.29;1.19;1.13;1.1;1.02;0.99;0.93;0.88;0.87;0.84","GIUSEPPE BORIANI;TATJANA POTPARA;DEIRDRE A. LANE;NIKOLAOS DAGRES;GREGORY Y.H. LIP;PETER SINNAEVE;HEIN HEIDBÜCHEL;MARIANNA MESCHIARI;DAN ATAR;LIEN DESTEGHE;A. JOHN CAMM;BOYOUNG JOUNG;CHAO TZE-FAN;EUE‐KEUN CHOI;HOLGER REINECKE;ITAMAR S SANTOS;JAN STEFFEL;JONAS OLDGREN;KARL GEORG HÆUSLER;MARK FIELD","1639;1170;1085;1007;991;816;813;784;782;780;776;763;763;763;763;763;763;763;763;763","GIUSEPPE BORIANI;MARIANNA MESCHIARI;MASSIMO GIRARDIS;CRISTINA MUSSINI;EMANUELA BIAGIONI;IRENE COLORETTI;GIOVANNI GUARALDI;ERICA FRANCESCHINI;MARIO SARTI;STEFANO BUSANI;MARCO VITOLO;ALESSIA VERDURI;A. J. M. CAVENAGH;AINE MCGOVERN;ALICE EINARSSON;ANGELINE PRICE;CAROLINE MURPHY;CHARLOTTE DAVEY;CHARLOTTE SILVER;DOLCIE PAXTON","1567;764;545;380;349;347;337;228;189;185;172;168;164;164;164;164;164;164;164;164","GIUSEPPE BORIANI;CRISTINA MUSSINI;MARIANNA MESCHIARI;GIOVANNI GUARALDI;STEFANO MELETTI;MASSIMO GIRARDIS;LAURA CORTESI;JESSICA MANDRIOLI;ERICA FRANCESCHINI;VANNI BORGHI;ROBERTO ADANI;GIANLUCA CUOMO;MARCO VITOLO;MARIANNA MENOZZI;MARIO SARTI;ANGELA TOSS;FABIO FACCHINETTI;GABRIELLA ORLANDO;ILARIA MARTINELLI;PATRIZIA SOLA","40;24;17;13;12;12;11;10;10;10;9;9;9;9;9;9;9;8;8;8","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;ENGINEERING;COMPUTER SCIENCE;ECONOMICS;SOCIOLOGY;MATHEMATICS;CHEMISTRY;PHILOSOPHY;MATERIALS SCIENCE;POLITICAL SCIENCE;BUSINESS;HISTORY;GEOLOGY","328;91;27;26;22;19;14;13;10;9;6;4;4;3;3;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;ONCOLOGY;CARDIOLOGY;GENETICS;IMMUNOLOGY;INTENSIVE CARE MEDICINE;PEDIATRICS;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;VIROLOGY;EMERGENCY MEDICINE;BIOCHEMISTRY;RADIOLOGY;PSYCHIATRY;PHYSICAL THERAPY;MECHANICAL ENGINEERING;CANCER RESEARCH;GYNECOLOGY;OPTICS","257;86;51;49;48;47;40;38;38;35;33;28;26;25;25;24;19;18;17;15;15","DISEASE;CANCER;COHORT;POPULATION;RETROSPECTIVE COHORT STUDY;GENE;ATRIAL FIBRILLATION;ADVERSE EFFECT;CHEMOTHERAPY;CONFIDENCE INTERVAL;OUTBREAK;PROPORTIONAL HAZARDS MODEL;CLINICAL TRIAL;PREGNANCY;STROKE (ENGINE);TRANSPLANTATION;PNEUMONIA;INCIDENCE (GEOMETRY);PROSPECTIVE COHORT STUDY;MYOCARDIAL INFARCTION","87;56;43;34;33;31;24;20;20;20;20;19;18;18;17;17;16;15;15;14","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;BREAST CANCER;CLINICAL ENDPOINT;HAZARD RATIO;IMMUNOTHERAPY;AMYOTROPHIC LATERAL SCLEROSIS;VIRAL LOAD;DEMENTIA;GENE EXPRESSION;MUTATION;EJECTION FRACTION;FINGOLIMOD;TELEMEDICINE;LIVER TRANSPLANTATION;METASTASIS;NATALIZUMAB;PROGRESSION-FREE SURVIVAL;PSEUDOMONAS AERUGINOSA;STATUS EPILEPTICUS;UNIVARIATE ANALYSIS","43;19;18;16;15;14;9;8;7;7;7;6;6;6;5;5;5;5;5;5;5","CORONAVIRUS DISEASE 2019 (COVID-19);ANTIRETROVIRAL THERAPY;PEMBROLIZUMAB;BRCA MUTATION;FRONTOTEMPORAL DEMENTIA;REVERSE TRANSCRIPTASE;TELEHEALTH;VITAMIN K ANTAGONIST;CARDIAC RESYNCHRONIZATION THERAPY;HORMONE RECEPTOR;LAMIVUDINE;NIVOLUMAB;TRANSCRIPTOME;TRASTUZUMAB;ACINETOBACTER BAUMANNII;ANTIMICROBIAL STEWARDSHIP;B-CELL ACTIVATING FACTOR;CEFTAZIDIME;COMPOUND HETEROZYGOSITY;DEEP BRAIN STIMULATION;FAMILY PLANNING;GENE EXPRESSION PROFILING;GERMLINE MUTATION;IMIPENEM;MACE;METASTATIC BREAST CANCER;NEOADJUVANT THERAPY;NONALCOHOLIC FATTY LIVER DISEASE;OBINUTUZUMAB;PROSTATECTOMY;RIVAROXABAN;SECUKINUMAB;TAMOXIFEN;USTEKINUMAB;USUAL INTERSTITIAL PNEUMONIA","43;7;6;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;FEMALE;COVID-19;MALE;ATRIAL FIBRILLATION;MIDDLE AGED;RETROSPECTIVE STUDIES;AGED;ADULT;ITALY;STROKE;SARS-COV-2;TREATMENT OUTCOME;RISK FACTORS;AGED, 80 AND OVER;BREAST NEOPLASMS;HIV INFECTIONS;BIOMARKERS;REGISTRIES","183;157;80;69;60;57;49;47;44;42;38;38;30;25;19;18;18;18;16;16","ATRIAL FIBRILLATION;CORONAVIRUS DISEASE 2019;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;CANCER IMMUNOTHERAPY;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;HEPATOCELLULAR CARCINOMA;PANCREATIC CANCER RESEARCH AND TREATMENT;ANALYSIS OF BRAIN FUNCTIONAL CONNECTIVITY NETWORKS;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;EPILEPSY AND SEIZURES;INFLAMMATION'S ROLE IN CANCER DEVELOPMENT AND PROGRESSION","19;12;10;9;8;8;8;7;7;6;4;4;4;4;3;3;3;3;3;3","PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;ATRIAL FIBRILLATION;STROKE (ENGINE);CLINICAL ENDPOINT;INTERQUARTILE RANGE;TREATMENT;BREAST CANCER;REGIMEN;CLINICAL CHARACTERISTICS;CONCOMITANT;DISCONTINUATION;HIV;METASTATIC BREAST CANCER;NEURODEGENERATION;CANCER RISK;DOLUTEGRAVIR;NATALIZUMAB;PROGRESSION-FREE SURVIVAL;REFRACTORY (PLANETARY SCIENCE)","22;19;18;17;16;10;10;9;9;7;6;6;6;6;6;5;5;5;5;5","ATRIAL FIBRILLATION;BREAST CANCER;COVID- PANDEMIC;CANCER PATIENTS;CELL CARCINOMA;CHINESE PATIENTS;COHORT STUDY;ELDERLY CHINESE;MULTIPLE SCLEROSIS;RETROSPECTIVE STUDY;AMYOTROPHIC LATERAL;COVID- PATIENTS;FIBRILLATION PATIENTS;HEPATOCELLULAR CARCINOMA;HOSPITALIZED PATIENTS;LATERAL SCLEROSIS;LUNG CANCER;PHASE II;PROGNOSTIC FACTORS;STATUS EPILEPTICUS;CARDIAC IMPLANTABLE;CARDIAC PACING;CROSS-SECTIONAL STUDY;ITALY RESULTS;MULTICENTER COHORT;MYOCARDIAL INFARCTION;PATIENTS TREATED;PEOPLE LIVING;ACUTE LYMPHOBLASTIC;ADVANCED HEPATOCELLULAR","26;14;11;10;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3","HR CI;RESEARCH FUNDING;COVID- PATIENTS;RISK FACTORS;COVID- PANDEMIC;ADVISORY COMMITTEES;ENTITYS BOARD;ATRIAL FIBRILLATION;AF PATIENTS;CONFIDENCE INTERVAL;INCREASED RISK;PATIENTS TREATED;ALL-CAUSE DEATH;BREAST CANCER;AOU POLICLINICO;REGGIO EMILIA;ADVISORY ROLE;COX REGRESSION;CV RISK;INTERVAL CI;MEDIAN AGE;MULTIVARIATE ANALYSIS;NECK SURGERY;CLINICAL PRACTICE;COHORT STUDY;COVID- PNEUMONIA;EMILIA MODENA;HAZARD RATIO;SPEAKERS BUREAU;CARDIOVASCULAR EVENTS","74;49;27;27;26;22;22;21;20;19;18;18;17;17;16;16;15;15;15;15;15;15;15;14;14;14;14;14;14;13",174,0.51,10.71,10.75,2,1,0,2,1,1,1.25,12,1,0,10.75,1,2.5,1.25,4,7,5,0,0,35,35,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,3.52,1345.67,5.97,13,0.52,94.64,1,0,5,0,11,0,0,8,0,15,7,0,0,0,0,0,0,25,0,0,22,3,0,0,0,0,0,0,0,0,"United States;Japan;United Kingdom;Netherlands;Switzerland;France;Italy","4;3;3;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3203 DENTISTRY;3207 MEDICAL MICROBIOLOGY;3213 PAEDIATRICS;48 LAW AND LEGAL STUDIES;4806 PRIVATE LAW AND CIVIL OBLIGATIONS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","24;13;9;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;LUNG;RARE DISEASES;CARDIOVASCULAR;HEART DISEASE;LUNG CANCER;PREVENTION;AUTOIMMUNE DISEASE;BREAST CANCER;DIGESTIVE DISEASES;HEMATOLOGY;INFECTIOUS DISEASES;AGING;ATHEROSCLEROSIS;COLO-RECTAL CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;DENTAL/ORAL AND CRANIOFACIAL DISEASE","21;17;10;7;6;5;3;3;3;3;2;2;2;2;2;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFECTION;RESPIRATORY;ORAL AND GASTROINTESTINAL","8;3;2;2;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","17;3;1;1;1;1;1","LUNG CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;EAR CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;GASTROINTESTINAL TRACT;HEAD AND NECK CANCER;HODGKIN'S DISEASE;KIDNEY CANCER;LARYNGEAL CANCER;LIVER CANCER;MELANOMA;NASAL CAVITY AND PARANASAL SINUS CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;STOMACH CANCER","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","10;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;FUTURE SCIENCE GROUP;SPRINGER NATURE;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP;ZENODO","11;9;2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;44 HUMAN SOCIETY;49 MATHEMATICAL SCIENCES;52 PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3213 PAEDIATRICS;33 BUILT ENVIRONMENT AND DESIGN;3303 DESIGN;38 ECONOMICS;3801 APPLIED ECONOMICS;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;4408 POLITICAL SCIENCE;4905 STATISTICS","31;11;9;7;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;BRAIN DISORDERS;NEUROSCIENCES;PREVENTION;BIOMEDICAL IMAGING;EPILEPSY;NEURODEGENERATIVE;RARE DISEASES;BIOTECHNOLOGY;BREAST CANCER;CEREBRAL PALSY;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COLO-RECTAL CANCER;DIGESTIVE DISEASES;GENETICS;HEMATOLOGY;INFANT MORTALITY;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);LYMPHOMA","12;7;6;6;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;NEUROLOGICAL;MUSCULOSKELETAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","6;3;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;8.1 ORGANISATION AND DELIVERY OF SERVICES","1;1;1","CLINICAL;POPULATION & SOCIETY;BIOMEDICAL","10;2;1","CLINICAL MEDICINE AND SCIENCE;HEALTH SERVICES RESEARCH","13;1","LUNG CANCER;BREAST CANCER;COLON AND RECTAL CANCER;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;PROSTATE CANCER","2;1;1;1;1;1;1","4 QUALITY EDUCATION","1"
"AOU_MODENA",2022,321,20.8006230529595,3.36448598130841,0.320872274143302,0.305295950155763,0.454828660436137,2.12079207920792,1.3972602739726,1.96,1.45,0.713395638629283,1,134,76,25,14,0.42,0.24,0.08,0.04,8.79,0.984468528473554,5.71553463349025,0.345794392523364,0.962616822429907,0.515,0.515,0.495,0.421,"GIUSEPPE BORIANI;MARCO VITOLO;GREGORY Y.H. LIP;TATJANA POTPARA;GIOVANNI GUARALDI;JACOPO FRANCESCO IMBERTI;MARCO PROIETTI;MARIO LUPPI;STEFANO MELETTI;FRANCISCO MARÍN;NICCOLÒ BONINI;JESSICA MANDRIOLI;MICHAEL NÄBAUER;DEIRDRE A. LANE;ZBIGNIEW KALARUS;CRISTINA MUSSINI;ALDO P. MAGGIONI;LEONARDO POTENZA;MARIANNA MESCHIARI;CRISTINA MUSSINI","52;22;21;19;18;17;16;14;13;13;12;12;12;11;11;11;11;11;10;10","GIUSEPPE BORIANI;JACOPO FRANCESCO IMBERTI;MARCO VITOLO;GIOVANNI GUARALDI;GREGORY Y.H. LIP;STEFANO MELETTI;DANTE ROMAGNOLI;ALBERTO BERARDI;MARCO PROIETTI;NICCOLÒ BONINI;FABIO FACCHINETTI;MARIO LUPPI;GABRIELE DONATI;GAETANO ALFANO;RICCARDO MAGISTRONI;FRANCESCO FONTANA;LICIA LUGLI;MANUELA SIMONI;FRANCESCA COPPI;GIADA GIOVANNINI","4.55;2.29;2.16;1.58;1.41;1.28;1.13;1.07;1.05;1.04;1.03;1.01;0.98;0.94;0.92;0.89;0.85;0.83;0.83;0.81","GIUSEPPE BORIANI;MARCO VITOLO;GIOVANNI GUARALDI;JACOPO FRANCESCO IMBERTI;MARIO LUPPI;STEFANO MELETTI;NICCOLÒ BONINI;JESSICA MANDRIOLI;CRISTINA MUSSINI;ALDO P. MAGGIONI;LEONARDO POTENZA;MARIANNA MESCHIARI;CRISTINA MUSSINI;VINCENZO LIVIO MALAVASI;FABRIZIO DI BENEDETTO;GABRIELE DONATI;JOVANA MILIĆ;FABIO FACCHINETTI;RICCARDO MAGISTRONI;VANNI BORGHI","52;22;18;17;14;13;12;12;11;11;11;10;10;10;9;9;8;8;8;8","GIUSEPPE BORIANI;JACOPO FRANCESCO IMBERTI;MARCO VITOLO;GIOVANNI GUARALDI;STEFANO MELETTI;DANTE ROMAGNOLI;ALBERTO BERARDI;NICCOLÒ BONINI;FABIO FACCHINETTI;MARIO LUPPI;GABRIELE DONATI;GAETANO ALFANO;RICCARDO MAGISTRONI;FRANCESCO FONTANA;LICIA LUGLI;MANUELA SIMONI;FRANCESCA COPPI;GIADA GIOVANNINI;AMEDEO LONARDO;FRANCESCA MISELLI","4.55;2.29;2.16;1.58;1.28;1.13;1.07;1.04;1.03;1.01;0.98;0.94;0.92;0.89;0.85;0.83;0.83;0.81;0.8;0.77","GIUSEPPE BORIANI;GREGORY Y.H. LIP;CRISTINA MUSSINI;GIOVANNI GUARALDI;MARIANNA MESCHIARI;MARCO PROIETTI;HEIN HEIDBÜCHEL;TATJANA POTPARA;MASSIMO GIRARDIS;STEFANO BUSANI;NICCOLÒ BONINI;GIULIO FRANCESCO ROMITI;CHRISTOPHE LECLERCQ;EMMA SVENNBERG;ERICA FRANCESCHINI;JACOPO FRANCESCO IMBERTI;MARCO VITOLO;DEIRDRE A. LANE;ANDREA COSSARIZZA;DAVID DUNCKER","818;632;451;337;299;289;254;254;242;242;238;233;211;211;209;209;209;208;201;184","GIUSEPPE BORIANI;CRISTINA MUSSINI;GIOVANNI GUARALDI;MARIANNA MESCHIARI;ERICA FRANCESCHINI;STEFANO BUSANI;NICCOLÒ BONINI;JACOPO FRANCESCO IMBERTI;EMANUELA BIAGIONI;IRENE COLORETTI;MARIANNA MENOZZI;MARCO VITOLO;ENRICO CLINI;MARIO LUPPI;JESSICA MANDRIOLI;WILLIAM GENNARI;MONICA PECORARI;MICHELA MAUR;CARLOTTA FARINELLI;ILENIA GATTO","808;363;323;299;209;206;203;176;173;173;149;140;134;129;128;120;108;107;106;106","GIUSEPPE BORIANI;MARCO VITOLO;CRISTINA MUSSINI;GIOVANNI GUARALDI;JACOPO FRANCESCO IMBERTI;JESSICA MANDRIOLI;NICCOLÒ BONINI;MARIANNA MESCHIARI;STEFANO MELETTI;MARIO LUPPI;FRANCESCO FONTANA;VINCENZO LIVIO MALAVASI;GAETANO ALFANO;STEFANO BUSANI;FABIO FACCHINETTI;VANNI BORGHI;FABIO SGURA;ANNA CHIARA VALENTI;FABRIZIO DI BENEDETTO;MANUELA SIMONI","51;19;17;16;16;11;11;10;10;9;9;9;7;7;7;7;6;6;6;6","MEDICINE;BIOLOGY;PHYSICS;ECONOMICS;PSYCHOLOGY;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;ENGINEERING;SOCIOLOGY;POLITICAL SCIENCE;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;GEOGRAPHY;HISTORY","312;80;33;19;17;16;16;15;14;11;8;5;3;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;ONCOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;INTENSIVE CARE MEDICINE;PSYCHIATRY;OPTICS;BIOCHEMISTRY;RADIOLOGY;VIROLOGY;NURSING;ENDOCRINOLOGY;CANCER RESEARCH;OBSTETRICS","266;59;52;44;44;43;38;35;33;33;31;24;23;20;20;20;19;18;15;15","DISEASE;CANCER;CONFIDENCE INTERVAL;COHORT;ATRIAL FIBRILLATION;POPULATION;GENE;RETROSPECTIVE COHORT STUDY;PROSPECTIVE COHORT STUDY;CLINICAL TRIAL;INCIDENCE (GEOMETRY);ODDS RATIO;ADVERSE EFFECT;HEART FAILURE;COHORT STUDY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);PREGNANCY;RANDOMIZED CONTROLLED TRIAL;PROPORTIONAL HAZARDS MODEL;OBSERVATIONAL STUDY","67;43;42;41;34;31;27;26;23;22;22;21;19;18;17;17;17;17;16;14","INFECTIOUS DISEASE (MEDICAL SPECIALTY);HAZARD RATIO;CLINICAL ENDPOINT;BREAST CANCER;EJECTION FRACTION;GESTATIONAL AGE;VIRAL LOAD;2019-20 CORONAVIRUS OUTBREAK;AMYOTROPHIC LATERAL SCLEROSIS;PHENOTYPE;DEMENTIA;COLORECTAL CANCER;FATTY LIVER;LIVER TRANSPLANTATION;CD8;CHRONIC LYMPHOCYTIC LEUKEMIA;FETUS;GESTATION;HEPATITIS B VIRUS;MUTATION;MYELOFIBROSIS;OVERWEIGHT;PERCUTANEOUS CORONARY INTERVENTION;PSORIATIC ARTHRITIS;TELEMEDICINE;UNIVARIATE ANALYSIS","25;24;16;13;11;9;9;8;8;8;7;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5","CORONAVIRUS DISEASE 2019 (COVID-19);ANTIRETROVIRAL THERAPY;MACE;NONALCOHOLIC FATTY LIVER DISEASE;LAMIVUDINE;ANDROGEN DEPRIVATION THERAPY;APREMILAST;COLONOSCOPY;FRONTOTEMPORAL DEMENTIA;IBRUTINIB;MYELOPROLIFERATIVE NEOPLASM;PREMATURE RUPTURE OF MEMBRANES;RESPIRATORY DISTURBANCE INDEX;RUPTURE OF MEMBRANES;STROKE VOLUME;TRANSCRIPTOME;ANAPLASTIC LYMPHOMA KINASE;ANDROGEN DEFICIENCY;CARDIAC RESYNCHRONIZATION THERAPY;DARATUMUMAB;DEEP BRAIN STIMULATION;FLUDARABINE;FOLLICLE-STIMULATING HORMONE;NEOADJUVANT THERAPY;NIVOLUMAB;PENETRANCE;PRENATAL DIAGNOSIS;STREPTOCOCCUS AGALACTIAE;SYSTEMIC THERAPY;TELEHEALTH;TRANSIENT ELASTOGRAPHY;TRIPLE-NEGATIVE BREAST CANCER;USTEKINUMAB;VITAMIN K ANTAGONIST;ZIDOVUDINE","25;8;5;5;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;ATRIAL FIBRILLATION;COVID-19;HIV INFECTIONS;MALE;AGED;RETROSPECTIVE STUDIES;STROKE;PROSPECTIVE STUDIES;MIDDLE AGED;NEOPLASMS;ADULT;ANTICOAGULANTS;RISK FACTORS;AMYOTROPHIC LATERAL SCLEROSIS;ANTI-HIV AGENTS;TREATMENT OUTCOME;SARS-COV-2","176;144;56;54;49;47;41;31;31;27;26;22;19;18;18;18;17;17;17;15","ATRIAL FIBRILLATION;CORONAVIRUS DISEASE 2019;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPILEPSY AND SEIZURES;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CARDIOTOXICITY OF CANCER TREATMENTS;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;LYMPHOID NEOPLASMS","27;9;8;7;7;6;6;6;5;5;5;4;3;3;3;3;3;3;3;3","ATRIAL FIBRILLATION;CLINICAL ENDPOINT;DISCONTINUATION;INTERQUARTILE RANGE;PANDEMIC;CARDIOVASCULAR RISK ASSESSMENT;STROKE (ENGINE);ANTIRETROVIRAL THERAPY;CARDIAC IMAGING;REGIMEN;2019-20 CORONAVIRUS OUTBREAK;ETIOLOGY;ARRHYTHMIAS;HIV INFECTION;STATUS EPILEPTICUS;TREATMENT;CONCOMITANT;DOLUTEGRAVIR;EPILEPSY;MACE","28;16;13;13;12;9;9;8;8;8;7;7;6;6;6;6;5;5;5;5","ATRIAL FIBRILLATION;CANCER PATIENTS;AMYOTROPHIC LATERAL;BREAST CANCER;LATERAL SCLEROSIS;COHORT STUDY;LIVER TRANSPLANTATION;MULTIPLE SCLEROSIS;PHASE II;STATUS EPILEPTICUS;CLINICAL PRACTICE;EUROBSERVATIONAL RESEARCH;LONG-TERM REGISTRY;PATIENTS UNDERGOING;PEOPLE LIVING;RESEARCH PROGRAMME;ABC PATHWAY;ACUTE LYMPHOBLASTIC;CARDIOVASCULAR RISK;CHRONIC LYMPHOCYTIC;COGNITIVE IMPAIRMENT;COVID- PANDEMIC;EUROPEAN PATIENTS;FATTY LIVER;FIBRILLATION PATIENTS;HEART FAILURE;LIVER DISEASE;LUNG CANCER;LYMPHOBLASTIC LEUKEMIA;LYMPHOCYTIC LEUKEMIA","40;8;7;7;7;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4","HR CI;AF PATIENTS;ABC PATHWAY;ATRIAL FIBRILLATION;MEDIAN AGE;ERECTILE DYSFUNCTION;MF PATIENTS;RISK FACTORS;HAZARD RATIO;CONFIDENCE INTERVAL;STATISTICALLY SIGNIFICANT;AHR CI;FIBRILLATION AF;PRIMARY OUTCOME;MULTIVARIATE ANALYSIS;ALL-CAUSE DEATH;ALL-CAUSE MORTALITY;CLINICAL PRACTICE;INTERVAL CI;AF PROGRESSION;DAY MORTALITY;INCREASED RISK;BREAST MILK;LOGISTIC REGRESSION;MAJOR BLEEDING;ADVERSE EVENTS;SIGNIFICANT REDUCTION;CLINICAL OUTCOMES;ODDS RATIO;PRIMARY ENDPOINT","63;39;35;33;32;29;29;29;27;24;23;22;22;22;20;19;19;19;19;18;18;18;17;17;17;16;16;15;15;15",177,0.55,9.05,8,1,1,0,2.5,1,1,1.25,11,1.5,0,8,0,1,1,3,6,4,0,0,17,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,2.94,869,4.32,11,0.58,116.26,1,0,3,1,8,0,2,4,0,15,3,0,0,0,0,0,0,18,1,0,18,1,0,0,0,0,0,0,0,0,"Italy;Germany;United States;Denmark","6;5;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3009 VETERINARY SCIENCES;3204 IMMUNOLOGY;3206 MEDICAL BIOTECHNOLOGY;3215 REPRODUCTIVE MEDICINE;44 HUMAN SOCIETY;4403 DEMOGRAPHY","19;13;4;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;CANCER;RARE DISEASES;DIGESTIVE DISEASES;CHRONIC LIVER DISEASE AND CIRRHOSIS;LIVER DISEASE;PATIENT SAFETY;PREVENTION;ASSISTIVE TECHNOLOGY;AUTOIMMUNE DISEASE;BIOENGINEERING;HEMATOLOGY;HEPATITIS;INFECTIOUS DISEASES;NEUROSCIENCES;BRAIN DISORDERS;BREAST CANCER;CARDIOVASCULAR","19;16;6;5;5;4;3;3;3;3;2;2;2;2;2;2;2;1;1;1","CANCER;RESPIRATORY;BLOOD;CARDIOVASCULAR;GENERIC HEALTH RELEVANCE;NEUROLOGICAL;INFECTION;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;SKIN","4;4;2;2;2;2;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;6.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","16;2;2;1;1;1;1","LUNG CANCER;NOT SITE-SPECIFIC CANCER;BREAST CANCER;ENDOMETRIAL CANCER;HEAD AND NECK CANCER;LIVER CANCER;PHARYNGEAL CANCER;SKIN CANCER","3;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","7;1;1",2,2236944,399354.35,5,9.5,7,1,3,149098.509803922,2.15293902281213,"POLICLINICO DI MODENA;UNIVERSITY OF MODENA AND REGGIO EMILIA;ABBVIE (UNITED STATES);ALMIRALL (SPAIN);ASTRAZENECA (SWEDEN);BAYER (GERMANY);EUROPEAN ACADEMY OF BOZEN;JAGIELLONIAN UNIVERSITY;MEDICAL UNIVERSITY OF GRAZ;PFIZER (UNITED KINGDOM);SANOFI (FRANCE);SERVIER (FRANCE);SPITALUL CLINIC COLENTINA;ST.-ANTONIUS-HOSPITAL GRONAU;TAKEDA (SWITZERLAND);UNIVERSITY OF BELGRADE;VRIJE UNIVERSITEIT BRUSSEL","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;EUROPEAN RESEARCH COUNCIL","1;1","EC & ERC - EUROPEAN UNION;COALITION S","2;1","ERC - SUPPORT FOR FRONTIER RESEARCH (ERC) (FUNDING SCHEME);ERC-2021-STG (CALL FOR PROPOSAL);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-JTI-IMI2-2020-23-TWO-STAGE (CALL FOR PROPOSAL);HORIZON.1.1 - EUROPEAN RESEARCH COUNCIL (ERC) (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","1;1;1;1","CLINICAL RESEARCH;ACQUIRED COGNITIVE IMPAIRMENT;AGING;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DEMENTIA;GENETICS;NEURODEGENERATIVE;NEUROSCIENCES;PATIENT SAFETY;PREVENTION","2;1;1;1;1;1;1;1;1;1;1;1;1;1","GENERIC HEALTH RELEVANCE;NEUROLOGICAL","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;8.3 POLICY, ETHICS, AND RESEARCH GOVERNANCE","1;1;1","NOT SITE-SPECIFIC CANCER","1","4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1;1","A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;A04 PSYCHOLOGY, PSYCHIATRY AND NEUROSCIENCE","1;1",NA,NA,19,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;FUTURE SCIENCE GROUP;KARGER PUBLISHERS;SPRINGER NATURE;TAYLOR & FRANCIS GROUP","9;3;2;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;44 HUMAN SOCIETY;31 BIOLOGICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH;4409 SOCIAL WORK;3105 GENETICS;3204 IMMUNOLOGY;3209 NEUROSCIENCES;3213 PAEDIATRICS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","33;9;8;8;3;2;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;PREVENTION;NEUROSCIENCES;PATIENT SAFETY;AGING;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPARATIVE EFFECTIVENESS RESEARCH;DIGESTIVE DISEASES;GENETICS;KIDNEY DISEASE;PEDIATRIC;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS;RARE DISEASES;REHABILITATION;BIOTECHNOLOGY;BREAST CANCER;HEMATOLOGY;HEPATITIS;INFANT MORTALITY","10;7;4;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","CANCER;INJURIES AND ACCIDENTS;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","8;2;1;1;1;1;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;6.7 PHYSICAL;2.4 SURVEILLANCE AND DISTRIBUTION;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","3;2;2;2;1;1","CLINICAL;BIOMEDICAL","9;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;BASIC SCIENCE","10;3;1","COLON AND RECTAL CANCER;KIDNEY CANCER;BREAST CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;LIVER CANCER;NERVOUS SYSTEM;PHARYNGEAL CANCER;PROSTATE CANCER;SARCOMA;STOMACH CANCER","3;2;1;1;1;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","2"
"AOU_MODENA",2023,365,19.0849315068493,3.11232876712329,0.301369863013699,0.265753424657534,0.326027397260274,2.04285714285714,1.44155844155844,1.83018867924528,1.6,0.712328767123288,4,165,61,17,28,0.45,0.17,0.05,0.08,3.14,0.71695223265922,5.47955390334572,0.328767123287671,0.953424657534247,0.539,0.533,0.499,0.516,"GIUSEPPE BORIANI;DAVIDE ANTONIO MEI;GIOVANNI GUARALDI;MARIO LUPPI;ANDREINA MANFREDI;JESSICA MANDRIOLI;CRISTINA MUSSINI;JACOPO FRANCESCO IMBERTI;MANUELA SIMONI;CARLO SALVARANI;MARCO SEBASTIANI;ROSARIO FOTI;NICCOLÒ BONINI;MARCO VITOLO;ERICA FRANCESCHINI;HELGA BERTANI;ANDRÉA BARBIERI;FLORENZO IANNONE;GREGORY Y.H. LIP;ILARIA MARTINELLI","47;15;14;13;13;13;13;13;13;12;12;11;11;11;11;11;11;10;10;10","GIUSEPPE BORIANI;AMEDEO LONARDO;DAVIDE ANTONIO MEI;JACOPO FRANCESCO IMBERTI;HELGA BERTANI;RITA CONIGLIARO;DANILO DONATI;GIOVANNI GUARALDI;GIUSEPPE GRANDE;SILVIA COCCA;NICCOLÒ BONINI;ANDREINA MANFREDI;MANUELA SIMONI;MARCO VITOLO;GIORGIO DE SANTIS;JESSICA MANDRIOLI;MARCO SEBASTIANI;VERONICA SAMPOGNA;MARIO LUPPI;GIULIO FRANCESCO ROMITI","5.03;2;1.53;1.5;1.42;1.36;1.35;1.31;1.26;1.22;1.2;1.18;1.15;1.13;1.11;1.05;1.01;1;0.89;0.86","GIUSEPPE BORIANI;DAVIDE ANTONIO MEI;GIOVANNI GUARALDI;MARIO LUPPI;ANDREINA MANFREDI;JESSICA MANDRIOLI;CRISTINA MUSSINI;JACOPO FRANCESCO IMBERTI;MANUELA SIMONI;CARLO SALVARANI;MARCO SEBASTIANI;NICCOLÒ BONINI;MARCO VITOLO;ERICA FRANCESCHINI;HELGA BERTANI;ANDRÉA BARBIERI;ILARIA MARTINELLI;RITA CONIGLIARO;GIUSEPPE GRANDE;DANIELE SANTI","47;15;14;13;13;13;13;13;13;12;12;11;11;11;11;11;10;10;10;9","GIUSEPPE BORIANI;AMEDEO LONARDO;DAVIDE ANTONIO MEI;JACOPO FRANCESCO IMBERTI;HELGA BERTANI;RITA CONIGLIARO;DANILO DONATI;GIOVANNI GUARALDI;GIUSEPPE GRANDE;SILVIA COCCA;NICCOLÒ BONINI;ANDREINA MANFREDI;MANUELA SIMONI;MARCO VITOLO;GIORGIO DE SANTIS;JESSICA MANDRIOLI;MARCO SEBASTIANI;VERONICA SAMPOGNA;MARIO LUPPI;FABIO FACCHINETTI","5.03;2;1.53;1.5;1.42;1.36;1.35;1.31;1.26;1.22;1.2;1.18;1.15;1.13;1.11;1.05;1.01;1;0.89;0.85","GIUSEPPE BORIANI;GREGORY Y.H. LIP;ANDREA DECENSI;CRISTINA MUSSINI;BRIAN OLSHANSKY;TATJANA POTPARA;CARLO SALVARANI;JESSICA MANDRIOLI;DAVIDE ANTONIO MEI;GIULIO FRANCESCO ROMITI;ANGELO GHIDINI;CARLOTTA PIPOLO;DANIELA LUCIDI;EUGENIO DE CORSO;MASSIMILIANO GARZARO;LAURA CORTESI;MARCO SEBASTIANI;FLORENZO IANNONE;GIULIA CASSONE;LAURENT FAUCHIER","220;114;77;71;68;66;65;62;61;61;59;57;57;57;57;56;56;55;55;55","GIUSEPPE BORIANI;CRISTINA MUSSINI;DAVIDE ANTONIO MEI;DANIELA LUCIDI;GIULIA CASSONE;LAURA CORTESI;ANDREINA MANFREDI;JACOPO FRANCESCO IMBERTI;MARIANNA MESCHIARI;MARCO SEBASTIANI;MARIO LUPPI;GIOVANNI GUARALDI;NICCOLÒ BONINI;SIMONA GUERZONI;ERICA FRANCESCHINI;JESSICA MANDRIOLI;MANUELA SIMONI;MARCO VITOLO;ANGELA TOSS;DANIELE SANTI","220;65;61;57;55;55;46;44;43;40;39;38;37;35;34;33;33;31;28;26","GIUSEPPE BORIANI;CRISTINA MUSSINI;DAVIDE ANTONIO MEI;ANDREINA MANFREDI;JACOPO FRANCESCO IMBERTI;GIOVANNI GUARALDI;MARCO VITOLO;ANDRÉA BARBIERI;HELGA BERTANI;JESSICA MANDRIOLI;NICCOLÒ BONINI;MANUELA SIMONI;ERICA FRANCESCHINI;GIULIA CASSONE;ILARIA MARTINELLI;MARCO SEBASTIANI;ELISABETTA ZUCCHI;LAURA CORTESI;MARIANNA MESCHIARI;MARIO LUPPI","47;17;15;13;12;12;11;11;11;11;11;10;9;9;9;9;8;8;8;8","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;MATHEMATICS;ENGINEERING;SOCIOLOGY;CHEMISTRY;ECONOMICS;POLITICAL SCIENCE;PHILOSOPHY;ENVIRONMENTAL SCIENCE;GEOGRAPHY;HISTORY;MATERIALS SCIENCE;BUSINESS;ART","357;75;35;26;25;18;13;13;11;11;7;6;3;3;3;3;2;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;ONCOLOGY;ENVIRONMENTAL HEALTH;GENETICS;PATHOLOGY;PEDIATRICS;GASTROENTEROLOGY;IMMUNOLOGY;RADIOLOGY;INTENSIVE CARE MEDICINE;PSYCHIATRY;PHYSICAL THERAPY;NURSING;OPTICS;GYNECOLOGY;BIOCHEMISTRY;FAMILY MEDICINE;PALEONTOLOGY","294;94;55;53;50;41;39;38;36;36;33;29;26;23;21;19;18;16;15;15","DISEASE;CANCER;POPULATION;COHORT;CONFIDENCE INTERVAL;HEART FAILURE;RETROSPECTIVE COHORT STUDY;ATRIAL FIBRILLATION;GENE;CHEMOTHERAPY;OBSERVATIONAL STUDY;PROSPECTIVE COHORT STUDY;RHEUMATOID ARTHRITIS;TRANSPLANTATION;ADVERSE EFFECT;INCIDENCE (GEOMETRY);DISCONTINUATION;PREGNANCY;PROPORTIONAL HAZARDS MODEL;COHORT STUDY","67;66;51;39;39;36;31;27;27;22;19;19;19;19;18;18;17;17;16;15","EJECTION FRACTION;HAZARD RATIO;BREAST CANCER;INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;AMYOTROPHIC LATERAL SCLEROSIS;COLORECTAL CANCER;IMMUNOTHERAPY;LIVER TRANSPLANTATION;MUTATION;INTERSTITIAL LUNG DISEASE;TOLERABILITY;ADENOCARCINOMA;DEMENTIA;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PLACEBO;TOCILIZUMAB;VIRAL LOAD;2019-20 CORONAVIRUS OUTBREAK;HEART RATE;INFERTILITY;PANCREATIC CANCER;PHENOTYPE;PROGRESSIVE DISEASE;PSORIATIC ARTHRITIS;SINUS RHYTHM;VASCULITIS;WEIGHT LOSS","23;22;21;18;13;10;9;9;9;9;8;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5","CORONAVIRUS DISEASE 2019 (COVID-19);CARDIAC RESYNCHRONIZATION THERAPY;ANTIRETROVIRAL THERAPY;METASTATIC BREAST CANCER;GIANT CELL ARTERITIS;NIVOLUMAB;CALCITONIN GENE-RELATED PEPTIDE;CARBOPLATIN;KRAS;MASTECTOMY;BENDAMUSTINE;BRCA MUTATION;BREAST RECONSTRUCTION;ESTROGEN RECEPTOR;EXOME SEQUENCING;FRONTOTEMPORAL DEMENTIA;IBRUTINIB;JANUS KINASE INHIBITOR;MALE INFERTILITY;NONALCOHOLIC FATTY LIVER DISEASE;PEMBROLIZUMAB;SOD1;STROKE VOLUME;TAMOXIFEN","18;7;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3",";HUMANS;FEMALE;RETROSPECTIVE STUDIES;MALE;COVID-19;TREATMENT OUTCOME;AGED;MIDDLE AGED;ADULT;ATRIAL FIBRILLATION;HIV INFECTIONS;ITALY;AMYOTROPHIC LATERAL SCLEROSIS;BREAST NEOPLASMS;CHILD;HEART FAILURE;STROKE;PROSPECTIVE STUDIES;QUALITY OF LIFE","200;165;51;43;37;26;24;23;22;18;17;16;16;14;14;14;14;14;13;12","ATRIAL FIBRILLATION;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;RHEUMATOID ARTHRITIS;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;MOLECULAR RESEARCH ON BREAST CANCER;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;CORONAVIRUS DISEASE 2019;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;INTEGRATION OF PALLIATIVE CARE IN END-OF-LIFE;LYMPHOID NEOPLASMS;MALE REPRODUCTIVE HEALTH;MICROSURGICAL RECONSTRUCTION TECHNIQUES;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;BREAST RECONSTRUCTION TECHNIQUES AND OUTCOMES","15;13;12;8;7;6;6;6;5;5;5;4;4;4;4;4;4;4;3;3","ATRIAL FIBRILLATION;DISCONTINUATION;CLINICAL ENDPOINT;ECHOCARDIOGRAPHY;TREATMENT;CARDIAC IMAGING;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;NEURODEGENERATION;STROKE (ENGINE);CARDIOVASCULAR RISK ASSESSMENT;INTERQUARTILE RANGE;NEOADJUVANT THERAPY;TOLERABILITY;ENDOSCOPIC STENTING;LEFT VENTRICULAR FUNCTION;METASTATIC BREAST CANCER;PANDEMIC;REGIMEN;TOCILIZUMAB;TREATMENT RESPONSE","18;17;13;12;10;9;9;8;8;7;7;7;7;6;6;6;6;6;6;6","ATRIAL FIBRILLATION;BREAST CANCER;COHORT STUDY;HEART FAILURE;RHEUMATOID ARTHRITIS;PATIENTS TREATED;INTERSTITIAL LUNG;AMYOTROPHIC LATERAL;LATERAL SCLEROSIS;PATIENTS PTS;RETROSPECTIVE COHORT;STEM CELL;LIVER TRANSPLANTATION;LUNG DISEASE;MULTIPLE SCLEROSIS;ARTHRITIS PATIENTS;CARDIAC IMPLANTABLE;EJECTION FRACTION;HEART RHYTHM;IMPLANTABLE ELECTRONIC;METASTATIC BREAST;PALLIATIVE CARE;PHASE II;CARDIAC RESYNCHRONIZATION;CELL ARTERITIS;DELPHI CONSENSUS;GIANT CELL;IMPLANTABLE DEFIBRILLATOR;ITALIAN SOCIETY;ITALIAN STUDY","20;17;13;12;11;9;8;7;7;7;7;7;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4","HR CI;RA PATIENTS;HEART FAILURE;CLINICAL OUTCOMES;RETENTION RATE;RISK FACTORS;MEDIAN AGE;ATRIAL FIBRILLATION;ADVERSE EVENTS;MEDIAN FOLLOW-UP;SARS-COV- INFECTION;MULTIVARIATE ANALYSIS;STATISTICALLY SIGNIFICANT;DISEASE ACTIVITY;OBSERVATIONAL STUDY;ALS PATIENTS;CONFIDENCE INTERVAL;CONSECUTIVE PATIENTS;PATIENTS TREATED;RHEUMATOID ARTHRITIS;AF PATIENTS;ALL-CAUSE DEATH;COX REGRESSION;EJECTION FRACTION;FAILURE HF;FIBRILLATION AF;INCLUDED PATIENTS;REGRESSION ANALYSIS;RETROSPECTIVE STUDY;COMPUTED TOMOGRAPHY","71;28;27;26;26;25;24;23;20;20;20;18;18;17;17;16;16;16;16;16;15;15;15;15;15;15;15;15;15;14",164,0.45,7,8.25,1,1,0,2,0,1,0,10,1,0,9.75,0,1,1,3,6,4,0,0,7,7,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,15,1.31,7,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CALVO ANDREA;CASALE FEDERICO;CHIÒ ADRIANO;D'OVIDIO FABRIZIO;DABERDAKU SEBASTIAN;DI CAMILLO BARBARA;DRORY VIVIAN;GOTKINE MARC;LUNETTA CHRISTIAN;MANDRIOLI JESSICA","1;1;1;1;1;1;1;1;1;1","AZIENDA OSPEDALIERA UNIVERSITARIA MODENA;HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT CO;ISTITUTI CLINICI SCIENTIFICI MAUGERI;MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER;NEMO LAB SRL;UNIVERSITA DEGLI STUDI DI PADOVA;UNIVERSITA DEGLI STUDI DI TORINO","1;1;1;1;1;1;1","31 BIOLOGICAL SCIENCES;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","1;1;1","ALS;BRAIN DISORDERS;CLINICAL RESEARCH;NEURODEGENERATIVE;NEUROSCIENCES;RARE DISEASES","1;1;1;1;1;1",NA,NA,"G16H50/20;G16H50/30","1;1","G06N7/01;G16B20/20;G16H50/20;G16H50/30","1;1;1;1",14,2.45,377.55,2.76,1,0.07,25.5,0,0,3,0,6,0,2,3,0,9,2,0,0,0,0,0,0,11,3,0,11,3,0,0,0,0,0,0,0,0,"Italy;United States","4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4204 MIDWIFERY;3207 MEDICAL MICROBIOLOGY;44 HUMAN SOCIETY;4403 DEMOGRAPHY","13;4;3;3;3;3;2;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;PEDIATRIC;PREVENTION;RARE DISEASES;CANCER;HEMATOLOGY;INFANT MORTALITY;INFECTIOUS DISEASES;LUNG;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN;ACUTE RESPIRATORY DISTRESS SYNDROME;AGING;AUTOIMMUNE DISEASE;BREAST CANCER;CARDIOVASCULAR;CONTRACEPTION/REPRODUCTION;ESTROGEN","11;9;3;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1","CANCER;INFECTION;REPRODUCTIVE HEALTH AND CHILDBIRTH;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;RENAL AND UROGENITAL;RESPIRATORY","3;2;2;1;1;1;1","6.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY","8;1;1;1;1;1","BREAST CANCER;ENDOMETRIAL CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;PANCREATIC CANCER","1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,"FRONTIERS;AMERICAN ASSOCIATION FOR CANCER RESEARCH;PUBLIC LIBRARY OF SCIENCE;ZENODO;KARGER PUBLISHERS","9;6;5;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3105 GENETICS;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3202 CLINICAL SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","33;14;12;8;7;6;5;3;2","CLINICAL RESEARCH;BREAST CANCER;CANCER;GENETICS;BRAIN DISORDERS;NEUROSCIENCES;PREVENTION;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;INFECTIOUS DISEASES;NEURODEGENERATIVE;AUTOIMMUNE DISEASE;BIODEFENSE;EMERGING INFECTIOUS DISEASES;IMMUNIZATION;LUNG;MULTIPLE SCLEROSIS;PNEUMONIA;RARE DISEASES;VACCINE RELATED;ALS","12;6;6;5;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;1","CANCER;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL","8;2;2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;6.3 MEDICAL DEVICES","6;2;1","CLINICAL;BIOMEDICAL","7;3","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","12;1","BREAST CANCER","8","3 GOOD HEALTH AND WELL BEING","1"
"AOU_MODENA",2024,328,17.7134146341463,2.58231707317073,0.295731707317073,0.323170731707317,0.335365853658537,1.99764150943396,1.40579710144928,1.73770491803279,1.44736842105263,0.600609756097561,3,131,64,24,24,0.4,0.2,0.07,0.07,0.99,1.03677823809509,4.33570581257415,0.323170731707317,0.963414634146341,0.535,0.501,0.488,0.475,"GIUSEPPE BORIANI;ROBERTO TEDESCHI;DANILO DONATI;HELGA BERTANI;FABIO VITA;DAVIDE ANTONIO MEI;STEFANO MELETTI;RITA CONIGLIARO;ANDREINA MANFREDI;PAOLO BOCCOLARI;ANGELA TOSS;FEDERICA LUMETTI;CESARE HASSAN;LUIGI GERRA;JESSICA MANDRIOLI;CARLO FABBRI;JACOPO FRANCESCO IMBERTI;RINAT BERNSTEIN‐MOLHO;ELISABETTA ZUCCHI;ANGELA TOSS","38;29;27;13;13;13;9;9;9;9;8;8;8;8;8;8;8;8;7;7","ROBERTO TEDESCHI;DANILO DONATI;GIUSEPPE BORIANI;AMEDEO LONARDO;PAOLO BOCCOLARI;DAVIDE ANTONIO MEI;DANIELA PLATANO;FABIO VITA;JACOPO FRANCESCO IMBERTI;FEDERICA GIORGI;FILIPPO PANTALEONI;STEFANO MELETTI;ŞENCAN ACAR;LUIGI TARALLO;LUIGI GERRA;GABRIELE DONATI;RITA CONIGLIARO;NICCOLÒ BONINI;HELGA BERTANI;GIORGIO DE SANTIS","5.65;5.23;4.76;3.21;2.16;1.98;1.64;1.57;1.54;1.48;1.15;1;1;0.95;0.94;0.9;0.9;0.86;0.85;0.83","GIUSEPPE BORIANI;DANILO DONATI;HELGA BERTANI;FABIO VITA;DAVIDE ANTONIO MEI;STEFANO MELETTI;RITA CONIGLIARO;ANDREINA MANFREDI;PAOLO BOCCOLARI;ANGELA TOSS;FEDERICA LUMETTI;LUIGI GERRA;JESSICA MANDRIOLI;JACOPO FRANCESCO IMBERTI;ELISABETTA ZUCCHI;ANGELA TOSS;MASSIMO DOMINICI;ILARIA MARTINELLI;MARIANNA MESCHIARI;LAURA CORTESI","38;27;13;13;13;9;9;9;9;8;8;8;8;8;7;7;7;7;7;7","DANILO DONATI;GIUSEPPE BORIANI;AMEDEO LONARDO;PAOLO BOCCOLARI;DAVIDE ANTONIO MEI;FABIO VITA;JACOPO FRANCESCO IMBERTI;FILIPPO PANTALEONI;STEFANO MELETTI;ŞENCAN ACAR;LUIGI TARALLO;LUIGI GERRA;GABRIELE DONATI;RITA CONIGLIARO;NICCOLÒ BONINI;HELGA BERTANI;GIORGIO DE SANTIS;ANDREINA MANFREDI;MARCO VITOLO;FABIO CATANI","5.23;4.76;3.21;2.16;1.98;1.57;1.54;1.15;1;1;0.95;0.94;0.9;0.9;0.86;0.85;0.83;0.82;0.8;0.74","DANILO DONATI;ROBERTO TEDESCHI;GIUSEPPE BORIANI;DANIELA PLATANO;PAOLO BOCCOLARI;ANGELO SQUERI;CARMINE PIZZI;CRISTINA SPAZIANI;DOMENICO TUTTOLOMONDO;ELISA GHERBESI;EMILIANO GUERRA;FRANCESCO ANGELI;KHRYSTYNA RYABENKO;LUCA BERGAMASCHI;MATTEO ARMILLOTTA;NICOLA GAIBAZZI;SILVIA GIANSTEFANI;STEFANO CARUGO;ANGELA TOSS;CHRISTOPHER B. GRANGER","67;65;60;37;31;25;25;25;25;25;25;25;25;25;25;25;25;25;20;20","DANILO DONATI;GIUSEPPE BORIANI;EMILIANO GUERRA;ANGELA TOSS;FILIPPO PANTALEONI;PAOLO BOCCOLARI;SALVATORE RUSSO;AMEDEO LONARDO;DAVIDE ANTONIO MEI;JACOPO FRANCESCO IMBERTI;NICCOLÒ BONINI;DIANA FERRARO;MARCO VITOLO;LUIGI GERRA;MASSIMO GIRARDIS;CRISTINA MUSSINI;MARIANNA MESCHIARI;ADRIANA CERVO;CLAUDIA PIOMBINO;ANDRÉA BARBIERI","65;59;25;19;16;16;14;13;13;13;13;12;12;11;11;10;9;7;7;6","GIUSEPPE BORIANI;DANILO DONATI;ANGELA TOSS;DAVIDE ANTONIO MEI;ANDREINA MANFREDI;STEFANO MELETTI;CRISTINA MUSSINI;FEDERICA LUMETTI;JACOPO FRANCESCO IMBERTI;MARCO VITOLO;GIUSEPPE GRANDE;LAURA CORTESI;MARIANNA MESCHIARI;AMEDEO LONARDO;NICCOLÒ BONINI;ILARIA MARTINELLI;LUIGI GERRA;ANNA ELISABETTA VAUDANO;CECILIA SIMONINI;ELISABETTA ZUCCHI","37;30;13;12;9;9;8;8;7;7;7;7;7;6;6;6;6;5;5;5","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PSYCHOLOGY;ENGINEERING;MATHEMATICS;PHYSICS;CHEMISTRY;PHILOSOPHY;SOCIOLOGY;POLITICAL SCIENCE;ECONOMICS;ART;BUSINESS;HISTORY;MATERIALS SCIENCE;ENVIRONMENTAL SCIENCE;GEOGRAPHY;GEOLOGY","318;71;37;28;25;21;19;15;10;10;9;7;4;4;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;INTENSIVE CARE MEDICINE;ONCOLOGY;PHYSICAL THERAPY;GENETICS;PATHOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;RADIOLOGY;PEDIATRICS;PHYSICAL MEDICINE AND REHABILITATION;GENERAL SURGERY;GYNECOLOGY;IMMUNOLOGY;GASTROENTEROLOGY;ARTIFICIAL INTELLIGENCE;BIOCHEMISTRY;ENDOCRINOLOGY;FAMILY MEDICINE","214;79;45;42;42;39;36;36;26;26;26;22;22;19;17;17;16;15;14;14;14","CANCER;DISEASE;COHORT;POPULATION;ATRIAL FIBRILLATION;RETROSPECTIVE COHORT STUDY;GENE;RANDOMIZED CONTROLLED TRIAL;OBSERVATIONAL STUDY;CONFIDENCE INTERVAL;COHORT STUDY;HEART FAILURE;PREGNANCY;NEUROLOGY;PROSPECTIVE COHORT STUDY;RHEUMATOID ARTHRITIS;ADVERSE EFFECT;OBESITY;ALTERNATIVE MEDICINE;CHEMOTHERAPY;ENDOSCOPY;EPILEPSY;REHABILITATION","49;46;30;27;24;22;20;20;16;15;13;13;13;12;12;12;11;11;10;9;9;9;9","BREAST CANCER;HAZARD RATIO;AMYOTROPHIC LATERAL SCLEROSIS;CLINICAL ENDPOINT;COLORECTAL CANCER;WARFARIN;CAPSULITIS;CONSTRUCT VALIDITY;DEMENTIA;EJECTION FRACTION;GERMLINE;IMMUNOTHERAPY;NEURORADIOLOGY;VIRAL LOAD;FATTY LIVER;GESTATIONAL AGE;LIVER TRANSPLANTATION;MULTICENTER STUDY;OVARIAN CANCER;CARDIOMYOPATHY;CHRONIC MIGRAINE;CISPLATIN;CRONBACH'S ALPHA;GENOME;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INFERTILITY;INFLAMMATORY BOWEL DISEASE;MUTATION;PHENOTYPE;PROGRESSION-FREE SURVIVAL;PROGRESSIVE DISEASE;PULMONARY FIBROSIS;RANDOMIZATION;RELIABILITY (SEMICONDUCTOR);SEROLOGY;TOLERABILITY;WEIGHT LOSS","24;11;7;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;COLONOSCOPY;NIVOLUMAB;CARDIAC RESYNCHRONIZATION THERAPY;CORONAVIRUS DISEASE 2019 (COVID-19);FRONTOTEMPORAL DEMENTIA;GERMLINE MUTATION;INFLAMMATORY BOWEL DISEASES;MASTECTOMY;METASTATIC BREAST CANCER;AXITINIB;BREAST RECONSTRUCTION;BRONCHOPULMONARY DYSPLASIA;CALCITONIN GENE-RELATED PEPTIDE;CARBOPLATIN;CHA2DS2–VASC SCORE;DNA MISMATCH REPAIR;HORMONE RECEPTOR;MALE INFERTILITY;RIVAROXABAN;SENTINEL LYMPH NODE;STEATOHEPATITIS;TAMOXIFEN","4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;ITALY;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ATRIAL FIBRILLATION;YOUNG ADULT;AGED, 80 AND OVER;ADOLESCENT;RISK FACTORS;ANTICOAGULANTS;CHILD;PROSPECTIVE STUDIES;STROKE;BREAST NEOPLASMS","217;111;59;54;46;38;36;27;20;19;17;15;12;11;11;9;8;8;8;7","ATRIAL FIBRILLATION;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;SHOULDER PATHOLOGY AND TREATMENT OUTCOMES;TREATMENT AND OUTCOMES OF HAND INJURIES;EPILEPSY AND SEIZURES;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;RHEUMATOID ARTHRITIS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;MANAGEMENT OF VALVULAR HEART DISEASE;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;BREAST RECONSTRUCTION TECHNIQUES AND OUTCOMES;CANCER IMMUNOTHERAPY;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS","18;12;11;10;7;7;7;6;5;5;4;4;4;4;4;3;3;3;3;3","ATRIAL FIBRILLATION;BREAST CANCER;ANTICOAGULANT THERAPY;TREATMENT;STROKE (ENGINE);CANCER SUSCEPTIBILITY;CLINICAL ENDPOINT;DISTAL RADIUS FRACTURES;ECHOCARDIOGRAPHY;LIVER DISEASE;METABOLIC SYNDROME;SHOULDER FUNCTION;SHOULDER PATHOLOGY;ASSOCIATION (PSYCHOLOGY);CANCER GENOMICS;CAPSULITIS;NEURORADIOLOGY;REHABILITATION;CANCER RISK;CARDIAC RESYNCHRONIZATION THERAPY","19;14;9;8;7;6;6;6;6;6;6;6;6;5;5;5;5;5;4;4","ATRIAL FIBRILLATION;BREAST CANCER;COHORT STUDY;RHEUMATOID ARTHRITIS;CANCER PATIENTS;LIVER DISEASE;OBSERVATIONAL STUDY;AMYOTROPHIC LATERAL;LATERAL SCLEROSIS;ADHESIVE CAPSULITIS;PROSPECTIVE STUDY;STEATOTIC LIVER;AORTIC VALVE;BRCA CARRIERS;CANCER RESULTS;CARDIOVASCULAR RISK;CELL CARCINOMA;CLINICAL OUTCOMES;HEART FAILURE;INFLAMMATORY BOWEL;ITALIAN SOCIETY;METABOLIC DYSFUNCTION-ASSOCIATED;MULTICENTER PROSPECTIVE;OVARIAN CANCER;RETROSPECTIVE COHORT;RETROSPECTIVE STUDY;SUBCLINICAL ATRIAL;ADVERSE EVENTS;ALZHEIMERS DISEASE;CLINICAL PRACTICE","21;17;13;9;8;8;7;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3","BREAST CANCER;ATRIAL FIBRILLATION;HR CI;SUPPORTING INFORMATION;KIDNEY CARE;RISK FACTORS;CLINICAL PRACTICE;CV RISK;LIVER DISEASE;SIGNIFICANT DIFFERENCES;HAZARD RATIO;KIDNEY DISEASE;MEDIAN MONTHS;PATIENTS TREATED;ADVERSE EVENTS;CKM COMORBIDITIES;PRIMARY OUTCOME;CHRONIC KIDNEY;ADHESIVE CAPSULITIS;AMYOTROPHIC LATERAL;CVD RISK;FIBRILLATION AF;HEART FAILURE;LATERAL SCLEROSIS;LOGISTIC REGRESSION;MEDIAN AGE;MEDIAN FOLLOW-UP;OBSERVATIONAL STUDY;REVERSED SUPRA;TP DISRUPTION","19;18;18;15;14;14;13;13;13;13;12;12;12;12;11;10;10;9;8;8;8;8;8;8;8;8;8;8;8;8",2,0.01,1.94,4.25,0,0,0,0,0,0,0,4.25,1,0,3.5,0,0,0,1.75,1.75,0,0,0,3.5,3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,2,552,0.26,0,0,41,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","1;1;1","BEHAVIORAL AND SOCIAL SCIENCE;CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DEPRESSION;HEMATOLOGY;LYMPHOMA;MENTAL HEALTH;PREVENTION;RARE DISEASES;REHABILITATION","1;1;1;1;1;1;1;1;1;1;1","GENERIC HEALTH RELEVANCE","1","7.1 INDIVIDUAL CARE NEEDS","1","COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA","1;1","6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"FRONTIERS","2","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES","4;2;2","AUTOIMMUNE DISEASE;BIOTECHNOLOGY;CANCER;LUNG;RARE DISEASES","2;2;2;2;2","RESPIRATORY","2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","2","BIOMEDICAL","2","CLINICAL MEDICINE AND SCIENCE","2","LUNG CANCER","2",NA,NA
